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Abstract 
 
Vaccination is one of the most effective public health interventions in the world, 
saving millions of lives and preventing the onset of debilitating diseases. With 
widespread emergence of multi-drug resistant pathogens, the importance of 
preventative medicine has become even more apparent. However, one of the 
limiting factors in developing novel vaccines that are both safe and highly 
immunogenic is the availability of adjuvant delivery systems licensed for human 
use. The purpose of this study was to investigate the role gold nanoparticles 
could play as an effective vaccine delivery system. A variety of coupling 
chemistries were explored for their ability to conjugate protein and 
polysaccharide antigens onto the surface of gold nanoparticles for the 
development of vaccines against a number of biologically important human 
pathogens including Y. pestis, B. mallei and S. pneumoniae. Retention of 
antigenicity and coupling efficiency of conjugated molecules was measured 
using characterisation techniques such as localised surface plasmon resonance 
and immunoblotting. Gold nanoparticle coupled antigens were then used to 
immunise mice and to measure the protective efficacy and the immunological 
response induced. The findings indicate antigen-specific immune responses are 
elevated when an antigen is coupled onto gold nanoparticles. Moreover, 
immunological data from nanoparticle coupled glycoconjugate vaccines against 
B. mallei and S. pneumoniae indicate the likely presence of a strong T cell 
immune response which is essential for providing immunological memory. 
Finally, an intracellular trafficking assay was carried out to identify some of the 
mechanisms that might be involved in uptake of gold nanoparticles into 
professional phagocytes. Confocal imaging of receptors associated with 
endosomal compartments revealed that gold nanoparticles may enter cells 
through multiple pathways. The findings reported in this study suggest that gold 
nanoparticles may be an excellent candidate for further investigation as a novel 
vaccine delivery system. 
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Chapter 1: Nanoparticles in Vaccine Delivery 
 
 
1.1 Introduction 
The discovery of vaccines is arguably one of the greatest achievements in 
medical science of the 20th century. Vaccination was pioneered by Edward 
Jenner who in 1796 showed that people were no longer susceptible to smallpox 
infection once they had been inoculated with cowpox, a far less severe disease 
[1]. Since then, global immunisation programmes have led to the eradication of 
smallpox and have almost completely eliminated many other infectious 
diseases including diphtheria, tetanus, poliomyelitis, measles, mumps, rubella 
and Haemophilus influenza type b [2]. Vaccination not only prevents many from 
suffering debilitating diseases but saves approximately 2 to 3 million lives 
globally every year [3]. 
Whilst varied in their composition and application, the mechanism by 
which all vaccines work is essentially the same. Consisting of a biological 
substance (antigen), which can be either a whole microbe (killed or attenuated) 
or microbial components, a vaccine stimulates an immune response. The 
antigen is then remembered by the immune system so that it can mount a more 
effective response should it encounter the corresponding microbe in the future. 
This is best achieved by inducing long-term protection in individuals, a hallmark 
of adaptive immunity rather than innate immunity which provides immediate yet 
short-lived protection. 
One approach for inducing an adaptive immune response is to immunise 
an individual with a live attenuated strain of a pathogen which has a significantly 
reduced virulence. These vaccines provide the immune system with the entire 
make-up of a microbe, enabling it to produce antibodies against conserved 
structures for future recognition. There are several approaches to attenuating 
microbes for use as a vaccine. One involves growing the microbe in artificial 
growth medium at a temperature lower than the human body. Over time this can 
be used to select for a mutant that grows well at lower temperatures but has 
reduced growth in humans. This allows the immune system to mount a 
response and eliminate the microbe before it causes infection. The cold-
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adapted influenza vaccine is an example of this approach [4]. A combinational 
vaccine against measles, mumps and rubella (MMR) was developed using 
another method, by growing the viruses in a foreign host. Both measles and 
mumps viruses are grown in chick egg fibroblasts to select for mutants with an 
enhanced virulence for the host. Subsequently, these mutants show a 
significant attenuation in humans and are selected as vaccine strains [5, 6]. 
Both of these methods of attenuation are particularly well suited to RNA viruses, 
which have a high mutation rate, but are rarely applied to bacterial pathogens. 
Recombinant DNA techniques to create attenuated mutants is used instead, 
such as the Vibrio cholerae CVD 103-HgR strain that does not express the 
enzymatically activate subunit of cholera toxin [7]. By priming the immune 
system with a living microbe the resulting response is similar to that of a natural 
infection. Live attenuated vaccines are therefore often able to elicit strong 
cellular and humoral responses that confer lifelong immunity after just one or 
two doses in childhood [8]. However, one of the major concerns with live 
attenuated vaccines is their potential for reversion to virulence [9]. There are 
also safety concerns with the use of some live vaccines in immunocompromised 
individuals [10]. Whilst some live vaccines can be lyophilised, they often have to 
be kept refrigerated to remain effective. This can be particularly problematic for 
vaccinating in developing countries which may lack widespread refrigeration. 
Another type of vaccine involves immunising with the whole microbe 
once it was been inactivated using heat, chemicals or radiation. These vaccines 
are termed killed whole cell (KWC) vaccines and consist of the microbe in its 
native wild-type form. Unlike live attenuated vaccines, KWC are unable to cause 
disease and do not require refrigeration. However the method used to kill the 
bacteria may affect its immunogenicity, with some studies suggesting that 
radiation treatment retains some of the antigenic structures destroyed by heat 
treatment [11]. One of the first KWC vaccines produced was against typhoid in 
1896, although its efficacy was not established until 1960 [12]. A two dose 
vaccination with KWC typhoid resulted in 73% efficacy over three years (95% 
confidence interval) [13]. However, adverse side-effects were reported in 17% 
of vaccine recipients and is therefore not available for use as a public health 
vaccine, despite being licensed [14]. Local reactions at the site of vaccination 
are a common feature of KWC vaccines but are often caused by an adjuvant 
which is added to boost the weak adaptive immune responses induced by 
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KWC. This is due to the fact that they are unable to replicate in the host, 
meaning periodic boosters must be given to maintain immunity. This can be a 
problem for people who do not have regular access to health care. Another 
disadvantage of a non-living vaccine is that they are unable to elicit CD8+ T cell 
responses which are important for protection against intracellular pathogens. A 
problem that is common to both types of vaccines, that are using the whole 
microbe as an immunogen, is the unspecificity of the immune response induced 
because some antibodies are raised against proteins that are not involved in 
virulence. There may also be some microbial proteins in the vaccine strain that 
down-regulate the adaptive immune response. 
Instead of using the whole microbe for immunisation, recent vaccine 
design strategies have focused on identifying microbial components (subunits) 
that best stimulate the immune system. These vaccines are much better 
characterised than whole microbial vaccines, making them safer for human use. 
Once identified, microbial components can be isolated in one of two ways: 
either by purifying directly from the microbe, or using recombinant DNA 
techniques to express the antigen in a foreign host and then purifying. An 
example of a recombinant subunit vaccine is the hepatitis B vaccine which uses 
Saccharomyces cerevisiae to express one of the viral envelope proteins, 
hepatitis B surface antigen (HBsAg) [15]. This vaccine induces a protective 
antibody response in over 90% of individuals, in whom protection is life-long 
[16]. However, like KWC vaccines, microbial components are often weak 
immunogens that require adjuvants to boost their efficacy. Adjuvants may be 
either organic or inorganic and function by delivering the antigen to antigen-
presenting cells (APCs) or by acting as an immunostimulant. There are 
currently very few adjuvants licensed for human use and those which are 
licensed can induce local reactions and may fail to generate strong cell-
mediated immunity [17-19]. Whilst the use of microbial components for vaccines 
remains appealing, there remains a great need for discovering novel adjuvants 
and delivery systems in order to develop safe and effective vaccines in the 
future. 
 
1.2 Vaccine-induced immunity 
The objective of any vaccine formulation is to activate an antigen-specific B 
and/or T cell immune response to induce an immunologically mediated 
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resistance to a disease [20]. The predominant interface between these two 
immune responses is APCs, particularly dendritic cells, which are widely 
distributed throughout the body as immature cells. APCs recognise a number of 
conserved structures in pathogens, termed pathogen-associated molecular 
patterns (PAMPs), by pattern recognition receptors such as toll-like receptors 
(TLR), which initiate an innate immune response, Table 1.1 [21-23]. APCs also 
undergo maturation upon antigen recognition which results in a redistribution of 
major histocompatibility complex (MHC) molecules from intracellular 
compartments to the cell surface, cytoskeleton reorganisation and the secretion 
of cytokines and chemokines to recruit other APCs [24-27]. 
 
 
 
 
 
 
Table 1.1. Pattern recognition receptors and their corresponding major ligand. 
 
 
 
 
Receptor Major Ligand (PAMPS) 
TLR 1 Triacyl lipoproteins 
TLR 2 Peptidoglycan and lipoproteins of Gram-negative bacteria 
TLR 3 Double-stranded RNA 
TLR 4 Lipopolysaccharide 
TLR 5 Flagellin from Gram-positive and Gram-negative bacteria 
TLR 6 Diacyl lipoproteins 
TLR 7 Single-stranded RNA 
TLR 8 Oligosaccharides 
TLR 9 Unmethylated CpG sequences in DNA 
TLR 10 Single-stranded RNA 
TLR 11 Profilin 
TLR 12 Profilin 
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Dendritic cells are capable of using a variety of endocytic mechanisms to 
engulf foreign antigens. Generally, but not exclusively, this process is receptor-
mediated whereby surface receptors capture microbes by binding to specific 
ligands [23, 28]. Endocytosis of bacteria and larger particles (> 0.5 µm) mostly 
occurs by either phagocytosis or macropinocytosis that form cell-surface 
extensions which engulf the pathogen [23, 29]. Phagosomes or 
macropinosomes then fuse with early and late endosomes as well as 
lysosomes to form phagolysosomes. These compartments contain proteolytic 
enzymes and reactive oxygen species that degrade bacterial peptides [30]. 
Degraded peptides are then displayed on MHC class II molecules for 
recognition by CD4+ T-helper (Th) cells which are able to stimulate both 
humoral and cellular arms of the adaptive immune response [31]. Once 
activated by APCs, CD4+ Th cells differentiate into one of two major subtypes of 
effector T cells; Th1 or Th2. This is regulated by the cytokine environment 
generated by APCs and other cells that form part of the innate immune 
response including natural killer cells, basophils and mast cells [32-34]. 
Interleukin (IL)-12 is believed to play a key role in the generation of Th1 cells, 
whereas IL-10 suppresses this development [35, 36]. 
Th1 cells play a pivotal role in cellular immunity against intracellular 
pathogens by inducing a predominantly pro-inflammatory response with the 
secretion of IL-2, interferon (IFN)-γ and tumour necrosis factor (TNF)-α [37, 38]. 
Moreover, a fraction of these Th1 cells will also persist as memory CD4+ T cells 
(Tm), providing a quantitatively enhanced response upon secondary infection 
[39]. IL-4 is responsible for stimulating the development of Th2 cells which are 
critical during infection by extracellular pathogens and secrete the anti-
inflammatory cytokines IL-4, IL-5 and IL-13 [40-42]. Th cells may also activate B 
cells in germinal centres (GC) leading to differentiation of GC B cells into 
memory B cells (Bm) or plasma cells [43]. Whilst naive B cells produce low 
affinity immunoglobulin (Ig)-M and IgD, Th activated B cells undergo Ig class 
switching to generate IgG, IgA or IgE depending on the cytokine environment 
[44]. Follicular helper T (Tfh) cells also play a key role in supporting B cell 
differentiation and Ig class switching. Tfh cells induce clonal proliferation and 
affinity maturation of B cells through a series of co-stimulatory markers, 
including IL-10 and IL-21, to generate antibodies of a higher binding capacity 
[45, 46]. The generation of effector Th cells is controlled by regulatory T cells 
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(Treg) which maintain immune homeostasis by secreting IL-10 and transforming 
growth factor (TGF)-β [47]. Tregs are also essential in preventing autoimmune 
diseases as well as allergic reactions by suppressing immune responses to self 
and non-self antigens [48-50]. 
In some cases antigens may be present in the cytosol of APCs as a 
result of infection from viruses, intracellular bacteria or non-phagocytic uptake. 
When this occurs, antigens are degraded by the proteasome before being 
transported to the endoplasmic reticulum (ER) by transporters associated with 
antigen presentation (TAP-1 and -2) and loaded onto MHC class I molecules 
[51]. MHC class I-peptide complexes that are translocated to the cell surface 
are recognised by CD8+ T cells which are subsequently activated in the 
presence of IL-2 from CD4+ Th1 cells and undergo clonal expansion as 
cytotoxic T cells (Tc) [25]. Tc cells are then able to induce cytolysis of infected 
cells using one of two mechanisms; granzyme-mediated or Fas-mediated 
apoptosis. In the first of these two pathways perforin and granzyme are 
released from Tc cells which form a pore in the plasma membrane of the target 
cell through which granzyme enters [52]. These molecules then stimulate the 
caspase cascade in the target cell, leading to apoptosis. The other mechanism 
of cytolysis employed by Tc cells is by the upregulation of FasL (CD95L) which 
binds with Fas (CD95) on target cells to initiate apoptosis [53]. Following 
infection, the majority (90-95%) of activated Tc cells will also undergo 
programmed cell death whilst the remaining antigen-specific CD8+ T cells will 
generate a pool of long-lived memory T cells, Figure 1.1 [54, 55]. 
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Figure 1.1. Activation of dendritic cells in response to different antigen stimuli. 
Antigens larger than 200 nm (e.g. bacteria) typically enter antigen-presenting 
cells via endosomal pathways (blue arrows). They are then degraded within a 
vesicle before the contents are displayed on the cellular surface by MHC II 
receptors and recognised by CD4+ T cells. Antigens smaller than 200 nm (e.g. 
viruses, nanoparticles) present in the cytosol (red arrows) are broken down and 
presented on MHC I receptors, which are recognised by CD8+ T cells. 
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Presentation of antigenic peptides to either MHC class I or class II 
molecules was originally believed to be dependent on whether proteins were 
produced endogenously or captured via endocytosis. However, it is now known 
that in some cases dendritic cells are able to load exogenous peptides onto 
MHC class I molecules in a process known as cross-presentation [56]. The 
precise mechanisms underlining this process are yet to be elucidated but 
involve fusion of phagosomes with the ER before being loaded onto MHC class 
I molecules [57]. Cross-presentation is critical for priming a CD8+ T cell 
response to intracellular pathogens without APCs becoming infected and avoids 
intracellular immune evasion strategies. Consequently, attempts have been 
made to develop vaccines against intracellular pathogens using cross-
presentation and this has been achieved using a variety of NP delivery systems 
[58-60]. 
Whilst an infection is likely to induce a mixed response of both B and T 
(CD4+ and CD8+) cells, the composition and delivery of vaccines has a direct 
influence on the type of immune response elicited. It stands to reason that 
tailoring a vaccine-induced immune response to a specific pathogen may be a 
useful strategy when designing a vaccine. Bacterial polysaccharide vaccines, 
for example, generally elicit B cell responses in a T-independent manner 
(lacking CD4+/CD8+ activation), although some studies have identified 
zwitterionic polysaccharides as stimulating CD4+ T cells [61]. Polysaccharide 
antigens are typically characterised by inducing an immune response which is 
isotype restricted and lacking T cell memory [62, 63]. However, by conjugating 
polysaccharides to a protein carrier (glycoconjugate) peptide antigens are 
recognised by CD4+ or CD8+ T cells and elicit a B cell response in a T-
dependent manner [64]. 
For vaccines against intracellular pathogens, inducing a CD8+ Th1 and/or 
CD8+ Tc cell response might be advantageous. Whereas this was previously 
limited to live attenuated vaccines, this type of immunity can now be achieved 
using novel adjuvants and delivery systems. 
 
1.3 Adjuvants 
For more than 70 years adjuvants have been added to vaccine formulations to 
either enhance or manipulate a vaccine induced immune response. Whilst the 
precise mechanism of how many adjuvants work is only poorly understood, 
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adjuvants can mediate their effect by extending the duration of an immune 
response, stimulating cell-mediated immunity or by modulating the antibody 
avidity and subclass distribution [65]. Stimulatory adjuvants such as 
unmethylated cytosine-guanine dinucleotides (CpG) found in bacterial DNA and 
monophosphoryl lipid A (MPLA) are characterised by their ability to activate co-
stimulatory signals or intracellular signalling pathways. For MPLA, its major 
receptor in humans has been identified as TLR 2 [66]. This triggers the release 
of pro-inflammatory cytokines via nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), an important feature of the innate immune response 
[67]. CpG however has been identified as binding to TLR 9 which, through the 
expression of co-stimulatory molecules, releases TNF-α and IL-12 to induce a 
potent Th1 response [68, 69]. Alternatively, cytokines can be used directly as an 
adjuvant, the most extensively studied being IL-2, IL-12 and IFNγ. However, 
problems with stability and a relatively high manufacturing cost means that the 
use of cytokines for routine vaccination is unlikely [70, 71]. 
Aluminium-based compounds (principally aluminium phosphate or 
hydroxide) remain the most widely used adjuvants incorporated into licensed 
human vaccines. However, the mechanism by which alum potentiates the 
immune response is poorly understood. It was initially believed to be due to a 
depot effect at the site of injection, prolonging exposure of the antigen to the 
immune system for a better response [72, 73]. This theory was later challenged 
by Holt who showed that excision of the injection site from guinea pigs did not 
interfere with the development of a humoral response [74]. Recent studies have 
also documented the rapid release of antigens from alum adjuvants; 
approximately 80% of aluminium phosphate adsorbed tetanus toxoid had 
disappeared from the site of injection within 4 hours [75, 76]. It is now believed 
that alum plays a more active role based on observations of its electrostatic 
interaction with lipopolysaccharide [77]; and its demanding effect on some 
protein antigens [78] leading to corrugated layers of aluminium oxyhydroxide 
held together with hydrogen bonds. Aluminium gel particles are generally no 
more than 10 µm in diameter, and antigens adsorbed to these particles maybe 
phagocytosed more readily than those without alum [79]. The generation of 
particulate molecules in vivo may create an inflammasome response which in 
turn may activate the Nlrp3 (NOD-like receptor family, pyrin domain containing 
3) [80, 81] causing an influx of eosinophils and an upregulation of MHCII 
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expression and antigen-presentation cell activity [82]. Once activated, this 
cytoplasmic Nlrp3 protein promotes the production of pro-inflammatory 
cytokines such as interleukin 1beta and interleukin 18 (IL-1β and IL-18) [80, 83]. 
Of these cytokines, IL-1β has been shown to be a potent stimulus for T-cell 
dependent antibody production in vivo [84]. Alternatively, prostaglandins or 
other moieties may mediate the inflammatory response to the alum [85]. 
Although alum is renowned for its ability to produce antibody responses, it 
induces strong CD4+ mediated cellular responses (predominantly Th2 but also 
Th1) and can also induce CD8+ T cell activation [82]. Stimulation of these 
cellular responses induces cellular memory which is important for protection 
against many pathogens as well as generating long-term protective immunity 
[86-88]. 
Whilst alum-based adjuvants are generally well tolerated, there may be 
some associated toxicity problems such as the formation of granulomas when 
subcutaneous or intradermal injection is preferred over intramuscular. Weak 
renal function can result in allergenicity and accumulation of aluminium which is 
not only toxic but has also been associated with amyotrophic lateral sclerosis 
and Alzheimer’s disease [76, 89-91]. Consequently, there is an urgent need to 
develop safe adjuvants which are able to stimulate both Th1 and Th2 immune 
responses. 
 
1.4 Nanoparticle vaccines 
Nanotechnology is an emerging field which focuses on manipulating matter on a 
nanometer scale. The International Organisation for Standardisation (ISO) 
defines a nanostructure as ‘an object that has at least one dimension within the 
nano-scale’; 1-1000 nm (1 nm = 10-9 m) [92]. The application of these nano-
structures, including nanoparticles (NPs), holds great promise for the 
development of a new generation of vaccines and adjuvants [93-100]. NP 
vaccines allow antigens to be either encapsulated within or decorated onto the 
surface of the NP. By encapsulating antigenic material, NPs provide a method 
for delivering antigens which may otherwise degrade rapidly upon injection or 
induce a short-lived, localised immune response. The large surface area of NPs 
also means that molecules decorated on the surface are at a high concentration 
and are presented to the immune systems in much the same way that it would 
be presented by the pathogen, thereby provoking a similar or even enhanced 
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response. Moreover, NPs made from some composites enable not only site 
directed delivery of antigens but also prolong the release of antigens to 
maximise exposure to the immune system. 
Whilst nanoparticles vary significantly in their composition, size and 
shape they can be broadly grouped into the following categories: Virus-like 
particles, liposomes, non-degradable and polymeric nanoparticles. A summary 
of nanoparticles studied as vaccine delivery systems is shown in Table 1.2. 
 
1.4.1 Virus-like particles 
Amongst some of the first studied NP delivery systems were virus-like particles 
(VLPs), attracting interest because of their ease of production and ability to 
stimulate strong immune responses [101-103]. Typically in the size range of 20-
150 nm, VLPs consist of a self-assembled viral envelope, generated from a 
single protein to form a multimeric complex displaying a high density of epitopes 
[102, 104]. Unlike viruses, VLPs assemble without encapsulating any viral RNA 
meaning they are non-replicating and non-infectious. Genes coding for viral 
integrase are also deleted prior to expression to prevent integration of the 
packed genome into the host cell and/or prevent recombination with live or 
defective virus in an infected individual [105]. VLPs can be engineered to 
express additional proteins either by fusing these proteins to the particle or by 
expressing multiple antigens [101, 106]. Using this approach, VLPs can be 
generated to provide protection not only against the virus of origin but also 
against heterologous antigens. Moreover, non-protein antigens such as 
polysaccharides or small organic molecules can be chemically coupled onto the 
viral surface to produce bioconjugate VLPs [107, 108]. 
The baculovirus expression system is most commonly used for the 
generation of VLPs, and has a good safety profile since baculoviruses do not 
naturally infect humans. The Autographa california multiple nuclear 
polyhedrosis virus (AcMNPV) is the most extensively studied VLP component 
[109]. In this system, a non-essential gene coding for the protein(s) forming the 
viral occlusion body (polyhedrin) is replaced with a gene of interest [104]. The  
vector encoding the modified VLP can then be used to infect insect cells (Sf9 or  
Sf21 derived from Spodoptera frugiperda, or BTI-TN-5B1-4 derived from 
Trichoplusia ni) to generate sufficient quantities of the viral protein which can 
then self assemble into multimeric complexes. The advantage of using such a 
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system is that not only does AcMNPV have a large genome (130 kb), allowing 
the insertion of multiple/large genes, but there is typically a high protein yield 
driven by the strong polyhedrin promoter [109]. Despite its versatility, the main 
disadvantage to the baculovirus/insect expression system is its inability to 
produce authentic recombinant mammalian glycoproteins due to differences in 
post-translational modification patterns between insect and mammalian cell 
lines [110]. One way to overcome this has been the development of 
“humanised” insect cell lines to constitutively express mammalian genes such 
as β1, 4-galactosyltransferase and α2,6-sialyltransferase to enable the 
expression of terminally galactosylated and sialylated glycoproteins [111-115]. 
Another problem associated with the baculovirus expression system is the 
resulting cell death and lysis of insect cells within a few days after infection with 
baculovirus. This can be problematic for proteins which are selected for 
secretion or are vulnerable to degradation. Subsequent efforts to alleviate this 
problem have been in the form of a non-lytic baculovirus developed by random 
mutagenesis resulting in almost a 10-fold decrease in cell lysis and a reduction 
in degradation of expressed protein [116]. 
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 Table 1.2. Examples of nanoparticle vaccine delivery systems
 Matrix/ expression system Size Antigen 
Route of 
immunisation 
References 
Virus like 
particles 
Baculovirus (Sf9, Sf21, Hi5); 
E. coli; 
Mammalian cells; 
S. cerevisiae 
55-60 nm 
(HPV) 
100-200 nm 
(HIV) 
80 -120 nm 
(H1N1) 
Major capsid protein, L1 (HPV); 
fms-like tyrosine kinase receptor ligand, FL, 
gag precursor protein, pr45, HIV env cDNA 
(HIV); 
Haemagglutinin, nicotinamide, matrix protein 
M1 (H1N1) 
Intramuscular, 
Subcutaneous, 
Intraperitoneal, 
Oral, 
Intranasal 
[97, 117-124] 
Liposomes 
Outer membrane vesicles 
(OMV) 
Phospholipid S100 and 
cholesterol; 
Phosphatidylcholine and 
cholesterol 
20-200 nm 
50-500 nm 
193 nm 
R32NS1 (Plasmodium falciparum); 
Cholera toxin; 
Circumsporozoite (P. falciparum); 
CtUBE fusion peptide (Helicobacter pylori); 
KWC Y. pestis 
Intramuscular, 
Intravenous, 
Subcutaneous, 
Oral, 
Intranasal 
[93, 125-129] 
Non-
degradable 
Gold; 
Silica; 
Carbon 
2-470 nm 
Plasmid DNA expressing haemagglutinin 1 
(Influenza); 
Hepatitis B 
Intradermal, 
Intramuscular, 
Subcutaneous, 
[100, 130-
134] 
Polymeric 
Poly(lactic-co-glycolic acid) 
(PLGA); 
Poly(lactic acid) (PLA); 
Poly(glycolic acid) (PGA); 
Chitosan; 
100-200 nm 
800 nm 
1-5 µm 
248 nm 
Docetaxel, TetHc (C. tetani), Hepatitis B, Dtxd 
(Corynebacterium diphtheriae) 
SBm7462 (Boophilus microplus); 
Rv1733c (Mycobacterium tuberculosis); 
SPf66 (P. falciparum) 
Intramuscular, 
Intravenous, 
[93, 94, 135] 
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1.4.2 Liposomes 
Like VLPs, liposomes are self-assembling but consist of a phospholipid bilayer 
shell with an aqueous core [136, 137]. They can be produced naturally from the 
outer membrane of Gram negative bacteria as outer membrane vesicles 
(OMVs) or generated synthetically. There are two main types of synthetic 
liposome, either unilamellar vesicles which consist of a single phospholipid 
bilayer, or multilamellar vesicles that are made of several concentric 
phospholipid shells separated by layers of water. As a consequence, liposomes 
can be tailored to incorporate either hydrophilic molecules into the aqueous 
core or hydrophobic molecules within the phospholipid bilayer. There are a 
large number of methods published for preparing liposomes [138-140]; 
however, they typically involve a reverse phase evaporation process by 
dissolving phospholipids (such as MPLA or phosphatidylcholine) in an organic 
solvent (e.g. chloroform, methanol). Water is then added, along with the 
antigen, and the solvent is evaporated resulting in the vesicles [141, 142]. 
Cholesterol can also be added to provide additional stability to the phospholipid 
bilayer [143]. Other approaches to encapsulate antigens in liposomes include 
using repeated freeze thaw cycles [141], a pH gradient [144] or an ammonium 
sulphate method [145] with antigen encapsulation rates varying between 25-
72% [128, 129, 146]. 
 
1.4.3 ISCOMs 
Colloidal saponin-containing micelles of around 40 nm can be used as self-
adjuvanting vaccine delivery systems and are collectively known as immune 
stimulating complexes (ISCOMs) [147]. Two types of ISCOMs have been 
described, both of which consist of cholesterol, phospholipid (typically either 
phosphatidylethanolamine or phosphatidylcholine) and saponin (most often Quil 
A from the tree Quillaia saponaria) [148-150]. Classically, ISCOMs have been 
used to entrap viral envelope proteins such as those from herpes simplex virus 
type 1, hepatitis B and influenza [65]. However, proteins from a range of 
bacteria and parasites including Escherichia coli, Brucella aborus and 
Plasmodium falciparum have also been used to assemble ISCOMs [151-153]. 
Complexes without viral proteins are also used and are often referred to as 
ISCOM matrices [148]. ISCOMs are self-assembling at an optimal ratio of 1:1:5 
(cholesterol:phospholipid:saponin) for matrices or 1:1:5:0.1/1 for classical 
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ISCOM forming in the presence of a non-ionic detergent, which is then removed 
using dialysis or ultracentrifugation [150, 154]. The resulting complex is a 
pentagonal dodecahedron arrangement of micelles containing saponin and lipid 
held together by hydrophobic interactions and stabilised through its negative 
surface charge [154, 155]. 
 
1.4.4 Polymeric nanoparticles 
Polymeric NPs have attracted attention for their ability to deliver drugs as well 
as for being biodegradable [156]. Moreover, the release kinetics of loaded drugs 
from polymeric NPs can be controlled by compositional changes to the 
copolymer [156]. This class of NP can be prepared from a range of polymers 
including poly(α-hydroxy acids), poly(amino acids) or polysaccharides to create 
a vesicle which can either accommodate or display antigens. The most 
commonly used poly(α-hydroxy acids) for preparing polymeric NPs are either 
poly(lactic-co-glycolic acid) (PLGA) or poly(lactic acid) (PLA) which are often 
synthesised using a double emulsion-solvent evaporation technique [157-159]. 
Firstly, a polymer of choice is dissolved in an organic solvent like ethyl acetate 
or methylene chloride followed by the addition of the antigen which is then 
vortexed to get a primary emulsion. A water-in-oil-in-water emulsion is then 
formed with the addition of an emulsifying agent (e.g. polyvinyl alcohol or 
polyvinyl pyrrolidine). This results in the polymer precipitating around the 
antigen. The solution is then left to allow solvent evaporation and then dried to 
prevent degradation of the polymer due to water-catalysed ester hydrolysis 
[160-164]. The use of this method is limited since antigen entrapment efficiency 
is low and there is a possibility of protein denaturation at the oil-water interface 
[165]. The addition of stabilizers such as surfactants or sugars, including 
trehalose and sucrose, provide stability against denaturation by keeping the 
protein hydrated in its native form. 
An alternative method for retaining encapsulated protein stability uses 
poly(amino acids) such as poly(γ-glutamic acid) (γ-PGA), poly(ε-lysine), poly(L-
arginine) or poly(L-histidine) which do not require an emulsion step in their 
synthesis [166-169]. These amphiphilic copolymers self-assemble via 
hydrophobic interactions to form polymeric structures consisting of a 
hydrophobic core and a hydrophilic outer shell [158, 170]. Moreover, γ-linked 
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glutamic acids in γ-PGA are not easily recognised by common proteases 
resulting in added stability [171, 172]. 
Hydrophilic polysaccharide polymers are also good candidates for 
vaccine delivery with both dextran and chitosan being chosen for preparing NPs 
[173-175]. Much attention has focused on chitosan NPs because of the 
biocompatibility of chitosan, its biodegradability into non toxic products in vivo 
and its ability to open up tight junctions between epithelial cells [176]. Chitosan 
NPs can be prepared in a number of ways. One method is a self-assembly 
technique through chemical modification, producing particles with a mean 
diameter of 160 nm [177]. Similarly, a complex coacervation process is 
sometimes used whereby particles form spontaneously when two hydrophilic 
colloids are mixed together, with chitosan precipitating around plasmid DNA 
[175]. These particles are 100-250 nm in diameter and protect the DNA from 
nuclease degradation. The emulsion-droplet coalescence technique pioneered 
by Tokumitsu and colleagues was developed for intra-tumoral injection [178]. It 
is based upon the emulsion crosslinking of chitosan and precipitation around 
the drug (gadopentetic acid). The particles formed were 450 nm in diameter and 
were appraised for their slow release and long-term retention within the tumour, 
making them an excellent delivery vehicle. An ionic gelation process based on 
the positively charged amino groups in chitosan and the negative charge of 
tripolyphosphate has also been used to prepare chitosan NPs in the size range 
of 20-400 nm [173, 179]. Sometimes these colloids will be further modified by 
the addition of an adjuvant on the surface, such as polyethylene glycol in order 
to aid absorption or to slow down release. 
 
1.4.5 Non-degradable nanoparticles 
In contrast to the above NPs that consist of biological or biodegradable 
materials, non-degradable NPs are also being investigated for vaccine delivery 
[132, 180-182]. Among those commonly studied for vaccine delivery include 
gold, platinum, carbon and silica, which are used to generate a shell in which to 
encapsulate antigens or to provide a surface for covalent attachment. Gold NPs 
in particular are considered favourable for biomedicinal use due to their 
biocomapatability, non-toxicity and pre-existing license for human use [183-
186]. Furthermore, the size of NPs made from gold, ranging from 1-100 nm, can 
be easily controlled by reducing a gold salt (H(AuCl4)) with various reducing 
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agents. The gold surface readily forms covalent bonds with thiol groups, 
allowing surface functionalisation with thiol containing compounds. Gold NPs 
synthesised using a gold salt reduction are typically monodisperse and uniform 
in shape, which is essential for maintaining antigen loading consistency 
between batches [187]. The smaller particles, formed from using a strong 
reducing agent, can then be grown to form larger particles with a desired aspect 
ratio using a “seeding” method with ceyltrimethlammonium bromide and silver 
acetate [133, 188-190]. Carbon NPs have also been investigated for their use in 
vaccine delivery including oral delivery [134]. Using silica NPs as a template, 
the particles are then carbonized at high temperatures under nitrogen gas and 
using sucrose as a carbon source. The resulting particle is over 450 nm in size 
with 50 nm mesopores embedded within the particle surface. Within these 
pockets a protein antigen can be protected from the harsh environment of the 
gastrointestinal tract, allowing oral administration to promote mucosal immunity 
[134]. An illustration of the various nanoparticle composites is shown in Figure 
1.2.
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Figure 1.2. Schematic representation of different nanoparticle vaccine delivery 
systems. (A) Virus-like particle, (B) Liposome, (C) ISCOM, (D) Polymeric 
nanoparticle, (E) Non-degradable nanoparticle. 
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1.5 Nanoparticle uptake and immunity 
The delivery of antigens to APCs is essential for developing antigen-specific B 
and T cell responses. This means that vaccine delivery systems are often 
targeted to these cells and modified to induce the desired immune response. By 
using NPs to deliver antigens, the efficiency of uptake into dendritic cells is 
significantly increased compared with soluble antigen alone; in some instances 
a 30-fold increase in uptake can be achieved [191, 192]. Similarly, studies 
comparing differences in uptake between micro- and nano- PLA particles have 
found that uptake by APCs is significantly increased for NPs. Chithrani et al. 
investigated the dependency of gold NPs size on uptake into HeLa cells by 
incubating cells with a range of NP sizes (14-100 nm) and then measuring their 
gold content using inductively coupled plasma atomic emission spectroscopy. 
The results showed that the optimal size for uptake was 50 nm and uptake 
increased significantly for the first 2 hours before it plateaued at between 4 and 
7 hours post exposure [193]. Particle shape and surface charge are also 
important physicochemical factors playing crucial roles in the interaction 
between particles and APCs. In general, cationic particles are taken up into 
cells much more readily than those with an overall negative surface charge due 
to the anionic nature of cell membranes, whilst spherical compared to rod-
shaped particles are also more readily endocytosed [194-196]. 
As well as the degree of uptake, the mechanisms by which NPs enter 
cells will have a direct impact on the type of immune response induced. This too 
is dependent on NP size, composition, shape and charge [29, 197-199]. Whilst 
PLGA microparticles typically enter macrophages through phagocytosis, there 
are a variety of mechanisms by which NPs may be internalised. It has been 
suggested that 43 nm polymeric NPs are taken up by HeLa cells via clathrin-
dependent endocytosis, whilst 24 nm particles enter a cholesterol-independent, 
non-clathrin and non-caveolar dependent pathway [200]. NP shape can have a 
significant effect on the ability of macrophages to internalise particles via actin-
driven movement of the macrophage membrane. Subsequently the 
phagocytosis of rod-shaped particles is often negligible when compared to 
spherical NPs [197, 201]. Both polymer and gold cationic NPs have been shown 
to enter various mammalian cell lines via non-endosomal pathways using a 
range of pharmacological inhibitors or cell lines with endogenous proteins 
considered essential for a transport mechanism knocked-out [202-207]. 
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When poly(amino acid) NPs with encapsulated ovalbumin were used to 
immunise mice, significantly higher levels of total IgG, IgG1 and IgG2a were 
induced compared with the response to soluble ovalbumin, suggesting the 
particles have the ability to prime humoral and cellular immune responses since 
CD4+ and CD8+ T cell activation produces IFNγ which induce Ig class switching 
to IgG2a [98, 99, 208]. Similarly, the loading of Hepatitis B core antigen into 
PLGA NPs (300 nm) induced a stronger cellular immune response in a murine 
model compared to Hepatitis B core antigen administered alone. Particle size 
also plays an important role in directing the immune response. Immunization 
with PLA NPs (200–600 nm) was associated with higher levels of IFNγ 
production related to a Th1 response. In contrast, immunization with PLA 
microparticles (2–8 µm) promoted IL-4 secretion related to a Th2 response 
[209]. Both PLGA NPs and liposomes are efficiently phagocytosed by dendritic 
cells in culture, resulting in their intracellular localization [210-212]. 
VLP’s have been shown to produce strong humoral immune responses 
that are able to protect against human papillomavirus (HPV) infection in both 
animal models and human clinical trials using the HPV L1 protein [118, 213-
216]. Through mimicking the native viral structure, VLP based vaccines 
(including those against influenza A and HIV) are able to enhance the 
production of neutralising antibodies by presenting antigens in their natural state 
as membrane-bound proteins rather than soluble ectodomains [217, 218]. 
However, this is mostly type-specific and may not protect against infection with 
heterologous types. Furthermore, cell mediated immune responses were also 
achieved with HPV VLPs, including T cell proliferation (CD4+ and CD8+) [96, 
219]. There is also an association of increases in Th1 and Th2 type cytokines 
(IFNγ and IL-5, IL-10 respectively) stimulated with VLP immunisation [219, 220]. 
Once in vivo, particulate vaccine formulations of all types constitute an antigen 
depot, the effect of which is to allow a gradual release of antigens, prolonging 
exposure of the immune system to the antigen and essentially providing a 
booster dose. The pharmacokinetics/pharmacodynanics of each formulation will 
determine how slowly or otherwise antigen is released from the depot. In 
general though, particulate formulations confer benefits in terms of a reduced 
need for the administration of booster doses and a self-adjuvanting effect due to 
the enhanced uptake of particulates by APCs. 
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1.6 Limitations and ongoing questions 
The limitations of using NPs for the delivery of vaccines range from concerns 
over the toxicity of the particles, to difficulties in producing the materials and 
presenting antigens in their native form. The production of suitable NPs can 
also present some technical challenges. For other systems there are concerns 
over the stability or potential to scale up production. One of the greatest 
obstacles with liposome delivery systems is their instability [221, 222]. One of 
the ways in which this has been overcome is by modifying the surface with a 
hydrophilic polymer, such as glycol (e.g. polyethylene glycol, glycol chitosan). 
This serves as a barrier to reticuloendothelial system cells to extend its 
circulatory lifetime [223, 224]. The scale-up of production of sterile polymeric 
particles has also been problematic, though this has to some extent been 
overcome by the introduction of scaled-up spray-drying techniques. This allows 
polymer and payload, together with a stabiliser such as trehalose, to be sprayed 
at high temperature (80-100oC) through an orifice in clean room conditions [174, 
225]. This is a batch process, typically yielding hundreds of milligrams of 
product (depending on equipment size and operating conditions), but care 
needs to be taken that a protein payload will not be damaged by either the heat 
or shear force. One way around this is to spray-dry the polymer and 
subsequently surface-absorb the protein antigen(s).  Additionally, in order to 
overcome the risk of traces of unacceptable solvents in the final NP product, 
super-critical fluid technology is being applied to the generation of NP [226, 
227]. In this approach, the PLGA polymer is solubilised in super-critical fluid 
solvent (freon/propanol) and the solution is compressed under pressure prior to 
introduction of the aqueous phase containing, for example, the recombinant 
protein. Polymeric particles then form of typical size range 300 nm-3 m. 
An ongoing concern with the introduction of NPs into biomedical 
applications has been their potential toxicity, not least because some materials 
which would otherwise be considered safe take on different characteristics in a 
nanoparticulate form and can sometimes become harmful [228]., In its naturally 
occurring mineral state titanium dioxide, for example, is biologically inert 
however, when administered as a NP smaller than 20 nm in diameter it causes 
an inflammatory reaction in animals and humans [229, 230]. Similarly, gold is 
generally regarded as a safe, inert material and is used routinely for medical 
implants. However, gold NPs with a diameter of 1.4 nm behave very differently 
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and have been shown to permeate cells and nuclear membranes and bind 
irreversibly in the major grooves of DNA causing instability [231]. The same is 
not true of all gold NPs and those of a slightly larger diameter (15 nm) are 
considered non-toxic at up to 60-fold higher concentrations [184, 232-234].  
Other toxicity concerns associated with NP is the accumulation within 
cells, particularly with continuous exposure or long-term use. Indeed, 
fluorescent quantum dots have been observed in mice 2 years after injection 
[235]. As previously mentioned, the methods used to characterise cellular 
trafficking of NPs are often carried out using pharmacological inhibitors or 
mutant cell lines. The problem with these experiments is the specificity of the 
methods for one mechanism of trafficking, so the data can often be difficult to 
interpret or sometimes contradictory to other literature. For example, whilst 
Rejman  et al. show that  treating B16 cells with chlorpromazine strongly inhibits 
the uptake of negatively charged 50 nm  polystyrene NPS compared with 200 
nm particles, Santos et al. report an opposite result [198, 205]. In many cases it 
is perhaps best to use a combination of various inhibitors and mutated cell lines 
with carefully selected controls. Another problem associated with 
pharmacological inhibitors is their cell line specific efficacy, meaning that care 
must be taken when interpreting results from such studies and perhaps 
highlights the need for using several different cell lines to draw conclusions 
applicable to an in vivo model. 
There are also some more specific concerns about components used in 
NPs. Despite the number of veterinary vaccines which utilise ISCOMs, there are 
uncertainties over the toxicity of some saponin-based adjuvants and this has to 
date prevented their licensure for use in humans. The toxicity of Quil A for 
example, has been identified in murines at an LD50 of 0.67 mg/kg [236]. Similar 
results have also been documented with subcutaneous and intraperitoneal 
administration of Quil A [237, 238] where it is believed to cause degeneration of 
the liver [149]. However, this has so far only been documented in rodents, with 
little toxicity reported in larger terrestrial animals including rhesus monkeys, 
chickens, dogs and cattle [239-242]. 
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1.7 Objectives 
This study has been carried out to explore the use of gold nanoparticles as a 
vaccine delivery system. A variety of different size nanoparticles are considered 
and characterised according to their physicochemical properties to select an 
optimal size for antigen loading. The objective is then to explore methods for the 
chemical conjugation of peptides and polysaccharides (lipopolysaccharide and 
capsular polysaccharide) onto gold nanoparticles and identify an appropriate 
strategy. It is then the intention to evaluate the immunogenicity and protective 
capacity of these vaccines through a series of immunological assays and 
animal studies. Finally, this study aims to identify some of the underlying 
mechanisms involved in macrophage uptake of gold nanoparticles. 
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Chapter 2: Materials and Methods 
 
 
2.1 Gold nanoparticle synthesis 
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich Co. 
Ltd. (Gillingham, UK) and all solutions were prepared in ultrapure water (18 MΩ-
cm at 25 °C, MilliQ, Millipore). 
All nanoparticle synthesis reactions were performed in glass beakers 
cleaned with Aqua Regia (1 volume of HNO3 and 3 volumes of HCl) and 
thoroughly rinsed with de-ionised water. 
Citrate reduced gold nanoparticles were synthesised using the method of 
Turkevich [189, 243]. In a glass beaker, 90 mL 1 mM gold(III) chloride trihydrate 
(HAuCl4 ·3H2O, 99.9%) was heated to 90 °C. The solution was stirred vigorously 
with a Teflon® coated magnetic bar as 10 mL 90 mM sodium citrate dihydrate 
(Na3C6H5O7 ·2H2O, 99%) was added rapidly from a plastic syringe. The reaction 
underwent a colour change of gold to black, to colourless, to ruby red. Once the 
solution had reached this point it was allowed to cool to room temperature and 
then stored in the dark until needed. 
 Borohydride-reduced gold nanoparticles were also synthesised based on 
several previously published methods [244-247]. To 94 mL 1 mM gold(III) 
chloride trihydrate, 3 mL ice-cold sodium borohydride (NaBH4, ≥99%) was 
added rapidly at either 100 mM or 400 mM (final concentration 5 mM and 20 
mM, respectively) followed by continuous stirring for 2 hours. These colloidal 
solutions were stored at room temperature in the dark. 
 
2.2 Nanoparticle characterisation 
Transmission electron microscopy was performed on the resulting borohydride 
and Turkevich colloid samples to image the resulting particles and assess their 
size distribution. A 2-4 μL drop of nanoparticle colloid was placed directly onto a 
copper/palladium mesh grid with a formvar/carbon support film. After drying 
under a hot lamp, the nanoparticles were viewed at 80,000 x magnification in a 
Jeol JEM-1400 TEM and image capture was carried out using Digital Micrograph 
software (Gatan). Nanoparticle sizes were measured using the particle size 
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analysis function of the software. This method is based on a high contrast 
between the image background and the nanoparticles. The algorithm detects 
dark pixels, which are assigned as nanoparticles based on their large scattering 
cross section from their metallic composition, their shape and the measured 
diameter. The nanoparticle diameter is equivalent to the greatest dimension of 
each patch of dark pixels, thus, nanoparticle sizes determined in this way are 
given as ‘equivalent spherical diameter’. 
 UV-visible absorbance spectra were recorded for nanoparticle colloids 
using 1 cm optical path length plastic cuvettes and a UV-visible spectrometer 
(Jenway 6705 UV/Vis spectrophotometer). 
Nanoparticle tracking analysis were performed with a NanoSight LM20 
(NanoSight, Amesbury, United Kingdom), equipped with a sample chamber with 
a 640-nm laser and a Viton fluoroelastomer O-ring. The samples were injected 
in the sample chamber with sterile syringes (BD Discardit II, New Jersey, USA). 
All measurements were performed at room temperature. The software used for 
capturing and analyzing the data was the NTA 2.0 Build 127. 
 
2.3 Bacterial culture 
Bacterial cultures were carried out in Luria Broth (LB) containing 10 g/L 
Tryptone, 5 g/L yeast extract, 10 g/L NaCl and pH 7.5. The solid medium, Luria 
Agar (LA), contained 1.5 % (w/v) standard microbiological agar; both were 
sterilised by autoclaving at 121oC for 15 minutes. All liquid cultures were 
incubated at 37oC, aerobically on a rotary shaker at 200 rpm.  
Optical density (OD) was preferentially used to monitor bacterial growth 
and replication. The OD of bacterial cultures at 600 nm (OD600) was measured 
in 1 cm optical path length cuvettes with a UV-Visible Spectrophotometer 
(Jenway). Alternatively, bacterial viable cell numbers were measured as colony 
forming units (CFU). For this, a sample of culture was 10-fold serially diluted in 
¼-strength Ringer’s solution (7.2 g/L NaCl, 170 mg/L CaCl2 and 370 mg/L KCl 
in ultrapure water, pH 7.2) and a known volume of each dilution was spread 
onto LA medium in a petri dish. Colonies were counted after an overnight 
incubation at 37oC. 
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2.4 Protein expression and purification 
Untagged recombinant F1-antigen was produced in E. coli JM101 containing 
plasmid pAH34L encoding the caf operon from Y. pestis strain GB and cultured 
in LB containing 50 µg/mL kanamycin [248]. The cultures were centrifuged at 
14,000 × g for 45 minutes at 4 °C and the cell pellet and flocculant layer 
resuspended in 200 mL phosphate-buffered saline (PBS), pH 7.2 and incubated 
with gentle rolling at room temperature for 30 minutes. The resuspension was 
centrifuged at 14,000 × g for 30 minutes and the supernatant was adjusted to 
50% ammonium sulphate saturation. After stirring for 1 hour, the fractionate was 
centrifuged at 14,000 × g for 30 minutes at 4 °C. The ammonium sulphate pellet 
was resuspended in PBS and dialysed against 4 × 2 L of the same buffer, 
overnight. The dialysed crude extract was centrifuged at 27 000 × g to remove 
insoluble material, followed by filter sterilisation using a 0.22-μm disposable 
filter (Amicon, Stonehouse, UK). Aliquots of 200 μL of the dialysed extract were 
applied to an FPLC Superose 12 HR 10/30 column that had been previously 
equilibrated with PBS. The rF1 was eluted with the same buffer at a flow rate of 
0.5 mL/minutes. Peak fractions were collected and analysed for F1 by SDS-
PAGE, Native PAGE and Western blotting (using a monoclonal antibody raised 
to F1). An enzyme-linked immunosorbent assay was performed to determine 
the concentration of F1 antigen produced, using purified F1 antigen from Y. 
pestis as a standard [249]. 
His-tagged recombinant TetHc was produced in E. coli BL21 containing 
plasmid pKS1 encoding the Hc fragment of TeNT from Clostridium tetani strain 
and cultured in LB containing 50 µg/mL kanamycin [250]. The cultures were 
grown to early log phase before the plasmid was induced with 1 mM IPTG for 4 
hours at 37 °C. The cultures were centrifuged at 14 000 x g for 20 minutes at 4 
°C and the cell pellet and flocculant layer resuspended in 100 mL BugBuster® 
(mixture of non-ionic detergents) solution, 30 Ku/µL lysozyme, 25 u/µL 
benzonuclease and 1 EDTA-free protease inhibitor tablet before incubating with 
gentle rolling at room temperature for 30 minutes. Insoluble cell debris was 
removed by centrifuging at 16,000 x g for 20 minutes at 4 °C and supernatant 
was added to HisBind column. The TetHc peptide was desalted in a PD10 
buffer exchange column before concentrating in a vivaspin 6 column at 4,000 x 
g for 20 minutes at 4 °C. The resulting solution was collected and analysed for 
TetHc by SDS-PAGE, and Western blotting (using a monoclonal antibody 
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raised to TetHc). A bicinchoninic assay (BCA) assay was performed to 
determine the concentration of TetHc antigen produced, using purified BSA as a 
standard. 
His-tagged recombinant Hcp1 (BMA_A0742; residues 1-169) from B. 
mallei  was expressed in E.coli (λDE3) Rosetta containing pET28a (+) 
expression vector (Novagen) and cultured in Overnight Express instant TB 
medium (Novagen) for 18-20 hours [251]. The culture was lysed using 10 x 
CelLytic B (Sigma) and purified by Ni2+ affinity chromatography. The Hcp1 
peptide was dialysed against two changes of 10 mM Hepes/150 mM NaCl pH 
7.4 and run on an SDS-PAGE to check for purity before being aliquoted and 
stored at -80 °C [251]. A bicinchoninic assay (BCA; Pierce) assay was 
performed to determine the concentration of the antigen produced, using 
purified BSA as a standard. 
His-tagged recombinant FliC (BPSL3319) from B. pseudomallei  was 
expressed in E. coli (λDE3) Rosetta containing pET28a (+) expression vector 
(Novagen) and cultured in Overnight Express instant TB medium (Novagen) for 
18-20 hours [251]. The cultures were lysed using 10 x CelLytic B (Sigma) and 
purified by Ni2+ affinity chromatography. The FliC peptide was dialysed against 
two changes of 10 mM Hepes/300 mM NaCl pH 7.4 and run on an SDS-PAGE 
to check for purity before being aliquoted and stored at -80 °C [251]. A 
bicinchoninic assay (BCA) assay was performed to determine the concentration 
of the antigen produced, using purified bovine serum albumin (BSA) as a 
standard. 
Purification of B. mallei and B. pseudomallei proteins was carried out by 
collaborators at the University of Texas, Austin, USA. 
 
2.5 Glycoconjugate quantification 
Confirmation of nano-glycoconjugate formation was done by measuring the 
absorbance spectra using a UV-visible spectrometer (Bio-Rad 680 microplate 
reader) where a red-shift in λmax of AuNPs was indicative of coupling to the 
surface. A two-colour Western blot was also performed, where possible, using a 
rabbit polyclonal antibody (pAb) raised against TetHc and either a mouse mAb 
against LPS or rabbit sera against CPS (Statens Serum Institut; Denmark) 
before incubating with a goat secondary antibody raised against either rabbit or 
mouse, tagged with an infrared dye at 680 nm or 800 nm (LI-COR®), 
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respectively. The two infrared channels could then be viewed simultaneously on 
an Odyssey® CLx. Protein concentrations were measured using a BCA assay. 
A modified version of a phenol-sulphuric acid assay was performed to 
determine the concentration of LPS conjugated onto AuNPs [262, 263]. As 
previously described, the MHDA linker attached to the AuNP surface was 
displaced using 11-mercapto-1-undecanol and the gold colloid removed by 
centrifugation. Next, 50 µL of cleaved LPS or CPS was added in triplicates to a 
96-well micro-titre plate alongside a known concentration of LPS or CPS. To 
each sample, 150 µL concentrated H2SO4 was added followed by the rapid 
addition of 30 µL 5% (w/v) phenol. The plate was covered and carefully floated 
on a static water bath for 5 minutes at 90 °C before cooling to room temperature 
and reading on a micro-titre plate reader (Bio-Rad 680 microplate reader) at 
490 nm. In addition to using an LPS standard, a monosaccharide mixture of β-D 
glucose and β-D galactose (a C2 epimer of talose) in a 0.8:1 molar ratio was 
chosen to reflect the β-D glucopyranose and α-L talopyranose composition of B. 
thailandensis LPS [264]. 
Since the centrifugation method of purifying AuNP conjugates was not 
completely efficient, a dilution of AuNPs matching the absorbance of cleaved 
polysaccharide at λmax was added to the standards to control for the effects 
AuNPs have on colorimetric assays. 
 
2.6 Immunisation/protection studies 
Chapter 3 Groups of 5 female 6-8 week old BALB/c mice were immunized once 
with 0.1 mL per mouse by the intra-muscular (IM) route: group 1 received  0.93 
µg F1-antigen conjugated NPs formulated in 0.26% (w/v) alhydrogel (AuNP-
F1/alhy); group 2 received 0.93 µg rF1-antigen conjugated NPs in PBS (AuNP-
F1/PBS); group 3 received empty NPs in PBS (NP/PBS); group 4 received 0.93 
µg F1 formulated in 0.26% (w/v) alhydrogel (F1/alhy); and group 5 received 
0.93 µg F1 in PBS (F1/PBS). Mice were bled from the lateral tail vein each 
week to obtain blood for antibody analysis. Mice were euthanized after six 
weeks with terminal blood sampling and splenectomy. Animal handling and 
immunisations were carried out by collaborators at the defence, science and 
technology laboratory (DSTL). 
Chapter 4 Groups of 9 female 6-8 week old BALB/c mice which were 
immunised three times at two-weekly intervals, receiving 0.1 mL per mouse by 
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the intra-peritoneal (IP) route. One week after the final boost, mice were bled 
from the lateral tail vein to obtain blood for antibody analysis. Three weeks after 
the final boost, the mice were challenged by the intranasal (IN) route with 2.27 x 
105 CFU 50 µL-1 (3 x LD50) B. mallei strain ATTCC 23344 (China 7). 
The groups of mice were as follows: group 1 received  AuNPs 
conjugated with 0.93 µg F1-antigen (NP-F1); group 2 received  AuNPs 
conjugated with 0.93 µg F1-antigen and 0.93 µg LPS (NP-F1-LPS); group 3 
received AuNPs conjugated with 0.93 µg TetHc (NP-TetHc); group 4 received 
AuNPs conjugated with 0.93 µg TetHc and 0.93 µg LPS (NP-TetHc-LPS); group 
5 received AuNPs conjugated with 0.93 µg LPS (NP-LPS); group 6 received 
0.93 µg LPS (LPS) and group 7 received PBS (PBS). All of the vaccine 
materials were formulated in PBS with 0.26% (w/v) alhydrogel. 
Mice were euthanized after three weeks when terminal blood sampling, a 
splenectomy and a lobectomy were performed at the end of the experiment. 
The protection study and organ removal were performed by collaborators at the 
University of Texas Medical Branch, Galveston, USA. 
Chapter 5 Groups of 6 female 6-8 week old MF1 mice were immunised 
by the subcutaneously (SC) route, three times bi-weekly receiving; 0.5 µg CPS 
conjugated to AuNPs (AuNP-CPS), 1 µg TetHc conjugated to AuNPs (AuNP-
TetHc), 0.5 µg CPS conjugated to 1 µg TetHc on AuNPs (AuNP-TetHc-CPS), or 
Prevnar 13® (Pfizer). Prevnar 13 contains 0.44 µg CPS serotype 3 in a 100 µL 
dose. One week after the final boost, mice were bled from the lateral tail vein to 
obtain blood for antibody analysis. Four weeks after the final boost, the mice 
were challenged by the intranasal route with 2.5 x 105 CFU 50 µL-1 S. 
pneumoniae strain Xen10. All of the vaccine materials were formulated in PBS 
with 0.26% (w/v) alhydrogel. Mice were euthanized after 10 days or at an earlier 
time point if clinical symptoms deemed it appropriate. 
 
2.7 Immunoanalysis 
Chapter 3 Serum from individual animals were assayed for F1-specific IgG titre 
using an enzyme-linked immunoassay (ELISA) [265]. Briefly, sera were 
aliquoted into microtitre wells pre-coated with 5 µg/mL F1 (in PBS). Binding of 
serum was detected using an HRP-conjugated goat anti-mouse IgG, anti-
mouse IgG1 or anti-mouse IgG2a (Abcam; 1:5000 in 1% skimmed milk in TBS) 
followed by incubation (37 °C, 1 hour). ABTS substrate was added (Pierce) and 
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the absorbance measured at 415 nm using a Multiskan plate reader. Titres 
were determined by comparison with a standard curve using Ascent software. 
Geometric mean titres were determined ± standard error of the mean for each 
treatment, allowing a statistical comparison of mean titres between groups, 
using the Student’s t-test. 
A method for detecting antibody binding competition to F1-antigen with a 
protective polyclonal macaque serum was based on Williamson et al., 2005 
[266]. F1-antigen was coated (5 µg/mL) onto microtitre plate wells followed by 
the addition binding of reference serum at a 1:10 dilution. Individual sera were 
added in duplicate in a 2-fold dilution series in 1% (w/v) skimmed milk powder in 
TBS. Naive macaque serum was used as a negative control. HRP-conjugated 
goat anti-mouse IgG (Abcam; 1:5000 in 1% skimmed milk in TBS) was added 
followed by incubation (37 °C, 1 hour). Plates were washed prior to the addition 
of ABTS substrate (Pierce) with subsequent reading of the absorbance at 415 
nm. 
Chapter 4 Sera was collected from animals 5 weeks post immunisation 
and assayed for antibody isotypes and IgG subclasses using an ELISA [265]. 
Microtitre plate wells were incubated with 50 µL 5 µg/mL LPS and an anti-
mouse Fab-specific antibody (both in PBS) overnight at 4 °C. The following day 
the plate was washed with 0.05% (v/v) Tween 20 in PBS and the wells blocked 
with 200 µL 3% (w/v) skimmed milk powder in PBS for 1 hour at 37 °C before 
washing again with Tween/PBS. Serum samples were diluted to 1:100 in 1% 
(w/v) skimmed milk powder in PBS before doing a 2-fold serial dilution on the 
plate. The appropriate antibody isotype or IgG subclass was diluted across the 
wells coated with anti-mouse antibody to construct a standard curve. Serum 
from mice given PBS was used as a negative control. The plate was incubated 
at 37 °C for 1 hour before it was washed three times with Tween/PBS. An 
appropriate isotype or IgG subclass specific goat anti-mouse horseradish 
peroxidise conjugate was added to the wells at a dilution specified by the 
manufacturer (Abam) followed by incubation at 37 °C for 1 hour. The plate was 
washed a further three times with Tween/PBS before adding an ABTS substrate 
(Pierce). The absorbance from the wells was measured at 415 nm using a 
Multiskan plate reader. Titres were determined by comparison with a standard 
curve using Ascent software. Geometric mean titres were determined ± 
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standard error of the mean for each treatment with a 95 % confidence limit, 
allowing a statistical comparison of mean titres between groups. 
Spleen and lungs were removed at the end of the experiment where they 
were then homogenised in Dulbecco’s Modified Eagles Medium before plating 
out onto media selective for B. mallei. Colony counts were performed and 
compared with relative tissue mass before they were plotted on a histogram and 
comparative statistics were carried out. 
Chapter 5 Serum was collected from animals 5 weeks post immunisation 
and assayed for antibody subclasses and IgG isotypes using an ELISA [265]. 
Briefly, microtitre plate wells were incubated with 5 µg/mL CPS and an anti-
mouse Fab-specific antibody (both in PBS) overnight at 4 °C. The following day 
the plate was washed with 0.05% (v/v) Tween 20 in PBS and the wells blocked 
with 200 µl 3% (w/v) skimmed milk powder in PBS for 1 hour at 37 °C before 
washing again with Tween/PBS. Serum samples were diluted to 1:100 in 1% 
(w/v) skimmed milk powder in PBS and diluted 2-fold down the plate. The 
appropriate antibody isotype or IgG subclass was diluted across the wells 
coated with anti-mouse antibody to construct a standard curve. Serum from 
mice given PBS was used as a negative control. The plate was incubated at 37 
°C for 1 hour before it was washed three times with Tween/PBS. An appropriate 
isotype or IgG subclass specific goat anti-mouse horseradish peroxidise 
conjugate was added to the wells at a dilution specified by the manufacturer 
(Abam) followed by incubation at 37 °C for 1 hour. The plate was washed a 
further three times with Tween/PBS before adding an ABTS substrate (Pierce). 
The absorbance from the wells was measured at 415 nm using a Multiskan 
plate reader. Titres were determined by comparison with a standard curve using 
Ascent software. Geometric mean titres were determined ± standard error of the 
mean for each treatment, allowing a statistical comparison of mean titres 
between groups. 
 
2.8 Flow cytometric analysis 
Spleens from individual mice were homogenised in Dulbecco’s Modified Eagles 
Medium supplemented with L-glutamine, penicillin and streptomycin and the 
suspension splenocytes washed by centrifugation (10,000 rpm; 5 minutes) prior 
to collecting the cell pellet and re-suspending the cells in DMEM supplemented 
as described above, with additional 10% (v/v) foetal calf serum. Live 
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splenocytes were enumerated and 200 µL of each was aliquoted in duplicate to 
the wells of a 96-well plate, and F1-antigen was added to each well at a final 
concentration of 25 µg/mL. Plates were incubated overnight (37 °C/5% CO2). 
The following day, plates were centrifuged and cell culture supernatants were 
collected and frozen (-80oC) pending analysis of cytokines by cytometric bead 
assay (Becton Dickinson, UK). Non-adherent splenocytes were removed after 
centrifugation, collected and stained with a mastermix of antibodies specific for 
surface markers CD3, CD4, CD8 and CD45, and each labelled with a different 
chromophore (Becton Dickinson, UK). Antibody-bound cells were analysed by 
fluorescence activated cells sorting (Cantifluor, Becton Dickinson, UK) and the 
percentage and activation status of cells in the mixed splenocyte suspension 
was determined. Splenectomy and flow cytometry was carried out by 
collaborators at DSTL. 
 
2.9 Live in vivo imaging 
The use of S. pneumoniae bioluminescence strain Xen10 enabled in vivo 
imaging of bacteria to track the progression of the disease. This was done by 
anaesthetising mice with nitrous oxide at given time points and imaging using 
an FxPro imaging system. 
 
2.10 Transmission electron microscopy 
The procedures used to prepare J774A.1 murine macrophages for 
electron microscopy imaging have been previously described [267-269]. Cells 
were grown on 3 cm glass bottom Mattel Petri sides (Mattek Co., USA) at a 
density of 2 x 105 and incubated overnight (37 °C/5% CO2). The following day, 
plates were incubated with 15 nm AuNPs for one hour before they were fixed 
with 4% paraformaldehyde (EM grade) and 1% glutaraldehyde (EM grade, 
TAAB, England) in 0.1 M cacodylic buffer  pH 7.2 for 10 minutes, then for a 
further 30 minutes in  4% paraformaldehyde (EM grade) in 0.1 M 
cacodylic buffer  pH 7.2. Cells were then washed in PBS for 10 minutes and 
then in distilled water for 10 minutes, two times. The cells were incubated in 1% 
osmium tetroxide (TAAB) in water for 1 hour in the dark (to counter-fix the 
membranes). The cells were then washed in distilled water 3 times, 10 minutes 
each. Uranyl Acetate (SIGMA, England) 1% in water was added for 1 hour. 
After washing with distilled water 3 times, 5 minutes each, the cells were 
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dehydrated in water/ethanol series 10 minutes each 50, 70, 90, and 100% 
(100% was repeated 3 times). After that the cells were incubated 
in ethanol/Epon812 (EMS, England) 1/1 for 1 h, and then in pure resin Epon812 
for a further 1 h. The cells with fresh resin were incubated in an oven at 65ºC for 
24 hours. Once the cells were incorporated into the resin block, thin (70 nm) 
sections cut with UltraCut-UCT (Leica, Netherlands) microtome were collected 
onto Formvar-coated copper slot grids and post-stained [with aqueous uranyl 
acetate or Reynold’s lead citrate (EMS)] to enhance contrast/visualization. Thin 
sections were surveyed using a JEOL 1014 electron microscope (JEOL, Japan) 
operated at 80 kV to assess the quality of ultrastructural preservation, collect 
sets of 2D images. 
 
2.11 Fluorescent particles 
Enhanced green fluorescent protein (eGFP; BioVision) was coupled onto 
AuNPs using the previously described carbodiimide coupling chemistry and 
characterised using previously described methods of UV/Vis spectrophotometry 
and band densitometry. 
 
2.12 Phagosomal staining 
The procedures used to prepare J774A.1 murine macrophages for 
confocal microscopy imaging were as follows. Cells were grown on 35 mm 
glass bottom, uncoated, µ-dish  (Thistle scientific) at a density of 2 x 105 and 
incubated overnight (37 °C/5% CO2). The following day, plates were washed 
with PBS for 10 minutes, three times before they were incubated with eGFP 
conjugated AuNPs for 2 hours and then fixed with 4% paraformaldheyde. The 
cells were washed with PBS for 10 minutes, three times, before adding a 
blocking/permeabilisation solution containing 0.2% saponin and 5% foetal 
bovine serum (FBS) in PBS for 10 minutes at room temperature. Following this, 
the cells were washed thoroughly with PBS for 10 minutes, three times. The 
presence of endosomal vesicles was detected using a rabbit anti-LAMP1 
polyclonal (Abcam; 1:1000 in 0.2% saponin and 5% FBS in TBS) followed by 
incubation (4 °C, 2 hours). The cells were washed with PBS for 10 minutes, 
three times before adding a Cy5 conjugated goat anti-rabbit polyclonal antibody 
(Abcam; 1:5000 in 0.2% saponin and 5% FBS in TBS) followed by incubation in 
the dark (4 °C, 2 hours). The cells were washed with PBS for 10 minutes, three 
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times before adding 1 drop of DAPI containing vectashield (Vector laboratories) 
to stain the cell nuclei. Cells were surveyed using a Zeiss LSM510 Meta 
confocal-laser scanning microscope (Zeiss, USA) to assess the localisation of 
AuNPs with endosomal compartments. 
 
2.13 Statistical analysis 
Statistical differences between mean values were calculated using an unpaired, 
two-tailed Student’s t-test or a one-way ANOVA with orthogonal contrast. A 
Mantel-Haenszel test was used to compare survival curve data. A p value of ≤ 
0.05 was considered significant. 
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Chapter 3: Protein Antigens Coupled to Gold 
Nanoparticles 
 
 
3.1 Introduction 
 
3.1.1 Gold nanoparticles 
The use of nanomaterials for biomedical purposes has increased significantly 
over the last 50 years with composites varying in size, shape and material. 
Gold, in particular, has attracted much interest due to its unique optical 
properties for imaging and site-directed release of drugs or antigens as well as 
being non-toxic and biocompatible [231, 270-274]. There are also established 
techniques for the fabrication of gold nanofibres (nanorods or nanotubes) and 
nanoparticles of various sizes with limited size dispersity [275]. The versatility 
and structural diversity of gold nanomaterials allows for a variety of approaches 
towards their application in therapy, biosensing and diagnostics. In this study, 
colloids were chosen over nanofibres based on their uniform presentation of 
antigens and uptake into APCs. 
 
3.1.2 Nanoparticle characterisation 
With a variety of methods available for synthesising nanoparticles of different 
shapes, sizes and compositions, it is important to be able to characterise 
accurately their physicochemical properties. Characterisation can be done using 
a variety of techniques; those which are relevant to this study are detailed 
below. 
 Electron microscopy is one of the most commonly used techniques for 
determining the size and shape of nanoparticles. Unlike optical microscopes 
which have a limited resolution of approximately 0.2 µm, electron microscopes 
are able to achieve better than 50 pm resolution. This is because electron 
microscopes utilise the electro-magnetic wave properties of electrons rather 
than visible light. Whereas the minimum wavelength for visible light is 
approximately 400 nm, for electrons operating at an accelerating potential of 
100 kV the minimum wavelength is approximately 1.2 pm, Equation 3.1. In this 
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study, transmission electron microscopy (TEM) was used to image gold 
nanoparticles in which a beam of electrons are accelerated through a vacuum 
and interact with the specimen. The resulting image is based on the diffraction 
of electrons as they pass through the specimen, although for gold nanoparticles 
this appears as an electron shadow as the electrons are unable to pass directly 
through. As well as providing a visual representation of nanoparticles, the mean 
size and distribution of particle size can also be measured using analytical 
software. 
 
 
 
 
 
 
 
Optical spectroscopy is a useful technique for determining the structure and 
composition of gold nanoparticles, where the extinction (absorbance and 
scattering) spectrum is dominated by a localised surface plasmon resonance 
(LSPR). This is also the property which gives colloidal gold its vibrant colours 
[276, 277]. In the presence of an incidence light, the surface plasmon is made 
up of oscillating free electrons on the metal surface which have a resonant 
frequency dependent on the size, shape and material of nanoparticles [278]. 
Consequently, the plasmon is sensitive to changes at the NP surface and is 
limited by the penetration depth of LSPR which is approximately 90 nm [279]. 
An association between plasmonic shifts and NP surface functionalisation 
means that this property can be exploited for determining the association of 
biomaterials and is exclusive of the surrounding media [274, 280, 281]. The 
result is a change in the wave propagation and therefore the position and 
intensity of the wavelength of maximum extinction (λmax) [282, 283]. The ability 
to characterise the NP surface using LSPR has been demonstrated both 
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theoretically and experimentally where λmax for coupled nanoparticles is 
significantly red-shifted from that of individual particles [278]. This also makes 
optical spectroscopy a useful method for measuring the stability of 
nanoparticles in suspension. The stability of nanoparticles is dependent on the 
electrostatic repulsion between particles due to surface ions or ligands. This can 
also be defined by the Hamaker constant, characterised by the polarisability of 
nanoparticles and the surrounding medium, which for metal nanoparticles is 
relatively large [284-286]. For spherical nanoparticles, the LSPR signal displays 
as a single peak due to a uniform surface polarization. However, for other 
nanomaterials with less symmetry, the LPSPR signal intensity reduces, λmax 
red-shifts and multiple peaks appear due to an increase in charge separation, 
Figure 3.1 [287, 288]. 
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Figure 3.1. The spectral properties of LSPR are dependent on size and shape 
of nanomaterials. The number of modes in which a nanomaterial can be 
polarised determines the number of LSPR peaks. Therefore spherical particles 
exist as a single peak whereas non-spherical particles exhibited multiple red-
shifted peaks. Image adapted from Hong et al. [289]. 
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3.1.3 Protein-based vaccines 
Protein-based vaccines (including toxins) have an advantage over other 
microbial component-based vaccines, such as polysaccharides and nucleic 
acids, in that they are recognised by T cells; an essential part of developing 
immunological memory. This is a result of peptide presentation on MHC I or 
MHC II molecules on the surface of APCs which activate CD8+ and CD4+ T 
cells respectively. Protective protein antigens are commonly membrane-bound 
to the pathogen and identified using a combination of genetic and 
immunoproteomic techniques such as two-dimensional electrophoresis and 
mass spectrometry. Whilst the first protein-based vaccines relied on purifying 
antigens from the hepatitis B virus (HBV) infected blood of human carriers, 
recent applications utilise recombinant DNA technology [290]. A diverse range 
of prokaryotic and eukaryotic cell lines have since been employed to express 
antigens which are then isolated to a high level of purity. The HBV vaccine later 
became the first licensed recombinant subunit vaccine in 1987 after its 
successful expression and purification in Saccharomyces cerevisiae [291, 292]. 
However, as previous discussed, protein-based vaccines often require an 
adjuvant to boost their immunogenicity. For the HBV vaccine, an alum-based 
adjuvant is commonly administered alongside immunisation. 
Other subunit vaccines benefit from particulate vaccine delivery systems 
which adjuvant the immune response, such as VLPs. A vaccine against the 
human papillomavirus (HPV) consists of a surface protein, L1, from either two 
or four strains of the virus [293, 294]. The protein is then recombinantly 
expressed in S. cerevisiae, a well characterised eukaryotic cell line, after which 
it spontaneously self-assembles into an empty capsid, or VLP. In some 
instances proteins themselves can have an adjuvantal effect and are covalently 
coupled or fused to antigens. Commonly referred to as ‘protein carriers’, these 
are often bacterial toxoids such as diphtheria and tetanus toxoid which are 
truncated, non-toxic forms of the original exotoxins. Diphtheria and tetanus 
toxoid are described as having universal Th epitopes, capable of eliciting both 
Th1 and Th2 responses [295-298]. As well being used in prophylactic 
formulations, tetanus toxoid has been studied as an immunotherapeutic vaccine 
against chronic HBV infection. By coupling tetanus toxoid to the HBV core 
protein, the vaccine was shown to elicit higher levels of HBV-specific Tc cells 
which play a key role in clearing infection [299]. A major structural protein of 
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Gram-negative flagella, FliC (flagellin), has also been studied for its adjuvantal 
role in vaccine formulations [300-303]. This has been attributed to its high 
affinity binding to TLR5, which plays a fundamental role in activating innate 
immunity [304, 305]. Through the induction of cytokines and chemokines, 
flagellin increases the recruitment of B and T lymphocytes to draining lymph 
nodes resulting in enhanced activation of B cells and the generation of plasma 
and memory cells [306, 307]. 
 
3.1.4 Objectives 
Whilst there are a wide variety of NP types to choose from, gold NPs are the 
subject of this study due to their excellent biocompatibility and low cytotoxicity 
[308]. The aim of this chapter will be to identify a gold nanoparticle composite 
suitable for vaccine delivery by comparing the physicochemical properties of 
different size gold colloids. A method of conjugating gold nanoparticles with 
previously identified antigenic peptides will then be explored with an aim to 
characterise the amount loaded and optimise the chemistry. The 
immunogenicity of a gold nanoparticle-antigen construct will then be assessed 
using a variety of immunological assays on sera derived from immunising 
BALB/c mice. 
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3.2 Materials and Methods 
 
3.2.1 Coupling chemistry for proteins onto gold nanoparticles 
Recombinant peptides were immobilised onto AuNPs using carbodiimide 
coupling chemistry. This was done by adding 0.1 mM 16-
mercaptohexadecanoic acid (MHDA) followed by 0.1% (v/v) Triton® X-100 to a 
gold nanoparticle solution and incubated for 4 hours at room temperature. The 
mixture was centrifuged at 13,000 x g for 10 minutes, the supernatant removed 
and the pellet re-suspended in 50 mM 2-(N-morpholino)ethanesulfonic acid 
(MES) buffer pH 5.5, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS, 98%), 0.6 mM and 0.15 
mM respectively were added before further adding the recombinant protein at 
the optimal concentration. The solution was incubated at room temperature for 
18 hours. 
Protein was added to the functionalised nanoparticles at a range of 
concentrations (10-100 µg/mL). The optimal concentration required to coat the 
gold nanoparticles was determined by those that did not undergo a colour 
change from burgundy to blue when 10% (w/v) NaCl was added to the solution. 
The appropriate concentration of protein was then used for conjugating to 
nanoparticles in further studies. 
 
3.2.2 Purifying protein conjugated nanoparticles 
Attempts at removing free protein from conjugates were first made using gel 
filtration chromatography. Solutions of F1- and TetHc-AuNP were added to 
Sepharose® 4B-cross linked chromatographic resin (GE Healthcare) in a 1.5 X 
30 cm2 column (flow rate of 1.3 ml minute-1). Eluted fractions of 0.5 mL were 
collected and their UV/Vis absorbance was measured at 280 and 520 nm. 
Centrifugation was also used to separate unbound protein by adding 
1.76 mM Triton X-100TM and spinning at 14,500 rpm for 10 minutes. AuNP 
conjugated proteins were resuspended in PBS with or without 0.26% (w/v) 
alhydrogel. 
 
3.2.3 Protein quantification 
Conjugated protein was released from AuNPs by displacing the MHDA linker 
from the gold using 0.1 mM 11-mercapto-1-undecanol (99%, Sigma-Aldrich) 
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and incubating at room temperature for 4 hours. The sample was separated 
through a NuPAGE® 4-12% Bis-Tris gel alongside known amounts of protein, 
before staining with Coomassie blue. Band densitometry, relative to a known 
standard, was used to determine the mass of protein released from the AuNPs. 
A BCA assay was used to support band densitometry data.  
Coupling of proteins to AuNPs was confirmed by measuring shits to the 
refractive index (RI) of AuNPs derived from the UV-visible absorbance spectra 
over the wavelength recorded. 
Matrix assisted laser desorption/ionisation (MALDI) time-of-flight (ToF) 
mass spectrometer (Applied Biosystems, Framingham, USA) was employed to 
measure the mass of gold nanoparticles with and without conjugated protein. 
Mass analysis was performed using a 355 nm Nb:YAG laser in positive reflector 
mode with a 20 kV acceleration voltage [252]. 
 
3.3 Results 
 
3.3.1 Gold nanoparticle synthesis and characterisation 
Citrate reduction of gold (III) cations was shown to form spherical nanoparticles 
in a thermally induced reaction where the diameter of the particles was 
controlled by the concentration of citrate. The particles remain stable due to an 
electrostatic repulsion of the citrate coated anionic surface of the gold 
nanoparticles [309]. NP size was measured using the particle size analysis 
function from TEM software (Gatan).This identified that those particles 
synthesised via strong borohydride reduction (20 mM) were spherical in 
appearance and had a broad distribution of particles sizes. They had a mean 
diameter of 5.3 ± 4.3 nm and a modal diameter of 2-3 nm, Figure 3.2. Gold NPs 
reduced using sodium citrate were also spherical but had a much narrower size 
distribution. The mean diameter of these particles was 15.6 ± 2.3 nm with a 
modal diameter of 14 nm, Figure 3.3. Weak borohydride (5mM) reduction of 
gold (III) formed NPs with a truncated icosahedral shape and large size 
distribution. The mean diameter of these particles was 45.6 ± 17.4 nm with a 
modal diameter of 35-39 nm, Figure 3.4. To determined the dispersity of NP 
size distribution, the coefficient of variation (that is, CV = σ/d where σ and d are 
the standard deviation and the mean size, respectively) was calculated whereby 
a CV of <5% is considered monodisperse and <15% indicates near 
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monodispersity [310]. Of the three NPs synthesised in solution, the two 
borohydride reduced NPs had a CV of 82% and 38% for 20 mM and 5 mM, 
respectively. Citrate reduced NPs had a CV of 14% meaning they were near 
monodisperse, whilst the other two solutions were polydisperse. 
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A      B 
 
Figure 3.2. Transmission electron  micrograph of gold nanoparticles formed by 
strong (20 mM) NaBH4 reduction (A) and histogram showing size distribution of 
particles (B). Bar is 50 nm 
 
A      B 
 
Figure 3.3. Transmission electron  micrograph of gold nanoparticles formed by 
sodium citrate (9 mM) reduction (A) and histogram showing size distribution of 
particles (B). Bar is 100 nm 
 
A      B 
 
Figure 3.4. Transmission electron micrograph of gold nanoparticles formed by 
weak (5 mM) NaBH4 reduction (A) and histogram showing size distribution of 
particles (B). Bar is 100 nm  
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Further characterisation of gold NPs was carried out by measuring their 
extinction spectra in a spectrophotometer and recording the wavelength at 
maximum extinction (absorbed/scattered (λmax)). The position and shape of the 
extinction profile is dependent on the size, shape and composition of NPs. As 
expected from the TEM data, colloids synthesised using borohydride reduction 
had broad extinction peaks with λmax at 505 and 555 nm for strong and weak 
NaBH4 reduction respectively. Citrate reduced gold NPs gave a single, narrow 
extinction peak with λmax at 519 nm, Figure 3.5. As citrate reduced NPs 
consistently demonstrated a spherical shape and narrow size distribution it was 
therefore decided that only citrate reduced NPs would be used for further study, 
which are herein referred to as AuNPs. 
The stability of AuNPs was measured over 300 days by recording the 
extinction spectra, Figure 3.6. Whilst λmax of 519 nm remained fairly constant (± 
0.94 nm) for the time period chosen, overall absorption fell by over 50% after 
180 days. This could be due to small changes in pH over time, causing some of 
the particles to aggregate and sediment which would reduce the concentration 
of particles in solution and subsequently the overall absorption. The maximum 
extinction for AuNPs over time was recorded to demonstrate the half-life of 
particles, which was approximately 200 days, Figure 3.7. As a result, a fresh 
batch of AuNPs was prepared every 6 months. Using NP tracking analysis by 
NanoSight NS500, which relates the rate of Brownian motion to particle size, 
the concentration of AuNPs was measured to be 1.37 x 1012 particles mL-1. 
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Figure 3.5. UV-visible extinction spectra for gold nanoparticles formed by 
reduction of gold (III) cations using either sodium borohydride (NaBH4) or 
sodium citrate. 
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Figure 3.6. UV-visible extinction spectra for citrate reduced gold nanoparticles 
over a 300 day period. 
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Figure 3.7. Maximum extinction of AuNPs over time, demonstrating the half-life 
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3.3.2 Peptide coupling and purification of nano-conjugates 
To prepare the AuNPs for conjugation to a protein carrier, 16-
mercaptohexadecanoic acid (MHDA), consisting of a thiol group at one end and 
a carboxyl group at the other, was added to the AuNP solution. The thiol groups 
in this molecule readily bind to gold resulting in a self assembled monolayer 
with projecting carboxyl groups. Carbodiimide chemistry was employed to carry 
out protein conjugation onto an MHDA linker attached to the surface of AuNPs. 
In this reaction, the terminal carboxyl group from MHDA reacts with EDC to 
form a mixture of unstable O-acylisourea intermediate isomers. These are 
susceptible to nucleophilic attack from primary amino groups which come from 
ε-lysine residues in the protein chosen for conjugation. Four proteins were 
individually coupled onto functionalised AuNPs; Y. pestis capsular F1 antigen 
(F1), tetanus toxoid (TetHc), B. mallei T6SS protein (Hcp1) and B. pseudomallei 
flagellin (FliC). The addition of NHS activates the MHDA linker by forming an 
NHS ester on the MHDA linker, with isourea acting as a leaving-group. This 
also prevents the formation of an undesirable N-acylisourea by rearrangement 
chemistry. The nucleophilic primary amine from the protein then replaces NHS 
in a SN2 type reaction and an amide bond between the protein and MHDA linker 
is formed, Figure 3.8. The reaction must be carried out in buffers which do not 
contain any carboxyl groups or amines to avoid any unwanted crosslinking, and 
at an acidic pH for greatest efficiency. For these reasons, MES buffer at pH 4.5 
was used. 
Separation of unbound protein from AuNP conjugated protein was first 
attempted by gel filtration chromatography. Samples containing F1 and TetHc 
conjugated AuNPs were loaded onto a 1.5 X 30 cm2 column containing 
Sepharose® 4B chromatographic resin and 0.5 mL fractions were collected 
before being measured using UV-visible absorption at 280 and 520 nm to 
identify protein and AuNPs, respectively. Unfortunately, the resin used was 
unable to separate sufficiently the unbound protein from AuNP-conjugated 
protein and were both eluted in the same fractions, Figures 3.9 and 3.10. 
Centrifugation at a range of speeds for various lengths of time was then used to 
separate bound/unbound protein but this resulted in aggregation of AuNPs. 
However, further optimisation showed that the addition of a non-ionic surfactant, 
Triton X-100TM at a concentration above its critical micelle concentration (CMC 
= 0.24 mM) was able to overcome this problem. Using Triton X-100 at a 
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concentration below the CMC was unsuccessful at preventing NP aggregation. 
Centrifugation at 14,500 rpm for 10 minutes was sufficient for pelleting 95% of 
colloidal gold from the solution. A calibration curve of colloidal dilutions was 
used to determine the separation efficacy using the centrifugation method, 
Figure 3.11. 
Functionalisation of AuNPs with MHDA, followed by protein coupling was 
confirmed by measuring the extinction spectra and observing a red-shift in the 
plasmon, Figure 3.12. When measured, λmax increased by 8 nm from 519 nm for 
bare AuNPs to 527 nm with MHDA attached and a further 5 nm to 532 nm with 
a protein conjugated. 
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Figure 3.8. Reaction scheme between MHDA linker and protein using 
EDC/NHS carbodiimide coupling chemistry 
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Figure 3.9. Gel filtration chromatography profile for F1 conjugated AuNPs. 
Fractions of 0.5 mL were collected from a 1.5 X 30 cm2 column containing 
Sepharose® 4B-cross linked chromatographic resin and the absorption 
measured at 280 and 520 nm. The resin was unsuccessful at separating the 
unbound protein from AuNP conjugated protein. 
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Figure 3.10. Gel filtration chromatography profile for TetHc conjugated AuNPs. 
Fractions of 0.5 mL were collected from a 1.5 X 30 cm2 column containing 
Sepharose® 4B-cross linked chromatographic resin and the absorption 
measured at 280 and 520 nm. The resin was unsuccessful at separating the 
unbound protein from AuNP conjugated protein. 
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Figure 3.11. Calibration curve of colloidal dilution. This was used to determine 
the efficacy of removing AuNPs by centrifugation. Each point represents the 
mean of three values and error bars represent the standard error of the mean. 
R2=0.9989 
 
 
 
 
 
 
 
 
Chapter 3                            Protein Antigens Coupled to Gold Nanoparticles 
55 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. UV-visible absorption spectra for AuNPs, AuNPs functionalised 
with MHDA and AuNPs functionalised with MHDA coupled with either F1, 
TetHc, Hcp1 or FliC 
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3.3.3 Nanoconjugate quantification 
The optimal concentration of protein required for saturating the gold surface 
was determined by adding 10% (w/v) NaCl to AuNPs conjugated to a range of 
protein concentrations, Figure 3.13. Since the Na+ ions in the salt neutralise the 
anionic surface of AuNPs, those which are not fully decorated with protein 
aggregate and fall out of suspension. For F1, this was determined to be 30 
µg/mL. For TetHc it was 35 µg/mL, Hcp1 was 25 µg/mL and FliC was 30 µg/mL. 
Quantification of protein loaded onto the NP surface was done using a 
combination of methods. The first involved displacement of the MHDA linker 
from the gold surface by adding 11-mercapto-1-undecanol. The solution was 
then run on an SDS-PAGE gel alongside a range of known protein 
concentrations to generate a calibration curve, Figures 3.14 and 3.15. Whilst 
AuNPs remain at the top of the well, the protein runs freely through the gel and 
the relative intensity of the protein band could be quantified against a standard 
curve of known concentrations. Using this technique, the amount of F1, TetHc, 
Hcp1 and FliC conjugated to AuNPs was 20 µg/mL, 28 µg/mL, 25 µg/mL and 20 
µg/mL respectively. 
 A BCA assay was also used to quantify the amount of protein coupled to 
AuNPs. As before, the protein coupled linker was displaced with 11-mercapto-1-
undecanol but then the released protein was separated from the AuNPs by 
centrifugation. This method of purifying the released protein was effective at 
removing over 95% of AuNPs determined by comparing absorption at λmax. 
However, since the colourimetric Cu2+ reduction of the BCA assay absorbs light 
at 562 nm, the remaining 5% colloid was enough the effect the results of the 
assay. To overcome this, the absorption spectra for the supernatant were 
recorded and bare nanoparticles were diluted to this value and added to the 
known concentration of protein to be used for the standard curve. Using this 
technique, the amount of F1, TetHc, Hcp1 and FliC conjugated to the AuNPs 
was 18 µg/mL, 30 µg/mL, 16 µg/mL and 12 µg/mL respectively. A summary of 
the measured protein concentrations is shown in Table 3.1 
MALDI-ToF was used for direct quantification of total protein load. It was 
hoped that by comparing the m/z of bare AuNPs to protein coupled AuNPs, the 
amount of protein coupled could be calculated using a known concentration of 
the protein as a standard, Figure 3.16. Unfortunately this was unsuccessful and 
the resultant spectrum shows peaks of approximately 197 m/z apart, the atomic 
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mass of gold, suggesting that gold is being ablated from AuNPs atom by atom 
but that the conjugates are too heavy to allow desorption from the matrix 
surface. 
Information regarding NP concentration, protein concentration and 
protein molecular weight was then used to determine the number of protein 
molecules per NP. The number of F1 proteins conjugated to each NP is 
approximately 72, for TetHc its 38, Hcp1 is 77.6 and FliC is 50.4 protein 
molecules NP-1. These numbers fit comfortably within the theoretical estimate of 
coupling capacity on AuNPs which is between 10 and 100 molecules NP-1. This 
is based on the surface area of AuNPs, which is approximately 640 nm2 (16 nm 
diameter) and assuming the protein molecules have a footprint of approximately 
25 nm2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. Aggregation assay to determine the minimum concentration of 
protein required to saturate AuNPs. Proteins at a range of concentrations were 
conjugated onto AuNPs and the minimum concentration required to saturate the 
surface was identified as the ones which did not undergo a colour change from 
burgundy to blue upon addition of 10% (w/v) NaCl. 
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Figure 3.14. Quantification of F1 conjugated onto AuNPs. Coomassie blue 
stained NuPAGE 4-12% Bis-Tris gel showing protein displacement from AuNPs 
(A); Perfect Protein™ marker (a), 0.3 µg F1 conjugated onto AuNPs and treated 
with 11-mercapto-1-undecanol (AuNP at top of lane) (b), 0.2 µg F1 (c). 
Standard curve used to calculate protein concentration released from 
nanoconjugates based on protein band intensity from known concentrations of 
the same protein (B). 
 
 
 
 
 
 
AuNPs 
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Figure 3.15. Coomassie blue stained NuPAGE 4-12% Bis-Tris gel showing 
AuNP displacement from 0.3 µg TetHc (A), 0.3 µg Hcp1 (B) and 0.3 µg FliC (C); 
Perfect Protein™ marker (a), AuNP-protein treated with 11-mercapto-1-
undecanol (AuNP at top of lane) (b and c) 
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Table 3.1.  Summary of measured protein concentrations conjugated to AuNPs 
 
Technique 
F1 conc. 
(µg/mL) 
TetHc conc. 
(µg/mL) 
Hcp1 conc. 
(µg/mL) 
FliC conc. 
(µg/mL) 
NaCl assay 30 35 25 30 
SDS-PAGE 20 28 25 20 
BCA assay 18 30 16 12 
Average 23 ± 4 31 ± 2 22 ± 3 21 ± 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                            Protein Antigens Coupled to Gold Nanoparticles 
61 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. MALDI-ToF spectra for AuNP-F1 showing desorption of atomic 
gold from the matrix surface. Measurements were taken using a 355 nm 
Nb:YAG laser in positive reflector mode with a 20 kV acceleration voltage 
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3.3.4 Immunisation study 
To evaluate the immunogenicity of an antigen coupled to AuNPs, BALB/c mice 
were immunised IM with a single dose of F1 conjugated AuNPs with or without 
an aluminium hydroxide adjuvant (alhydrogel). The experiment ran for six 
weeks and the development of antibody to F1-antigen in sera was measured 
using an ELISA, Figure 3.17. Control mice received F1-antigen in either 
alhydrogel or PBS, or AuNPs alone. After 14 days, mice given AuNP-F1/alhy 
had the highest level of F1-antigen-specific antibody when compared with mice 
immunised with AuNP-F1/PBS (p < 0.01). Mice immunised with F1/alhy 
generated a greater IgG titre than those in the groups with PBS instead of 
alhydrogel (p < 0.01). There was a significant decline in IgG titres in mice 
immunised with unconjugated F1-antigen with or without alhydrogel from days 
35 or 21 days respectively, post immunisation (p < 0.01). Mice given AuNP-
F1/alhy showed no decline in IgG titre at 42 days post-immunisation. Mice 
immunised with empty AuNPs alone did not develop antibody against F1-
antigen (data not shown). IgG subclasses were also measured and showed the 
concentration of F1-specific IgG2a in mice immunised with AuNP-F1/PBS was 
significantly increased compared with mice administered unconjugated F1/PBS 
(p <0.05). Formulation of AuNP-F1/alhy significantly increased both IgG1 and 
IgG2a responses, (p <0.01 and p <0.05, respectively), compared with AuNP-F1/ 
PBS. However, in all of the immunised groups the concentration of F1-specific 
IgG1 exceeded IgG2a, Table 3.2.  
Sera collected from mice in individual treatment groups was assessed for 
the ability to compete with sera from macaques previously immunised with F1-
antigen. This serum has been shown to provide passive protection to mice from 
a Y. pestis challenge [311]. The sera from mice immunised with F1-antigen 
formulations was able to displace the macaque sera, Figure 3.18. Sera from 
animals immunised with AuNP-F1/alhy competed most successfully with the 
macaque antibody, with a significantly greater percentage binding than any 
other group for the intial two dilutions (p < 0.01). Sera from mice immunised with 
AuNP-F1 or unconjugated F1-antigen competed similarly with the macaque 
sera. 
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Figure 3.17. Concentrations of F1-specific total IgG in sera from BALB/c mice 
at different times after giving a single dose of the immunogens indicated. After 
14 days, mice immunised with gold AuNP-F1/alhy generated a significantly 
higher IgG titre compared with AuNP-F1/PBS or unconjugated F1-antigen in 
PBS (p < 0.01). AuNP-F1/alhy immunised mice did not show a decline in IgG at 
42 days post-immunisation. Each point is the mean of values from five mice. 
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Table 3.2. Measurements of F1-specific IgG1 and IgG2a isotypes in sera taken 
from six immunised mice. 
 
 
 
 
 
 
 
 
Group IgG1 (µg/mL) IgG2a (µg/mL) 
Ratio 
IgG1:IgG2a 
 
AuNP-F1/alhy 
 
23 ± 4 1.7 ± 0.1 13.75 
 
AuNP-F1/PBS 
 
6.6 ± 0.9 0.9 ± 0.1 6.72 
 
F1/alhy 
 
13 ± 3 0.9 ± 0.2 14.57 
 
F1/PBS 
 
6.4 ± 0.4 0.5 ± 0.1 14.04 
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Figure 3.18. Competitive ELISA for binding to F1-antigen. After 14 days, mice 
immunised with AuNP-F1/alhy generated significantly higher IgG titre compared 
with AuNP-F1/PBS and unconjugated F1-antigen in PBS (p < 0.01). Mice dosed 
with AuNP-F1/alhy did not show a decline in total IgG at 42 days post-
immunisation. Each point is the mean of values from five mice. 
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3.3.5 Flow cytometric analysis 
Flow cytometry of splenocytes showed that a high percentage of cells positive 
for the activation/maturation marker CD45 existed in all treatment groups (Table 
3.3). CD4+ cells as a percentage of cells bearing the pan T-cell marker (CD3)  
exceeded CD8+ cells as a percentage of the CD3+ population by approximately 
2:1 for all treatment groups, with no significant differences between groups. 
Analysis of IFNγ in culture supernatants of splenocytes re-stimulated ex vivo 
with F1-antigen, revealed a significantly reduced level from cells obtained from 
mice immunised with AuNP-F1/alhy, compared with those from mice 
administered F1/PBS (p < 0.05), indicating the anti-inflammatory influence of 
alhydrogel in the vaccine formulation. 
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Table 3.3.  Percentage of CD3+ splenocytes displaying the activation marker 
CD45 on ex vivo re-stimulation with F1-antigen. 
 
 
 
 
 
 
 
 
 
 
 
Group 
CD45+ (% of CD3+ cells 
± s.e.m.) specifically 
activated by F1 ex vivo 
IFNγ  output (ng/mL ± 
s.e.m.) in recall 
response specific for  
F1 
 
AuNP-F1/alhy 
 
 
90 ± 2 
 
327 ± 24 
 
AuNP-F1/PBS 
 
 
86 ± 5 
 
704 ± 187 
 
F1/alhy 
 
 
82 ± 10 
 
542 ± 121 
 
F1/PBS 
 
 
75 ± 14 
 
775 ± 113 
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3.4 Discussion 
 
3.4.1 Gold nanoparticle synthesis 
AuNPs synthesised in this study were characterised using TEM, where the 
shapes of particles can be visualised and their sizes measured. Using this 
technique, we determined that reduction of gold (III) with a weak borohydride 
solution resulted in particles smaller than those generated with a higher molar 
borohydride solution. In both cases there was a wide distribution of sizes 
suggesting NaBH4 might not be suitable for producing a monodisperse 
population of nanoparticles, likely to be due to the strength of borohydride as a 
reducing agent. Whilst NaBH4 is added quickly to gold (III), the gold is likely to 
reduce at varying degrees as the concentration of NaBH4 equilibrates through 
the solution resulting in nanoparticles of different sizes. The solutions were 
stirred vigorously upon addition of a reducing agent, and for 2 hours afterwards, 
but the presence of irregular shapes when using NaBH4 at a lower 
concentration suggests the solution has not been stirred fast enough despite 
this being done a maximum speed of 500 rpm. AuNPs formed using sodium 
citrate as a reducing agent produced spherical colloids with a mean diameter of 
16 ± 2 nm. These were much more uniform in shape, as calculated using the 
coefficient of variation, and had a narrower size-distribution. This is significant 
because the ability to produce spherical nanoparticles of a consistant size and 
shape is important for maintaining consistency of antigen loading between 
nanoparticle batches.  
UV-visible spectrophotometry was also used to characterise the 
nanoparticles, which typically have a distinctive absorption and scattering 
pattern in the visible range of the electromagnetic spectra. From this we can 
ascertain that decreasing the concentration of NaBH4 increases the mean 
diameter of the nanoparticles in solution based on the λmax red-shift. Also, 
reduction using sodium citrate forms nanoparticles which are slightly larger than 
those produced using 20 mM NaBH4 but much smaller than those using 5 mM 
NaBH4. The shape of the extinction spectra indicates dispersity of nanoparticles 
within the solution since a broadening of the extinction peak is indicative of a 
broad size and shape distribution [312, 313]. Whilst a narrow peak is present for 
sodium citrate reduced AuNPs, there is a much broader peak for those reduced 
using NaBH4. Since the end use of these nanoparticles is to conjugate antigenic 
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material for use as a vaccine, its is favourable to have a uniform population of 
nanoparticle shape and size within a solution and between batches. This is to 
ensure a consistant mass of immunogen is coupled to the gold surfaces and 
they are similarly presented to the immune system. For this reason, only citrate 
reduced AuNPs were chosen for further study. 
 The stability of AuNPs was measured over a 300 day time period by 
recording the absorption spectra. Whilst λmax of 519 nm remained fairly constant 
(± 0.94 nm) for the time period chosen, overall absorption fell by more than 50% 
after 180 days. This is likely to be the result of small changes to pH within the 
solution over time which would affect the surface charge on the nanoparticles 
and cause some of the particles to aggregate and sediment. This would reduce 
the concentration of particles in solution and subsequently total absorption. This 
data helped us to ascertain that AuNPs are stable enough to be used for 
vaccine production and determine the maximum time for which these particles 
can be stored before use. As a result of these studies, a fresh batch of AuNPs 
was prepared every 6 months for the duration of the work described here. 
 
3.4.2 Peptide coupling to gold nanoparticles 
Under physiological conditions, proteins readily bind to the surface of 
nanoparticles using hydrophobic and electrostatic interactions to form a protein 
corona [314-317]. Whilst this simple method for coupling proteins is effective 
under controlled conditions, in a biological fluid there is a rapid dynamical 
exchange between the adsorbed proteins and those in sera, resulting in loss of 
protein carrier [318, 319]. There is also some evidence of reduced activity and 
protein denaturation when adsorbed to a nanoparticle surface [320]. It was 
therefore decided that a covalent coupling approach for attaching proteins to 
AuNPs would be best suited for vaccine delivery of antigens. The advantages of 
using gold for bioconjugation is that it readily reacts with both thiol and amide 
groups, allowing for direct conjugation of molecules, including proteins, onto the 
surface [321-323]. Although nanoparticles have a much larger surface to 
volume ratio compared to macromolecules, direct coupling to the nanoparticle 
surface is only really suitable for DNA vaccines or small drug molecules. For 
larger molecules, such as proteins, a spacer is often used to tether the molecule 
to the nanoparticle surface to maximise the surface area and prevent steric 
hindrance. Quite often the spacer used for conjugating onto gold will consist of 
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an aliphatic carbon chain with a thiol group at one end, which binds to the gold, 
and a carbonyl group at the other which is used to conjugate the molecule of 
interest [132, 324, 325]. In this study 16-mercaptohexadecanoic acid was 
chosen as a spacer, which forms a self-assembled monolayer on the gold 
surface and projects carboxyl groups. Carbodiimide chemistry was used to 
conjugate proteins to the spacer due to the mild reaction conditions required so 
as to not alter the conformation of antigenic epitopes. 
 Once the minimal protein concentration  required for AuNP saturation 
was determined, a combination of several methods was used to quantify the 
amount of protein conjugated. The main difficulty with this was the complete 
separation of nanoparticles and coupled protein once they had been covalently 
linked. Once initial efforts of acid hydrolysis, enzymatic degradation 
(chymotrypsin) and pH changes failed to isolate the protein without first 
degrading it, I began to look into small molecules which may be able to displace 
the MHDA linker. Three molecules were investigated for their ability to 
competitively bind to the gold surface; 11-mercapto-1-undecanol, 11-
mercaptoundecanoic acid and mercaptoethanol. Of which 11-mercapto-1-
undecanol proved the most successful after incubating at room temperature for 
4 hours. Moreover, a novel method was devised to purify the nanoparticles via 
simple centrifugation. Prior to this study, purification of functionalised 
nanoparticles involved specialised diafiltration or chromatography techniques 
which are not only time-consuming but can affect the stability of the colloid [326, 
327]. However, it was determined that by supplementing the soution with a non-
ionic surfactant at concentrations above the known critical micelle concentration 
the particles could be easily purified without aggregation, making it possible to 
produce and batches of AuNPs much more efficiently. However, there were 
some problems with this purification method since there would still be traces of 
AuNPs in the protein supernatant which would interfere with colorimetric assay 
results due AuNP characteristic scattering patterns of light in the red end of the 
spectrum. This was overcome by reading the absorbance at λmax of the 
released protein, diluting some bare AuNPs to this value and adding this to the 
standard curve to be used in a BCA assay. One of the problems with this 
method is the adsorption of proteins onto the added AuNPs and the changes 
this can have on the activity of the protein (mentioned above). In conjunction 
with this method protein was removed from AuNPs, again using 11-mercapto-1-
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undecanol, and run through an SDS-PAGE gel alongside a range of known 
protein concentrations to generate a calibration curve. The density of these 
bands were then measured and calibrated to the standard curve. Whilst this 
method also has its limitations and may not release 100% of the bound protein, 
the results from this assay were the most replicable. A combination of band 
densitometry and BCA assay were used to calibrate the amount of protein 
conjugated onto AuNPs. 
 
3.4.3 Immunisation study 
The immunogenicity of an antigen coupled to AuNPs was evaluated in BALB/c 
mice using F1 as the model antigen since previous studies have shown that IM 
immunisation with recombinant F1-antigen induces a protective immune 
response against Y. pestis [265, 328, 329]. Previously, this was delivered by 
encapsulating the antigen, alongside recombinant V antigen (a secreted Y. 
pestis protein), within polylactide microspheres [265, 330]. Although promising, 
the immune response to this vaccine was slow to develop and was atrributed to 
the slow release of antigen from the microparticles; something which is true of 
many encapsulation strategies [331-333]. 
When immunised IM into mice, F1 conjugated to AuNP induced IgG 
responses which were superior to the responses induced by F1-antigen alone. 
The immune response seen in AuNP-F1/alhy immuninised mice is also more 
prolonged, when compared to other immunisation groups, Figure 3.19. The 
elevated and sustained response to F1 when coupled onto AuNPs suggests 
there was a depot effect created by the combination of AuNPs and alhydrogel 
enabling the recruitment of APCs to the site of immunisation for increased 
antigen processing by immune cells. NP conjugated F1 also generated higher 
IgG2a titres suggesting activation of Th1 cells. However, IFNγ levels from 
splenocytes taken from mice immunised with AuNP-F1/alhy were lower than 
from mice immunised with F1/PBS or with AuNP-F1/PBS. This is likely to be 
due to the effect alum adjuvants have on activating a Th2 immune response. As 
a consequence, cytokines associated with a Th2 response suppress Th1 
production and result in lower levels of IFNγ [334, 335]. Unlike other studies 
using microspheres to deliver antigens, our data show no delay in inducing an 
antigen-specific antibody response. This is likely to be attributed to the 
presentation of F1-antigen on the NP surface. Similarly an attenuated strain of 
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Salmonella Typhimurium expressing F1-antigen on its surface was a potent 
immunogen and protected mice against challenge with Y. pestis [248]. 
Other studies have reported AuNPs enhancing the ability of antigen to 
evoke antibody responses compared with antigen given alone [133, 336, 337]. 
In the case of merozoite surface protein 1 or Nogo-66 receptor, coupling to 
AuNPs resulted in antibody responses exceeding those elicited by the antigen 
given with Freunds adjuvant [336, 337]. Some studies have also reported that 
the use of alum as an adjuvant further enhanced the responses elicited by 
antigen bound to AuNPs [336] but others have used antigen bound to AuNPs 
without an additional adjuvant [133, 337]. In this study, the use of alum as an 
adjuvant enhanced the antibody response to F1-antigen linked to AuNPs. 
Whilst mice were not challenged on this study, the ability of sera from 
mice immunised with AuNP-F1 to compete with a protective macaque 
antiserum for binding to F1-antigen indicates that AuNP-F1 has induced a 
protective antbody response [338-340]. This suggests that the conjugation of 
F1-antigen to AuNPs has been succesfully achieved without interference of 
protective B-cell epitopes in F1-antigen. 
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Figure 3.19. Development of F1-specific IgG concentrations from BALB/c mice 
over time. 
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3.4.4 Conclusions 
Through the experiments described in this chapter, we have determined a 
production method which results in nanoparticles that are optimized for vaccine 
delivery in terms of size, shape, and monodispersity. We have characterised 
these nanoparticles through a variety of methods to demonstrate their suitability 
for use in vaccine production and identified the maximum time for which they 
can be safely stored without losing viability. This provides us with an ideal 
baseline from which nanoparticle vaccines can be developed and tested. We 
have also demonstrated the ability to successfully couple four different protein 
antigens (Hcp1, FliC, F1 and TetHc) onto the AuNPs using carbodiimide 
chemistry and proven that the proteins were bound to the AuNPs, showing the 
ability to reproducibly produce and quantify subunit vaccine candidates. We 
have shown that immunising mice with AuNP-F1 resulted in a greater total 
antigen-specific antibody response than F1 alone and higher levels of IgG2a 
titres, which suggests Th1 activation which is ideal for producing a vaccine 
capable of long term protective immunity. Further, competitive displacement of 
protective macaque antiserum suggests that the same epitopes are important 
for protection but the immunogenicity of the antigen is improved. 
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Chapter 4: A Glycoconjugate Vaccine against Glanders 
 
 
4.1 Introduction 
 
4.1.1 Burkholderia 
The Burkholderia genus currently includes over 40 species, including some 
environmental and clinically important pathogens [341]. The genus was 
proposed in 1992 based on 16S rRNA sequences, DNA-DNA homology values 
and phenotypic characteristics. The genus includes seven species, which were 
previously classed under the genus Pseudomonas [342]. Within this genus is 
the aerobic, Gram-negative, bacterium Burkholderia mallei which is the 
causative agent of glanders in humans. However, the pathogen mostly affects 
equines and humans are considered accidental hosts. B. mallei is unable to 
survive in the environment alone, so instead infected animals serve as a natural 
reservoir for this obligate parasite. A whole genome shotgun approach was 
used to sequence the genome of B. mallei ATCC 23344 which identified two 
circular chromosomes of 3.5 megabase pairs and 2.3 megabase pairs in size, 
with a G+C content of 68% and a total of 5535 predicted coding sequences 
[343]. 
A clonal relative of B. mallei is B. pseudomallei which causes a severe 
and potentially fatal human disease known as melioidosis. It too is an aerobic, 
Gram-negative bacterium but unlike B. mallei is motile and able to survive in the 
environment without a host. Subsequently, B. pseudomallei is cultured easily 
from the environment and is commonly found in wet soil and surface water in 
the tropics. Isolated in 1996 from a 34-year old female diagnosed with acute 
melioidosis in Thailand, the genome for B. pseudomallei strain K96243 was 
sequenced and shown to be composed of two chromosomes (4.07 and 3.17 
megabase pairs) [344]. With 5855 predicted coding sequences between the two 
chromosomes it is one of the most complex bacterial genomes sequenced to 
date. Genome analysis identified the large chromosome as carrying genes 
mainly associated with core functions necessary for metabolism and cell 
growth, whilst the smaller chromosome encodes for accessory functions such 
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as adaption and survival in different environments. An interesting feature of the 
genome is the presence of 16 genomic islands, making up 6.1 % of the total 
genome. The absence of these islands from other closely related Burkholderia 
species, suggest horizontal gene acquisition by B. pseudomallei has played a 
pivotal role in the genetic evolution of this species [344]. 
Genome wide comparisons between B. mallei and B. pseudomallei 
reveal 99% homology and suggests B. mallei has evolved from a single clone of 
B. pseudomallei and undergone ‘genomic downsizing’ [345]. Consequently, it is 
believed that this has resulted in a loss of ability to survive in the environment. 
Also within the Burkholderia genus is B. thailandensis, a close relative of 
B. pseudomallei which coexists in the environment and was previously believed 
to be a biotype of B. pseudomallei. Comparisons between these two “biotypes” 
determined that  whilst B. thailandensis was able to assimilate L-arabinose and 
demonstrated a median lethal dose (LD50) of 10
6-107 CFUs in a Syrian hamster 
model of infection, B. pseudomallei was unable to and demonstrated an LD50 of 
2-10 CFUs [346, 347]. Differences between these two biotypes became more 
apparent after 16S rDNA phylogenetic analysis and a new species was 
proposed, with the less virulent biotype being designated as B. thailandensis.  
[348]. 
 
4.1.2 Glanders and melioidosis 
Glanders, sometimes referred to as farcy, is one of the oldest known infectious 
diseases, having first being described in 350 BC by Aristotle [349]. However, it 
was not until 1882 that the causative agent, B. mallei, was first isolated from an 
infected horse liver [350]. Throughout history there have been several incidents 
where B. mallei has been used as a biological weapon to infect livestock and 
contaminate animal feed, including during World War I and II and later by the 
Soviet Union for use in Afghanistan [351, 352]. Since B. mallei is unable to 
survive in the environment infected equines serve as the reservoir for the 
bacterium. The disease will then typically manifest into either an acute infection 
in mules or donkeys, leading to mortality within a few days, or a chronic 
infection in horses, where infection can linger for a few months or even years 
but will still most often result in fatality [353-357]. Clinical signs of glanders 
infection vary but are often characterised by nodules on the extremities of 
infected animals. These can ulcerate and result in an infectious discharge 
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allowing the transmission to other healthy animals or humans. Symptoms in 
humans are much the same as they are in equines with the thickening of lymph 
vessels and nodule formation producing a suppurative exudate [358, 359]. 
Mortality rates vary significantly depending on the route of transmission but 
range from 95% if untreated down to approximately 40% with an intensive 
course of antibiotics [360, 361]. 
B. pseudomallei is most commonly found in wet soil and surface water in 
areas such as southeast Asia and northern Australia where transmission occurs 
mostly through subcutaneous inoculation or inhalation [362-364]. The biggest 
incidence of melioidosis is in northern Thailand where it accounts for 20% of all 
community-acquired septicaemia and 40% of all sepsis-related mortality [365-
367]. Clinical manifestations are protean and can mimic symptoms of other 
diseases such as tuberculosis, leading to misdiagnosis and disease progression 
[368-370]. The disease can be described as being either acute septicaemia or a 
chronic localised infection [367]. Whilst there is usually no evidence of infected 
wounds or trauma, the disease is characterised by abscess formation in the 
liver and/or spleen as well as pneumonia, which is present in over 50 % of 
cases [371-375]. Recurring infections and latency are also a problem for 
patients with melioidosis. 
There is currently no vaccine against either glanders or melioidosis and 
they are both naturally resistant to several classes of antibiotics [376, 377]. Due 
to their associated high mortality rates and potential to be transmitted by 
aerosols, both pathogens are classed as Tier 1 select agents by the Centers for 
Disease Control and Prevention and are considered to be potential candidates 
for weaponisation and bioterrorism. Subsequently, there has been renewed 
scientific investigation into these bacteria in recent years. 
 
4.1.3 Virulence factors 
Virulence in B. mallei and B. pseudomallei is multifactorial and a number of 
virulence mechanisms have been identified, some of which are listed in 
appendix table A. One of the virulence factors which distinguish B. mallei from 
B. pseudomallei is flagellin, encoded by fliC. FliC is known to be involved in 
motility of B. pseudomallei, while B. mallei lacks fliC and is non-motile [378].  B. 
thailandensis is similar to B. pseudomallei in that it is motile and encodes a fliC 
gene, but the B. thailandensis fliC gene is significantly shorter than B. 
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pseudomallei fliC and can be used to discriminate between the two otherwise 
highly homologous genomes [349, 361, 379].  
The role of flagellum-mediated motility in virulence has largely been 
attributed to its ability to enhance the invasion of host epithelial cells [359, 377, 
380, 381]. Whilst B. pseudomallei flagellin mutants remain virulent in mice and 
hamsters when delivered intraperitoneally, they are attenuated when deposited 
intranasally suggesting the flagellin-based motility and its role in virulence is 
dependent on the route of infection [377, 380]. Antibodies raised against B. 
pseudomallei FliC have been shown to reduce bacterial motility as well as 
providing passive protection against B. pseudomallei infection in a diabetic rat 
model [382]. Additionally, FliC has been recognised as a TLR5 agonist in other 
motile bacteria, stimulating pro-inflammatory cytokines such as TNF-α which 
are involved in activation of the innate immune [383]. 
B. mallei and B. pseudomallei also encode type VI secretion systems 
(T6SS) and have four and six gene clusters in their respective genomes [384, 
385]. Whilst the functionality for the majority of these gene clusters is currently 
unknown, there is one homologous T6SS gene cluster shared in both B. mallei 
(T6SS-1; BMAA0744-0730) and B. pseudomallei (tss-5; BPSS1496-1511) that 
has been demonstrated to play an essential role in virulence role in animals 
[384, 386]. There is also some evidence that T6SS also plays a role in 
multinucleated giant cell formation since these were absent when mammalian 
cells were infected with B. pseudomallei T6SS mutants [351, 387]. Activation of 
T6SS-1 has been closely linked to both the VirAG-regulated two-component 
system and BMAA1517, an AraC-type regulator, whereby overexpression of 
either system results in a 30- or 12- fold increase in T6SS-1 transcription, 
respectively [384]. Upon activation of T6SS-1, some of the key effectors are a 
family of haemolysin-coregulatory proteins (Hcp) that share homology to Vibrio 
cholerae Hcp [388]. This family of proteins have been identified as interacting 
with valine-glycine repeat protein G (VgrG) to assemble into a structure which 
resembles the cell-penetrating needle of a bacteriophage tail [389-391]. 
However, as well as being a component of the T6SS, Hcp proteins are also 
secreted in vivo as sera from mice, horses and humans react with Hcp1 [357]. 
As an effector, Hcp1 (BMAA0742) forms a hexameric ring structure which may 
form a channel in the target cell membrane to allow other macromolecules to be 
transported [384]. The T6SS-1 protein Hcp1 has also been shown to provide 
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significant protection against a lethal inhaled B. mallei and B. pseudomallei 
challenge in a murine model of infection [251]. 
B. mallei and B. pseudomallei both produce an extracellular capsular 
polysaccharide, previously characterised as type I O-polysaccharide (O-PS), 
composed of -3)-2-O-acetyl-6-deoxy-β-D-manno-heptopyranose-(1- [392, 393]. 
The role of capsular polysaccharide in virulence has been demonstrated in 
animal models of infection whereby B. pseudomallei capsular mutants are 
highly attenuated in both mice and hamsters and B. mallei capsular mutants are 
avirulent [394-396]. The explanation for this phenotype is believed to be the role 
capsule plays in evading host defence, specifically the complement system, by 
reducing C3b-mediated opsonisation and phagocytosis [397]. The capsule is 
also believed to be required for survival and replication in macrophages by 
protecting the bacterium from reactive nitrogen and oxygen intermediates [398]. 
The absence of the gene cluster expressing this polysaccharide from B. 
thailandensis has been suggested as one of the factors contributing to its 
relative avirulence [357, 394, 397]. However, two strains of B. thailandensis, 
E555 and CDC3015869, were recently discovered to have acquired the gene 
cluster necessary for capsular polysaccharide and have been shown to 
expressneither exhibited enhanced levels of virulence compared with wild-type 
B. thailandensis strains in mice or hamsters [399, 400]. The authors suggest 
that the major ecological driving force behind this acquisition may have been 
down to environmental pressures rather than a requirement to infect mammals 
[399]. 
Another extracellular polysaccharide produced by B. pseudomallei and 
B. mallei is lipopolysaccharide (LPS). As a major component of Gram-negative 
cell envelopes, the LPS is composed of three covalently linked domains [401]. 
The first is a hydrophobic domain known as lipid A which anchors LPS into the 
bacterial outer membrane. This component is believed to be responsible for the 
endotoxic activity associated with LPS by activating TLR4 and triggering 
inflammatory responses such TNF-α and IL-6 [402]. Next are a core of non-
repeating oligosaccharides commonly consisting of 3-deoxy-D-
mannooctulosonic acid (KDO), which acts as an intermediate linker between 
lipid A and the distal polysaccharide. The polysaccharide is referred to as the O-
antigen and its variability defines the serological specificity in an organism. For 
B. mallei, B. pseudomallei and B. thailandensis the O-antigen is a repeating D-
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glucose and L-talose with a general structure of -3)-β-D-glucopyranose-(1–3)-6-
deoxy-α-L-talopyranose-(1- in which 33% of the L-talose residues contain 2-O-
methyl and 67% contain 2-O-acetyl substitutions. B. pseudomallei and B. 
thailandensis also have an O-acetyl substitution at the 4’ position on L-talose 
whilst B. mallei has an additional substitution of 3-O-methyl substitution on L-
talose [264, 357, 403]. The lack of acetylation at the 4’ position on L-talose in B. 
mallei has been attributed to the absence of the oacA gene which encodes O-
antigen acetylase A in B. thailandensis and its homolog BPSL1936 in B. 
pseudomallei K96243 [404, 405]. Despite these minor differences in structure, 
the biosynthesis cluster responsible for the O-antigen moiety of LPS described 
is the same in B. mallei and B. pseudomallei. Strains which produce this 
genotype are described as typical (LPS genotype A) and include all strains of B. 
mallei and B. thailandensis that have so far been tested [406]. There is however 
some diversity amongst B. pseudomallei strains where LPS genotype A 
accounts for 97.7% of Asian strains and 85.3% of Australian strains [406]. 
Atypical strains are either genotype B or B2, depending on the biosynthetic 
gene cluster responsible for generating the O-antigen, and are so-called 
because they are both serotype B reactive. Of the two atypical gene clusters, B 
is the most common accounting for 2.3% of Asian strains and 13.8% of 
Australian strains. So far, only 7 strains of B. pseudomallei have been identified 
as producing LPS genotype B2 [406]. In strains where the LPS O-antigen 
biosynthesis cluster is missing or defective, LPS is described as “rough”. These 
three separate serotypes of B. pseudomallei LPS (A, B and rough) are 
antigenically distinct by immunoblotting [407].  
The primary role of the O-antigen is to protect the bacterium against host 
defences. This has been demonstrated by constructing mutants of the gene 
cluster in B. pseudomallei required for O-antigen synthesis and showing they 
are more susceptible to macrophage killing by RAW 246.7 cells and serum 
killing by the complement system [403, 408]. Since LPS is a major component 
of the bacterial outer membrane, the specificity of the O-antigen is an important 
antigen for triggering host recognition. Passive protection studies of mAb’s 
raised against B. mallei or B. pseudomallei LPS O-antigen were protective 
against a lethal challenge of glanders or melioidosis in a mouse model of 
infection [409-412]. 
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In addition to LPS O-antigen, two other polysaccharide loci have been 
identified in B. pseudomallei termed type III O-PS and type IV O-PS which 
encode genes with predicted functions relating to polysaccharide biosynthesis 
and transport [344, 413]. Mutants lacking either type III or type IV O-PS show 
an increased time to death in a mouse model of B. pseudomallei compared with 
wild-type [413]. However, neither cluster is present in B. mallei [343]. 
 
4.1.4 Objectives 
Previous immunisation studies using LPS purified from B. pseudomallei and B. 
thailandensis have shown this to provide partial protection against murine 
melioidosis [413, 414]. However, since LPS is a T-independent antigen, 
protection is short-lived and animals eventually succumb to disease after 
approximately 20 days. In order to convert the immune response to one that is 
T-dependent, polysaccharides can be conjugated to a protein carrier for 
presentation on MHC I/II molecules. This has been shown with the 
Haemophilus influenza type b (Hib) and meningococcal type C vaccine [258, 
415]. The aim of the work reported in this chapter is to improve the protection 
afforded by B. thailandensis LPS by conjugating it to a protein carrier in the 
hope of inducing a T-dependant immune response. The protein carriers were 
initially Y. pestis capsular F1 antigen, which was shown in the previous chapter 
to be highly immunogenic on AuNPs, and tetanus toxoid Hc fragment (TetHc), 
which is the current choice of protein carrier for several licensed glycoconjugate 
vaccines [416-418]. The efficacy of using Burkholderia specific proteins FliC 
and Hcp1 was also explored due their reported ability to provide some degree 
of protection [251, 419]. 
 The use of gold nanoparticles in this vaccine construct should not only 
improve the immunogenicity of the vaccine but also act as a surface onto which 
the coupling chemistry can proceed. It is hoped that this will improve the 
conjugation efficiency. 
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4.2 Materials and Methods 
 
4.2.1 LPS purification 
LPS was extracted from B. thailandensis E264 using a modified hot-phenol 
extraction method [253]. Cultures were grown as either an overnight culture in 
LB containing 50 µg/mL kanamycin or as a lawn on LA bioassay dishes 
containing 50 µg/mL kanamycin for 18-20 hours before colonies were 
suspended in ice cold 50 mM Na3PO4 with 5 mM EDTA pH 7.4. The cultures 
were lysed for 16 hours at 4 °C with 15,000 units of lysozyme per mg of 
bacteria, before adding 20 µg/mL DNase and RNase in MgCl2 and leaving to 
digest for a further 16 hours at room temperature. Proteinase K (50 µg/mL) was 
added and incubated at room temperature for 6 hours. A 90% (w/v) phenol 
solution heated to 70 °C was added in equal volume to the digested culture with 
continuous mixing for 20 minutes at 70 °C. The solution was dialysed against 
de-ionised water for approximately 3 days, changing the buffer daily. The 
dialysed solution was lyophilised and dissolved in 10 mM Tris with 1 mM CaCl2 
and 1 mM MgCl2 to a concentration of 30 mg/mL. DNase and RNase were 
added at 20 µg/mL for 2 hours at 37 °C before adding proteinase k at 50 µg/mL 
for 4 hours at 37 °C and then ultracentrifuging at 105 x g for 3 hours. The 
resulting pellet was solubilised in de-ionised water before dialysing against de-
ionised water for 16 hours. The solution was lyophilised once more before it 
was dissolved in de-ionised water or 50 mM MES buffer pH 5.5, aliquoted and 
stored at -80 °C. The purity of LPS was checked by running on a NuPAGE 4-
12% Bis-Tris gel with silver staining, and Western blotting using a monoclonal 
antibody (mAb) specific for B. pseudomallei LPS O-antigen (CC6). 
 
4.2.2 Coupling chemistry for LPS onto gold nanoparticles 
A reductive amination approach was initially taken to couple LPS onto protein 
carriers [254]. This was done by partially oxidising LPS by incubating 16 mg 
LPS with 4 µM sodium meta-periodate in the dark at 23 °C for either 30, 60 or 
90 minutes. Ethylene glycol was then added to quench any residual periodate. 
The oxidised LPS was dialysed in ultrapure water overnight at 4 °C and 
lyophilised. AuNPs coupled with either TetHc or an aminated MHDA linker were 
prepared as previously described before being centrifuged and resuspended in 
1 mg/mL oxidised LPS in 0.5 M sodium cyanoborohydride (in 0.1 M sodium 
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bicarbonate), pH 8.1. The mixture was allowed to incubate at room temperature 
for 7 days with gentle agitation. Aliquots were taken at various times points to 
measure the absorption spectra for a spectral shift in λmax as an indicator of 
conjugation, however no shift was recorded. A second approach following a 
modification of protocols based on oxime coupling was also employed [255-
257]. AuNP coupled proteins were centrifuged at 13,000 x g for 10 minutes 
before they were resusupended in an solution containing 0.6 mM EDC, 0.15 
mM NHS and 0.1 mM O-(carboxymethyl)hydroxylamine hydrochloride in 50 mM 
MES buffer pH 5.5. LPS (100 µg/mL) was added to aminooxylated proteins and 
allowed to incubate at room temperature for 18 hours. 
A third approach using a modified thiol maleimide chemistry was then 
applied [258]. To make a 1 mL solution of LPS coupled to AuNPs, 4.3 µL 40 
mM EDC and 17.3 µL 10 mM NHS was added to 0.26 mg LPS in 50 mM MES 
buffer pH 5.5 and incubated at room temperature for 15 minutes. Following this, 
10.9 µL 800 µm 6-maleimidocaproic acid hydrazide, trifluoroacetic acid salt 
(EMCH; >90%, Pierce) was added to the LPS solution and incubated at room 
temperature for a further 15 minutes. The pH of the LPS solution was adjusted 
to 7.0 using sodium hydroxide and left to incubate for an hour. Meanwhile, 
AuNPs coupled with a protein carrier of choice was suspended in 874.6 µL 
potassium phosphate buffer pH 7.5 before adding 25.4 µL 250 mM S-
acetylthioglycolic acid N-hydroxysuccinimide ester (SATA; >95%) and 
incubating at room temperature for 60 minutes. Hydroxylamine and EDTA were 
then added to the AuNP solution to quench the reaction with SATA. LPS was 
centrifuged in a Vivaspin® 6 centrifugal concentrator (Sartorius) for 15 minutes 
at 3220 x g and desalted into 5 mM EDTA in PBS pH 7. The AuNP solution was 
also centrifuged, at 13366 x g for 10 minutes before resuspending into the LPS 
solution and incubating at room temperature for 4 hours. The conjugation 
reaction was quenched with 5 mM N-ethylmaleimide; the nano-glycoconjugates 
were centrifuged and resuspended in PBS with or without 260 µL 13 mg/mL 
alhydrogel. 
 LPS was also conjugated onto MHDA functionalised AuNPs without any 
protein. To MHDA AuNPs, 4.5 µM hydrazine dihydrochloride (>99.9%) and 0.9 
µM EDC was added to aminate the terminal carboxyl regions before coupling 
with LPS, using the thiol maleimide approach as described above. 
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4.3 Results 
 
4.3.1 LPS extraction 
LPS was extracted from B. thailandensis E264 using a modified hot-phenol 
extraction method [253]. Cultures of B. thailandensis were grown either in LB 
broth or on LA bioassay dishes before LPS was extracted. The quantity and 
quality of LPS purified from bacteria grown in these two ways was compared by 
running through an SDS-PAGE gel and either silver staining or blotting with a 
monoclonal antibody against the O-antigen. Both methods gave a yield of 
approximately 8% LPS from the total dry cell weight, which is in general 
agreement with literature values on Gram-negative bacteria composition [420-
422]. There are, however, clear differences between the two forms of purified 
LPS with the plate-cultured LPS producing a strong band between 35-75 kDa 
on a silver stained protein gel with some additional low molecular weight bands, 
Figure 4.1 A. The broth-cultured LPS also has a strong band of around 50 kDa 
on a silver stained protein gel but is a smaller band than the plate cultured LPS 
and has an additional ladder banding pattern below 35 kDa which was not seen 
from the plate cultured LPS, Figure 4.1 B. This suggests that the purity of LPS 
is higher when purified from plates compared with broth culture. The gels were 
then transferred onto a nitrocellulose membrane which was probed with a mAb 
raised against the O-antigen of B. pseudomallei LPS (CC6). This showed the O-
antigen to be present in the 40-80 kDa region which correlates with the strong 
band from the silver stain. There is a stronger band seen from plate cultured 
LPS rather than from broth suggesting a higher content of O-antigen present. 
For this reason, B. thailandensis LPS purified from bioassay plates was used for 
subsequent studies. 
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Figure 4.1. Silver stained NuPAGE 4-12% Bis-Tris gel of 3 µg LPS purified from 
B. thailandensis (A); Perfect Protein™ marker (i), LPS purified from plates (ii 
and iii), LPS purified from broth (iv). Western blot of B. thailandensis LPS 
separated using a NuPAGE 4-12% Bis-Tris gel and stained using a mouse 
monoclonal antibody, CC6 (B); IRDye® (680/800) protein marker (i), LPS 
purified from plates (ii and iii), LPS purified from broth (iv and v). 
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4.3.2 Nano-glycoconjugate synthesis 
Several methods of bioconjugation were attempted for conjugating LPS onto 
protein couple AuNPs. The first of which was reductive amination, which is 
currently one of the most popular methods for coupling glycoconjugate vaccines 
and involves the nucleophilic addition of an amine group to a carbonyl. The 
carbonyl in this case was an aldehyde formed by mild periodate oxidation of the 
vicinial diols in the LPS core region. The resulting Schiff base rapidly hydrolyses 
in aqueous solution and must therefore undergo borohydride reduction to a 
more stable alkylamine. Based on literature values, a range of conditions were 
tested for coupling via reductive amination however, none of these were 
successful and measurements from UV/Vis spectra showed no change to λmax, 
Figure 4.2 A [423-425]. Another chemistry that was attempted was oxime 
coupling which is also a nucleophilic addition reaction. Oxidation of LPS was 
again required to generate aldehydes in the core region which react with 
aminooxy groups to form an oxime [256, 257]. Analysis of nano-
glycoconjugates using UV/Vis spectroscopy indicated that some degree of 
surface modification had taken place and a phenol-sulphuric acid assay 
confirmed the presence of LPS, however this was small, Figure 4.2 B. Further 
attempts to optimise this method were unsuccessful. 
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Figure 4.2. UV-visible absorption spectra showing the efficiency of conjugation 
chemistry using either reductive amination (A) or oxime coupling (B). Displayed 
are AuNPs (black), AuNPs functionalised with MHDA (red), AuNPs 
functionalised with MHDA coupled with TetHc (blue) and AuNPs coupled with 
TetHc and B. thailandensis LPS (green). 
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Conjugation of LPS onto protein coupled AuNPs was most successful using 
thiol-maleimide chemistry, Figure 4.3. Firstly, nucleophilic carbon atoms in 
carboxyl groups of the LPS core region were activated using EDC and NHS to 
give amine reactive NHS esters. The addition of EMCH to LPS formed a 
peptide bond between the hydrazide group and sites of EDC/NHS activation, 
whilst projecting a sulpho-reactive maleimide group. Free maleimide groups 
from EMCH in solution were quenched by desalting into a buffer containing 
EDTA. The carrier protein, (TetHc, F1, Hcp1 or FliC) onto which LPS was 
conjugated, had additional thiol groups incorporated using SATA. These were to 
act as sacrificial thiol groups so as to protect the native disulphide groups and 
hence preserve the 3D configuration and activity of the protein. Hydroxylamine 
was added to deacetylate the newly introduced, protected sulphydryl groups. 
The sulphonated protein-AuNPs were then purified using centrifugation and 
resuspended into the maleimide-containing LPS where a stable thioether 
linkage is formed between LPS and the protein. The reaction was quenched 
with the addition of ethylmaleimide and EDTA was added to chelate any 
divalent metals present that would otherwise promote oxidation of sulfhydryl 
groups. The skeletal structure of B. thailandensis LPS, showing the sites of 
conjugation, is shown in Figure 4.4. 
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Figure 4.3. Reaction scheme of the thiol-maleimide coupling between LPS and 
a chosen protein carrier; (1) NHS activation of carboxyl groups in LPS core, (2) 
EMCH linker addition onto LPS, (3) Introduction of terminal thiol groups onto 
AuNP coupled carrier protein using SATA, (4) Reaction between maleimide 
LPS and thiolated protein leads to thioether bond formation. 
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Figure 4.4. Skeletal structure of B. thailandensis LPS where R = OMe, R’ = 
OAc (33 % of all 6dLTal residues); R = OAc, R’ = H (67 % of all 6dLTal 
residues). O-antigen repeating unit has been highlighted and carboxyl sites for 
conjugating protein carriers are circled. Lipid A region adapted from Brett et al. 
[426]. 
Core region 
O-antigen 
Lipid A 
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Confirmation of nano-glycoconjugate formation was performed by measuring 
the absorbance spectra of AuNPs, Figure 4.5. An increase in the penetration 
depth of the AuNP plasmon, as indicated by red-shift in λmax of 9 nm from 532 
nm for AuNP-TetHc to 541 nm, indicates an increase in the mean diameter of 
AuNP conjugates as a result of LPS conjugation. The extinction peak is also 
much broader for AuNP-TetHc-LPS which suggest the size distribution of 
particles is much larger. This is likely to be due to variable lengths of the 
repeating O-antigen disaccharide on the particles. A two-colour Western blot 
was used to confirm co-conjugation of TetHc and LPS on AuNPs, Figure 4.6. 
After displacing the glycoconjugate from AuNPs using 11-mercapto-1-
undecanol the conjugate was separated using SDS-PAGE and transferred onto 
a nitrocellulose membrane which was incubated with a rabbit pAb specific to 
TetHc and a mouse mAb specific to LPS. Secondary antibodies against rabbit 
and mouse with an IR tag of 680 nm and 800 nm, respectively, were then 
added before the blot was visualised. This revealed the presence of both TetHc 
and LPS, however the LPS coupled onto TetHc appears to be of a lower 
molecular weight to the native LPS; this could be due to one of two reasons. 
Firstly, the thiol-maleimide chemistry between LPS and the protein could favour 
LPS of a smaller molecular weight, suggesting the larger molecular weight LPS 
is lost during purification and not seen on the gel. Alternatively, the attachment 
of TetHc to LPS could cause it to move atypically through the gel due to 
changes to the overall surface charge of the molecule. 
A phenol-sulphuric acid assay was used to determine the concentration 
of LPS present in nano-glycoconjugates. Using concentrated sulphuric acid, 
LPS was hydrolysed and dehydrated into monomeric furfural molecules which 
then formed a chromagen upon addition of phenol [427]. This method allows for 
a reliable and sensitive determination of polysaccharides down to 1 nmol, with a 
linear relationship between absorbance and concentration up to 150 nmol [263]. 
A typical calibration curve for this assay is shown in Figure 4.7. Using this 
assay, the amount of LPS measured on nano-glycoconjugates was determined 
to be 8.4 ± 0.5 µg/mL. 
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Figure 4.5 UV-visible absorption spectra for glycoconjugates using thiol 
maleimide coupling chemistry. Displayed are AuNPs (black), AuNPs 
functionalised with MHDA (red), AuNPs functionalised with MHDA coupled with 
TetHc (blue) and AuNPs coupled with TetHc and B. thailandensis LPS (green). 
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Figure 4.6. Two-colour western blot of AuNP-TetHc-LPS separated using a 
NuPAGE 4-12% Bis-Tris gel (A); IRDye® (680/800) protein marker (a), AuNP-
TetHc-LPS treated with 11-mercapto-1-undecanol (b-d), TetHc (e-h), LPS (i-k). 
Individual IR channels shown for 680 nm (red) (B) and 800 nm (green) (C). A 
rabbit pAb against Hc and a mouse mAb against LPS were used to bind TetHc 
and LPS, respectively. Goat anti-rabbit IRDye® 680 and anti-mouse IRDye® 
800 secondary antibodies were used to detect primary antibody binding. 
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Figure 4.7. Typical calibration curve for phenol-sulphuric acid assay showing 
the relationship between absorption values and LPS concentrations. This was 
used to determine the concentration of LPS conjugated to protein coupled 
AuNPs. Each point represents the mean of three values and error bars 
represent the standard error of the mean. R2=0.9984. 
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4.3.3 Serum antibody responses 1 
An immunisation and protection study was designed in collaboration with 
colleagues at UTMB to test the protection of nano-glycoconjugate vaccines 
against a B. mallei inhalation challenge. Immunisations were carried out at 
UTMB in BALB/c mice with a priming dose followed by two booster 
immunisations of LPS coupled to a protein carrier on AuNPs with an aluminium 
hydroxide adjuvant (alhydrogel). Five weeks post immunisation 100 µL of blood 
was taken from the tail vein of each mouse and shipped to Exeter where 
antibody isotypes and IgG specific subclasses were measured using an ELISA. 
A typical calibration curve used to calculate the antibody concentrations is 
shown in Figure 4.8. In this initial study the nano-glycoconjugates we were 
interested in were LPS conjugated to either F1 or TetHc coupled AuNPs (AuNP-
F1-LPS and AuNP-TetHc-LPS, respectively). Total IgG concentrations showed 
that animals immunised with AuNP-F1-LPS or AuNP-TetHc-LPS generated the 
highest response compared to all other groups and were both significantly 
higher than those immunised with LPS alone (p < 0.001, Figure 4.9). Mice 
immunised with AuNP-TetHc-LPS developed a significantly higher IgG 
response compared with those immunised with AuNP-F1-LPS (p < 0.05), but 
not significantly different to those immunised with AuNP-LPS. Interestingly, the 
total IgG response seen in animals immunised with LPS was comparable to 
those given AuNP-F1. 
LPS-specific IgG concentrations were also measured and showed a 
similar pattern to total IgG in the degree of response generated, Figure 4.10. 
The greatest LPS-specific IgG response was seen in animals immunised with 
AuNP-TetHc-LPS, which was significantly higher than those immunised with 
AuNP-LPS and LPS alone (p < 0.001) as well as AuNP-F1-LPS (p < 0.005). 
The second highest anti-LPS IgG was generated in mice immunised with AuNP-
F1-LPS which was significantly higher than mice immunised with AuNP-LPS or 
LPS alone (p < 0.05 and 0.01 respectively). In order to understand the type of 
immune response generated better, IgG subclasses IgG1 and IgG2a were also 
measured, Figure 4.11. The first observation is that the amount of IgG1 present 
relative to IgG2a is significantly higher for both AuNP-F1 and AuNP-LPS groups 
(p < 0.001). In all other groups, the observed concentrations of IgG1 and IgG2a 
are comparably similar with the exception of AuNP-TetHc-LPS where IgG2a is 
significantly higher than IgG1 (p < 0.001). Moreover, whilst IgG1 and IgG2a 
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concentrations account for the majority of total IgG measured in all other groups 
(> 70%), these subclasses account for only 26% of total IgG measured from 
mice immunised with LPS. 
Since LPS is a T-independent antigen, IgM responses were also 
measured, Figure 4.12. Mice immunised with AuNP-F1-LPS generated the 
greatest IgM response which was significantly higher than those given AuNP-
LPS or LPS (p < 0.05 and 0.005 respectively). A similarly high response was 
also measured in mice immunised with AuNP-TetHc-LPS, significantly higher 
than LPS (p < 0.05). There was also a statistically significant difference in IgM 
concentration between mice immunised with AuNP-LPS and LPS alone (p < 
0.01). Immunoglobulin class switching was shown by expressing IgM and IgG 
titres as a percentage of the overall immune response (IgM + IgG). The data 
shows a class switch to an IgG dominant response only in mice immunised with 
AuNP-TetHc-LPS. In all other mice vaccinated with an LPS containing 
immunogen there was an equal contribution of IgM and IgG to the overall 
immune response, Table 4.1. 
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Figure 4.8. Typical calibration curve showing the relationship between 
absorption values and antibody concentrations. This was used to determine the 
concentration of antibody subclasses in mouse sera. Each point represents the 
mean of three values and error bars represent the standard error of the mean. 
R2=0.9973. 
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Figure 4.9. Total IgG concentration in sera collected from eight mice, five 
weeks post immunisation with the antigen indicated and determined using 
quantitative ELISA. Error bars represent the standard error of the mean; 
asterisks indicate significant differences (p < 0.001). 
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Figure 4.10. LPS specific IgG concentration in sera collected from groups of 
eight mice, five weeks post immunisation with the antigen indicated and 
determined using quantitative ELISA. Error bars are calculated using the 
standard error of the mean. ** p < 0.01, *** p < 0.001. 
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Figure 4.11. LPS specific IgG and IgG subclass concentration in sera collected 
from groups of eight mice, five weeks post immunisation with the antigen 
indicated and determined using quantitative ELISA. Error bars represent the 
standard error of the mean; asterisks indicate significant differences (p < 0.001). 
 
 
 
 
Chapter 4                                  A Glycoconjugate Vaccine Against Glanders 
101 
 
 
 
 
 
 
 
Figure 4.12. LPS specific IgM concentration in sera collected from groups of 
eight mice, five weeks post immunisation with the antigen indicated and 
determined using quantitative ELISA. Error bars are calculated using the 
standard error of the mean. * p < 0.05, ** p < 0.01. 
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4.3.4 Protection study 
Three weeks after the final immunisation boost of nano-glycoconjugates, 
BALB/c mice were challenged IN with 2.27 x 105 CFU 50 µL-1 (3 x LD50) B. 
mallei China7 strain and their mean time to death was recorded, Figure 3.10. 
The experiment was terminated at 21 days post challenge, which is within the 
known range of protection seen from LPS alone [414]. Following termination of 
the experiment the mice demonstrating the greatest survival were those 
immunised with LPS and AuNP-F1-LPS with 100% survival, Figure 4.13. Other 
groups with high levels of survival were those immunised with AuNP-TetHc-LPS 
and AuNP-LPS, giving an 89% and 78% survival, respectively, although this 
was not significantly different to groups with 100% survival. Control mice 
receiving PBS, AuNP-F1 or AuNP-TetHc had a sharp decline in survival after 4 
days with only AuNP-F1 and AuNP-TetHc groups making it to the end of the 
study with 11% and 22% survival, respectively. There was a statistically 
significant difference between animals immunised with material containing LPS 
compared to control animals (p < 0.001). 
Spleens and livers were removed from five surviving mice of each LPS, 
AuNP-LPS, AuNP-F1-LPS and AuNP-TetHc-LPS immunised groups to 
determine bacterial load, Figures 4.14 and 4.15. Whilst colony counts of greater 
than 1 x 106 were recovered from all spleens, there were significantly lower 
counts found in mice immunised with AuNP-TetHc-LPS and AuNP-LPS 
compared with AuNP-F1-LPS and LPS (p < 0.05). Bacterial colonies recovered 
from the lungs were much lower (> 1 x 103) and there was no significant 
difference between immunisation groups. 
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Figure 4.13. Survival curve for groups of 10 BALB/c mice challenged IN with 3 
x LD50 B. mallei China7, 4 weeks post IP immunisation with 3 x 100 µL doses of 
AuNP-LPS, LPS, AuNP-F1, AuNP-F1-LPS, AuNP-TetHc or AuNP-TetHc-LPS. 
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Figure 4.14. Colony counts of B. mallei taken from homogenised spleens 
removed three weeks post challenge and plated onto selective Ashdown’s 
medium. Each point is the mean of values from five mice immunised with LPS, 
AuNP-LPS, AuNP-F1-LPS or AuNP-TetHc-LPS and then challenged with 3 x 
LD50 B. mallei China 7. Error bars represent the standard error of the mean; 
asterisks indicate significant differences (p < 0.05). 
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Figure 4.15. Colony counts of B. mallei taken from homogenised lungs and 
plated onto selective Ashdown’s medium. Each point is the mean of values from 
five mice immunised with LPS, AuNP-LPS, AuNP-F1-LPS or AuNP-TetHc-LPS 
and then challenged with 3 x LD50 B. mallei China 7. A lobectomy was 
performed three weeks post challenge. Error bars are calculated using the 
standard error of the mean. 
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Table 4.1. Summary of results from “immunisation study 1”. Darkest coloured 
boxes indicate the highest response induced by the immunogens indicated. 
 
 
 
 
 
 
 
Group 
% 
survival 
Total IgG 
(µg/mL) 
IgG2a:1 
LPS 
specific 
IgG 
(µg/mL) 
Total IgM 
(µg/mL) 
IgG, % IgM, % 
AuNP-F1 11 137 ± 1 0.1 11.0 ± 1.5 29 ± 1 27.7 72.3 
AuNP-F1-
LPS 
100 205 ± 4 1 63 ± 2 58 ± 2 52 48 
AuNP-
TetHc 
22 98 ± 2 0.6 11 ± 0.3 35 ± 0.2 24 76 
AuNP-
TetHc-
LPS 
89 228 ± 2 1.1 106.4 ± 0.6 51 ± 2 67.8 32.2 
LPS 100 129 ± 6 1.6 45.1 ± 1.5 36 ± 0.5 55.4 44.6 
AuNP-LPS 78 163 ± 31 0.6 43 ± 0.2 47 ± 0.1 48 52 
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4.3.5 Serum antibody responses 2 
The previous immunisation study was repeated but on a larger scale to 
accommodate some additional protein carriers including the Burkholderia 
proteins Hcp1 and FliC. Antibody isotypes and IgG specific subclasses were 
measured from sera collected from animals 5 weeks post immunisation. Total 
IgG concentrations show that animals immunised with AuNP-FliC-LPS and 
AuNP-FliC generated the greatest overall response, Figure 4.16. Whilst the total 
IgG was significantly higher than all other groups (p < 0.01) there was no 
significant difference between AuNP-FliC-LPS and AuNP-FliC IgG 
concentrations. Conversely, there was a significant difference between AuNP 
glycoconjugates and their protein carrier counterparts; AuNP-F1 compared with 
AuNP-F1-LPS (p < 0.005), AuNP-TetHc compared with AuNP-TetHc-LPS (p < 
0.001) and AuNP-Hcp1 compared with AuNP-Hcp1-LPS (p < 0.05). Animals 
immunised with AuNP-LPS generated a higher IgG concentration than those 
immunised with LPS alone (p < 0.005). 
LPS-specific IgG concentrations were also measured and showed a 
much more definitive picture to the degree of response generated, Figure 4.17. 
Here, the highest IgG titre came from mice immunised with LPS which is 
perhaps surprising considering the poor survival rate of these animals. This was 
closely followed by AuNP-Hcp1-LPS although there was no significant 
difference between the two groups. The antigen-specific IgG concentrations 
generated in animals immunised with material containing LPS was significantly 
higher than their protein carrier counterparts without LPS (p < 0.001). There 
was a statistically higher concentration of LPS-specific IgG raised in mice 
immunised with LPS compared with AuNP-LPS (p < 0.001). IgG subclasses 
IgG1 and IgG2a were also measured to better understand the type of immune 
response generated, Figure 4.18. There is a predominant IgG1 immune 
response in all nano-glycoconjugate groups, with the exception of AuNP-F1-
LPS, accounting for >70% of the total LPS-specific IgG concentration. However, 
in LPS immunised animals, IgG1 accounts for just 22% of LPS-specific IgG and 
the combined total of IgG1 and IgG2a makes up just less than half of the total 
LPS-specific IgG. This result was also apparent in the first immunisation study 
so an ELISA measuring the remaining IgG isotypes was set up, Figure 4.19. 
The shows that just over a third of the total LPS-specific IgG titre from LPS 
immunised mice is comprised of IgG3 in both immunisation studies. 
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Total IgM concentrations were also measured to determine its role in 
protection against B. mallei, Figure 4.20. As with the IgG concentration data, a 
significantly higher concentration of IgM was raised in animals immunised with 
material containing LPS compared to their protein carrier alone counterparts (p 
< 0.001). The highest titres were raised in animals given AuNP-LPS which were 
only marginally higher than those with LPS alone (p < 0.05). Whilst high IgM 
concentrations were measured from mice given AuNP-F1-LPS and AuNP-
TetHc-LPS, relatively low IgM concentrations were measured in AuNP-Hcp1-
LPS and AuNP-FliC-LPS immunised mice, when compared with the other 
groups. Immunoglobulin class switching was shown by expressing IgM and IgG 
titres as a percentage of the overall immune response (IgM + IgG). In contrast 
with the previous study, the data shows a class switch to an IgG dominant 
response only in mice immunised with AuNP-Hcp1-LPS. There was an equal 
contribution of IgM and IgG to the overall immune response in mice immunised 
with AuNP-FliC-LPS. None of the other immunisation groups were able to class-
switch, Table 4.2. 
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Figure 4.16. Total IgG concentration in sera pooled from groups of eight mice, 
five weeks post immunisation with the antigen indicated and determined using 
quantitative ELISA. Error bars are calculated using the standard error of the 
mean. * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 4.17. LPS specific IgG concentration in sera pooled from groups of eight 
mice, five weeks post immunisation with the antigen indicated and determined 
using quantitative ELISA. Error bars represent the standard error of the mean; 
asterisks indicate significant differences (p < 0.001). 
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Figure 4.18. LPS-specific IgG and IgG subclass concentrations in sera pooled 
from groups of eight mice, five weeks post immunisation with the antigen 
indicated and determined using quantitative ELISA. Error bars are calculated 
using the standard error of the mean. 
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Figure 4.19. Side-by-side comparison of LPS-IgG isotypes taken from mice 
immunised with LPS in “immunisation study 1” (LPS 1) and “immunisation study 
2” (LPS 2) Error bars are calculated using the standard error of the mean. 
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Figure 4.20. LPS specific IgM concentration in sera pooled from groups of eight 
mice, five weeks post immunisation with the antigen indicated and determined 
using quantitative ELISA. Error bars represent the standard error of the mean; 
asterisks indicate significant differences (p < 0.05). 
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Table 4.2. Summary of results from “immunisation study 2”. Darkest coloured 
boxes indicate the highest response induced by the immunogens indicated. 
 
 
 
 
 
Group 
Total IgG 
(µg/mL) 
IgG2a:1 
LPS 
specific 
IgG 
(µg/mL) 
Total IgM 
(µg/mL) 
IgG, % IgM, % 
AuNP-F1 275 ± 18 1 3 ± 0.3 22 ± 5 12.5 87.5 
AuNP-F1-
LPS 
335 ± 8 0.9 19 ± 2 82 ± 34 18.7 81.3 
AuNP-
TetHc 
238 ± 6 1 2.8 ± 0.2 20 ± 2 12.6 87.4 
AuNP-
TetHc-LPS 
360 ± 12 0.7 32 ± 4 106 ± 23 23.3 76.7 
LPS 321 ± 13 0.9 67 ± 5 136 ± 7 33.1 66.9 
AuNP-LPS 366 ± 9 0.7 28 ± 6 154 ± 29 15.4 84.6 
AuNP-Hcp1 350 ± 1 1.2 2 ± 0.1 14 ± 3 14.3 85.7 
AuNP-
Hcp1-LPS 
380 ± 2 0.7 63 ± 9 31 ± 6 67 33 
AuNP-FliC 395 ± 10 1 3 ± 0.3 12 ± 0.7 18.1 81.9 
AuNP-FliC-
LPS 
394 ± 4 0.9 27 ± 4 32 ± 11 45.7 54.3 
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4.4 Discussion 
 
4.4.1 LPS extraction 
B. thailandensis was chosen as a source of LPS for the construction of a 
glycoconjugate vaccine against melioidosis and glanders. Not only does B. 
thailandensis LPS have greater immunological activity in murine macrophages 
when compared with LPS from B. pseudomallei but it has been shown that LPS 
from B. thailandensis displays comparable levels of protection against glanders 
and melioidosis in a murine model of infection [414, 422, 428] (personal 
communication). Moreover, there is a material handling consideration; B. 
thailandensis is a biosafety level two (BLS-2) agent so the associated costs and 
hazards are reduced when compared with B. pseudomallei and B. mallei, which 
are both BLS-3 agents. 
LPS was purified from B. thailandensis strain E264 analysed by SDS-
PAGE showed a ladder banding pattern concentrated around 35-75 kDa, similar 
in appearance to other published reports of LPS, not only from B. thailandensis 
but also from numerous strains of B. pseudomallei and B. mallei  [403, 405, 
414, 422, 429]. Additional bands of lower molecular weight were also seen on 
the silver stained gels, which are likely to consist of O-antigen monomers and 
protein impurities. The appearance of these impurities are a lot more prevalent 
in the LPS sample purified from broth culture which suggests that purifying LPS 
from Petri dishes results in a sample of higher purity. Western blotting using 
CC6 mAb to compare the O-antigens of LPS purified from bacteria grown in 
broth to those which were grown on plates showed that the density of the O-
antigen was a lot greater in plate purified LPS. Whilst this helped to identify the 
best method for LPS extraction, it also highlights some potential environmental 
factors which may influence the biosynthesis of Burkholderia LPS. Biofilm 
formation has previously been associated with LPS biosynthesis in other Gram-
negative bacteria, and it is possible the expression of LPS by B. thailandensis is 
upregulated upon biofilm formation [430-433]. 
 
4.4.2 LPS coupling 
In this study, LPS was covalently linked to one of four different protein carriers 
which were immobilised onto AuNPs; F1, TetHc, Hcp1 and FliC. Not only do 
AuNPs act as an immunostimulant for vaccine delivery but also a catalytic 
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surface onto which conjugation chemistry can be performed [434]. This is an 
important feature since many glycoconjugate chemistries suffer from a very 
poor yield. Whilst a reductive amination approach is traditionally used to couple 
polysaccharides onto protein carriers, this requires alkaline conditions owing to 
the high pKa of the ε amino group on the proteins lysine residues. This method 
of coupling is not only slow and inefficient, typically taking several days, but it 
forms reversible Schiff bases which require reduction in order to stabilise the 
linkage formed [257, 435-438]. A borohydride salt is often used as the reducing 
agent for this chemistry which is not only toxic but can hydrolyze pH sensitive 
polysaccharides, such as the one from Neisseria meningiditis A, and could 
reduce the ability to provide protective epitopes [257]. As a result, a thiol-
maleimide approach was taken to couple LPS onto the chosen protein carriers 
in this study. Confirmation of conjugation was confirmed by measuring a shift in 
the λmax of AuNPs from 532 nm for AuNP-TetHc to 541 nm for AuNP-TetHc-
LPS; indicating an overall increase in the mean diameter of AuNP conjugates. 
The extinction peak is also much broader for AuNP-TetHc-LPS suggesting the 
size distribution of particles is much broader which is likely to be due to variable 
lengths of the repeating O-antigen disaccharide on the particles. 
A two-colour western using a rabbit pAb against TetHc and a mouse 
mAb raised against LPS O-antigen identified the presence of both antigens after 
displacing the conjugate from AuNPs and running on an SDS-PAGE. Not only 
does this confirm the presence of both antigens but also the structural integrity 
of their respective epitopes after covalent coupling, based on the reactivity with 
their respective antibodies. Whilst TetHc bands appear to be the same 
molecular weight as the native protein in the adjacent wells, LPS released from 
the glycoconjugate is of a lower molecular weight to the native LPS. This 
observation was also made of a recently characterised B. pseudomallei 
glycoconjugate using a diphtheria toxoid protein carrier [439]. Despite no 
rationale being provided for this phenomenon, it is possible that the attachment 
of a protein carrier to LPS could cause it to move atypically through the gel due 
to changes in the overall surface charge of the molecule. 
The quantification of coupled LPS was carried out using a phenol-
sulphuric acid assay [262, 263, 440, 441]. Using this fast and reliable method it 
is possible to accurately determine the carbohydrate content with a detection 
limit of 1 nmol over the dynamic range 1-150 nmol. This method required a 
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large amount of optimisation, but was indispensible for maintaining a constant 
batch of nano-glycoconjugates for immunisation studies thereafter. The 
concentration of LPS detected on nano-glycoconjugates was determined as 9.6 
µg/mL; approximately 20% of the initial LPS used for coupling. 
 
4.4.3 Immunoglobulin G response 
Antibody classes and isotypes were measured from sera in an attempt to 
identify some of the immunological processes that had been triggered by the 
different vaccines. Over the two immunisation studies, total IgG concentrations 
were highest amongst mice immunised with AuNP-TetHc-LPS compared with 
AuNP-F1-LPS. This is likely to be a result of the additional epitopes provided by 
the carrier protein for recognition by CD4+ Th cells. An increase in IgG 
concentrations when TetHc is used as a protein carrier instead of F1 suggests 
TetHc is a stronger immunogen. This could reflect a higher capacity of TetHc to 
provide antigenic epitopes for recognition by B cells. In the second experiment, 
TetHc was shown again to be a stronger immunogen compared to F1 by 
inducing a higher IgG titre. However, the addition of two nano-glycoconjugates 
using Burkholderia specific proteins (Hcp1 and FliC) to the immunisation study 
resulted in even higher IgG titres. One explanation for a significantly higher IgG 
response from nano-glycoconjugated LPS over uncoupled LPS could be its 
presentation to immune cells. Since the coupling chemistry is selective for 
nucleophilic carbonyl groups in the LPS core region, this leaves the O-antigen 
and lipid A regions free. Whilst the O-antigen provides epitopes for the 
development of antigen-specific antibodies, the lipid A region is a potent agonist 
for TLR4 and evokes a strong immune response from interaction with B 
memory cells. Comparisons between the two experiments show that total IgG 
measured from sera is far greater in the second experiment (2-fold). This could 
be attributed to environmental factors, such as stress of the animals, or batch 
variation of nano-vaccines due to the chemical synthesis or even degradation 
during shipment to UTMB if the samples were handled incorrectly. 
Whilst a high immune response from a vaccine is a promising start, the 
generation of antigen-specific antibodies from memory B cells is key to 
preventing future infections. Consequently, LPS-specific IgG concentrations 
were measured and revealed a similar trend to the total IgG measurements; 
mice immunised with nano-glycoconjugates generated the highest responses. 
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The LPS-specific IgG concentrations from mice immunised with nano-
glycoconjugates was significantly higher than the LPS-IgG from mice 
immunised with LPS alone. This effect may also be due to the presentation of 
LPS in its coupled form and the high density of O-antigen epitopes localised on 
an AuNP surface compared with uncoupled LPS. In the second immunisation 
study, LPS-IgG titres of mice immunised with nano-glycoconjugates and AuNP-
LPS were all similar but significantly lower than the levels measured in the initial 
study by approximately 66%. The highest LPS-IgG titres were found in mice 
immunised with LPS alone. With the exception of AuNP-Hcp1-LPS, which 
generated similarly high levels of IgG, all nano-glycoconjugates generated an 
LPS-IgG response which was less than half that generated by LPS immunised 
mice. This contradictory result to the first experiment could be due to oxidation 
of the O-antigen over time as the conjugates prepared for the second 
experiment were produced using LPS that had been stored for over a year 
following the previous experiment. This underscores the potential importance of 
using high quality LPS for vaccine production, which will be taken into 
consideration in future experiments. Whilst western blot analysis confirmed the 
integrity of the epitope to which it is raised, there may be other epitopes on the 
O-antigen which are no longer available for binding. There may also be 
unforeseen complications with the coupling chemistry affecting the structural 
integrity or presenting LPS in an undesirable conformation. 
Overall, the data presented here suggests that by co-immunising LPS 
with a protein carrier, the total IgG immune response is greater than immunising 
with either a protein or LPS alone. Moreover, the LPS-specific response is also 
greater when LPS is immunised as a glycoconjugate and even more so when 
the protein to which it is coupled is a Burkholderia antigen. This could be due to 
the recruitment of TH cells, by the protein component of the vaccine, which 
activate B-cells into generating a higher concentration of LPS-IgG. 
 
4.4.4 Immunoglobulin class switching 
Evidence of an immunoglobulin class switching event was determined by 
measuring IgM titres and comparing with IgG to identify whether the immune 
response induced in vaccinated mice was in a T-dependent manner. This 
follows the rationale that if CD4+ Th cells are present and encounter activated B 
cells they may skew a class switch recombination event from producing IgM to 
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IgG. Across the two immunisation studies class switch recombination was only 
present in mice immunised with nano-glycoconjugate vaccines. However, the 
dominance of IgG from the TetHc and Hcp1 containing nano-glycoconjugate 
immunised mice suggests that these are the most potent activators of T cells. 
Differentiation of CD4+ T cells into either Th1 or Th2 were then 
interpreted by measuring IgG subclass concentrations since IFN-γ, produced by 
Th1 cells, promotes an IgG switch towards IgG2a whereas TH2 cells support the 
generation of IgG1. IgG subclasses from the first study showed that only those 
immunised with AuNP-TetHc-LPS induced a skewed Th1 response, 
demonstrated by a dominant IgG2a titre. Mice immunised with AuNP-F1-LPS 
displayed a balanced IgG1/2a, and therefore a Th/Th2, immune response. 
These data suggest that mice immunised with either nano-glycoconjugate 
vaccine in the first study would have been able to develop memory T cells for 
protection against subsequent challenges in the future. None of the mice in the 
second experiment were able to generate an IgG subclass switch, meaning the 
Immunoglobulin class switch seen in AuNP-Hcp1-LPS immunised mice was 
probably due to CD4+ Th2 cells. This could be explained by unforeseen 
complications with the coupling chemistry. 
In both experiments, the proportion of IgG1 and 2a as a percentage of 
the IgG were much lower in mice immunised with LPS alone than for other 
immunisation groups. Other LPS-specific IgG subclasses including IgG2b and 3 
were measured from sera of LPS immunised mice and revealed that IgG3 
constituted a significant proportion of the converted IgG from IgM. This is due to 
the interaction of LPS with TLR4 and the resulting signalling molecules, in 
particular IL-10, which results in the generation of IgG3 [391, 442]. The reason 
for the apparent absence of IgG3 from sera other LPS containing immunogens 
could be explained by the production of IFN-γ, predominantly by T cells, which 
inhibits LPS-mediated switching to IgG3 and IgG2b [389]. Whilst the data 
suggests that a TH1 skewed immune response was only induced in two of the 
vaccine candidates tested, the generation of CD4+ T cell mediated immunity 
has been shown to be important for protection against B. pseudomallei infection 
[443]. 
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4.4.5 Survival and tissue colonisation 
It has previously been established that B. thailandensis LPS is able to protect 
against a lethal challenge of glanders and melioidosis so it was not surprising to 
find that mice immunised with LPS alone should retain 100% survival 
throughout the study. This level of protection was also seen in mice immunised 
with AuNP-F1-LPS and similarly with AuNP-TetHc-LPS and AuNP-LPS. 
However, the scope of the first study (21 days) was not sufficient to determine 
whether a long-term memory response that would provide protection beyond 
the timescale within which LPS alone is protective was generated by the nano-
glycoconjugates. Future studies will be necessary to determine if the conjugates 
are able to successfully extend protection from challenge with wild-type bacteria 
beyond this point.  
Whilst sterile immunity was not achieved in any of the groups, a 
significantly lower bacterial count was recovered from the spleens of mice 
immunised with AuNP-TetHc-LPS and AuNP-LPS compared with the spleens 
from mice immunised with AuNP-F1-LPS or LPS (p < 0.05). When colony 
counts were taken from lung tissue, there were no significant differences 
between the groups of immunised mice to the bacterial burden in the lungs. 
However, the fewest bacterial counts were also taken from mice immunised 
with AuNP-LPS. Perhaps if the mice were immunised via a different route, i.e. 
IN, this may have a bigger influence on the colonisation of the lungs by B. 
mallei. 
A comparison between IgM titres and bacterial colony counts from the 
spleen suggests there may be a negative correlation between the two. This is 
not entirely unexpected, since the spleen is a major site for IgM antibody 
production and LPS is a T-independent antigen associated with inducing a 
strong IgM antibody response [422, 444, 445]. However, the significant increase 
in IgM titres of mice immunised with AuNP-LPS over LPS alone, in both 
experiments, suggests that AuNPs themselves play a significant role in 
generating IgM antibodies. Usually triggered by oligodeoxynucleotides with CpG 
motifs, TLR 9 activation is known to mediate IgM production of CD27+ memory 
B cells [446-448]. The elevated production of IgM in mice immunised with 
AuNPs suggests this may serve as an additional agonist to TLR 9. IgM plays a 
key role in pathogen opsonisation by activating the Complement system, 
specifically the Classical Pathway, to induce the binding of C3b onto antigens 
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[449]. It is therefore possible that the high levels of IgM concentrations seen in 
mice given AuNP-F1-LPS, AuNP-TetHc-LPS and AuNP-LPS relative to those 
induced by LPS are the reason for a reduced bacterial burden in these groups 
of mice due to improved clearance of bacteria and infected cells. The significant 
decrease in bacterial colony counts taken from spleen tissue are promising sign 
of moving closer to a vaccine which not only protects, but is able to provide 
sterile immunity. The correlation seen here between elevated IgM titres and 
reduced bacterial numbers suggest that IgM may play a key role in providing 
sterile immunity. 
 
4.4.6 Conclusions 
Growing B. thailandensis on LA plates produces LPS with a much higher O-
antigen density than when grown in LB broth and with fewer impurities. 
 Covalent coupling of LPS onto AuNP conjugated proteins was 
successfully achieved using thiol-maleimide chemistry and quantified using a 
phenol-sulphuric acid assay. 
 The choice of protein carrier used in glycoconjugate vaccine has an 
effect on immunoglobulin titres, with the highest being afforded by antigens able 
to provide a higher capacity of antigenic epitopes for recognition by B cells 
Coupling LPS onto protein carriers resulted in a balanced Th1/ Th2 
immune response. 
A high concentration of IgM results in fewer bacterial colonies of infected 
tissues. 
Future studies will be required to determine if the nano-glycoconjugates 
are capable of providing long term protection based on the T-dependent 
immune response that is induced.  
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Chapter 5: A Glycoconjugate Vaccine against 
Pneumococcus 
 
5.1 Introduction 
 
5.1.1 Pneumococcus 
Streptococcus pneumoniae (pneumococcus) is a facultatively anaerobic, Gram-
positive, α-haemolytic bacterium. As with all bacteria belonging to the genus 
Streptococcus, S. pneumoniae is a commensal bacterium that colonises the 
throat and upper respiratory tract (nasopharynx) of humans [450]. S. 
pneumoniae is also responsible for a range of invasive and non-invasive 
pneumococcal diseases including pneumonia, meningitis and septicaemia 
[451]. Invasive pneumococcal disease constitutes a major global health concern 
in both developed and developing countries. However, those most at risk are 
children under the age of two years old. Pneumococcal pneumonia is the 
leading cause of childhood mortality and accounts for 9% of all deaths in the 
developing world [452]. 
Like many invasive bacteria, S. pneumoniae is surrounded by a capsular 
polysaccharide (CPS) which serves as a key virulence determinant. CPS is 
crucial during colonisation of the nasopharynx and prevents mechanical 
clearance by mucous secretion [453]. The electronegativity of CPS also 
prevents uptake by APC’s and serves as a barrier to reduce exposure to 
antibiotics [454, 455]. The presence of immunochemically distinct CPS with very 
little cross-reactivity between S. pneumoniae strains has led to the identification 
of over 40 different serogroups and 90 different serotypes [456]. The CPS 
associated with these serotypes varies significantly in their structural 
composition. However, only a fraction of those identified are commonly 
associated with causing invasive pneumococcal disease with 12 serogroups 
attributing to over 80% of clinical isolates, Figure 5.1 [457]. The prevalence of 
these disease associated serotypes varies significantly with age, sex and 
geography. For example, serotypes 14, 6B, 19F and 18C are statistically more 
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prevalent among children whereas serotypes 3, 4 and 9V are more common in 
adults [9]. 
 Benzylpenicillin is currently the drug of choice for treatment of 
pneumococcal infections. However, recent years has seen a dramatic increase 
in the number of multi-drug resistant strains; in some areas as many as 35% of 
pneumococcal isolates are penicillin resistant [458-460]. With invasive 
pneumococcal infections a global health burden and the reduced efficacy of 
antibiotic treatment there is an urgent need to develop a safe and effective 
pneumococcal vaccine capable of providing protection against every S. 
pneumonia serotype. 
 
 
 
 
 
 
 
Figure 5.1. Serogroups most commonly associated with causing invasive 
pneumococcal disease. Figure adapted from Scott et al. [457]. 
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Table 5.1. Structural diversity of S. pneumoniae capsular polysaccharide 
serotypes commonly associated with disease. 
S. pneumoniae 
serotype 
Structure Reference 
Type 1 
→4)-α-GalA -(1→3)-α- GalA-(1→3)-α-
6dGalNAc4N -(1→ 
[461] 
Type 2 
→4)-β-D-Glcp-(1→3)-[α-D-GlcpA-(1→6)-α-D-
Glcp-(1→2)]-α-L-Rhap-(1→3)-α-L-Rhap-
(1→3)β-L-Rhap-(1→ 
[462] 
Type 3 →3)-β-D-GlcA-(1→4)-β-D-Glcp-(1→ [463] 
Type 4 
→3)-β-D-ManpNAc-(1→3)-α-L-FucpNAc-
(1→3)-α-D-GalpNAc-(1→4)-α-D-
Galp2,3(S)Py-(1→ 
[464] 
Type 5 
→4)-β-D-Glcp-(1→4)-[α-L-PnepNAc-(1→2)-β-
D-GlcpA-(1→3)]-α-L-FucpNAc-(1→3)-β-D-
Sugp-(1→ 
[465] 
Type 6B 
→2)-α-D-Galp-(1→3)-α-D-Glcp-(1→3)-α-L-
Rhap-(1→4)-D-Rib-ol-(5→P→ 
[466] 
Type 9N 
→4)-α-D-GlcpA-(1→3)-α-D-Glcp-(1→3)-β-D-
ManpNAc-(1→4)-β-D-Glcp-(1→4)-α-D-
GlcpNAc-(1→ 
[467] 
Type 9V 
→4)-α-D-GlcpA(2/3OAc)-(1→3)-α-D-Galp-
(1→3)-β-D-ManpNAc(4/6OAc)-(1→4)-β-D-
Glcp-(1→4)-α-D-Glcp-(1→ 
[468] 
Type 14 
→4)-β-D-Glcp-(1→6)-[β-D-Galp-(1→4)]-β-D-
GlcpNAc-(1→3)-β-D-Galp-(1→ 
[469] 
Type 18C 
→4)-β-D-Glcp-(1→4)-[α-D-Glcp(6OAc) 
(1→2)][Gro-(1→P→3)]-β-D-Galp-(1→4)-α-D-
Glcp-(1→3)-β-L-Rhap-(1→ 
[470] 
Type 19F 
→4)-β-D-ManpNAc-(1→4)-α-D-Glcp-(1→2)-α-
L-Rhap-(1→P→ 
[471] 
Type 23F 
→4)-β-D-Glcp-(1→4)-[α-L-Rhap-(1→2)]-[Gro-
(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→ 
[472] 
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5.1.2 Pneumococcal Vaccines 
A polysaccharide vaccine against pneumococcal infection has been available 
since 1983 which contains CPS from 23 different serotypes (PPV23; serotypes 
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 
22F, 23F and 33F) [451]. The serotypes chosen for this vaccine represent 85-
90% of those that cause invasive pneumococcal infections [452]. The PPV23 
vaccine modulates immunity by stimulating B cells in a T-independent manner, 
which in turn generates high titres of IgM [473]. The high avidity associated with 
IgM enhances opsonisation, phagocytosis and killing of S. pneumoniae. 
However, because the immune response is T-independent there is no 
immunological memory generated and serotype specific antibody levels decline 
substantially after 5-10 years [452]. Moreover, PPV23 is not effective in children 
under the age of two among whom 80% of invasive pneumococcal disease 
occurs [474]. The efficacy of PPV in adults over the age of 65 years also 
remains uncertain [475]. 
These shortcomings let to efforts to design a new and improved 
pneumococcal vaccine based on the strategy employed by the glycoconjugated 
Hib vaccine, which resulted in a reduction of infection rates by >90% after it was 
licensed in 1987 [476, 477]. To create a glycoconjugate vaccine against S. 
pneumonia, diphtheria toxoid cross-reactive material 197 (CRM197) was used as 
a protein carrier to which CPS from thirteen different serotypes was coupled 
(serotypes 1, 3, 4, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) [478]. Unlike some 
toxoid antigens which are heat inactivated, CRM197 is a non-toxic mutant of the 
original diphtheria exotoxin having a single amino acid substitution from glycine 
to glutamate in position 52 [97]. This mutation renders the protein non-toxin but 
remains immunogenic. Conjugation of CPS onto CRM197 results in T cell 
activation as APCs display peptides on either MHC I or MHC II molecules. By 
inducing a T-dependent immune response, B cells are able to undergo isotype 
switching and develop memory B and T cells. This tridecavalent glycoconjugate 
vaccine is currently manufactured by Pfizer under the brand name Prevnar 13® 
and is included in the UK childhood vaccination programme for all children 
under the age of two. 
Since the introduction of pneumococcal vaccines, there has been a 
dramatic reduction in the global incidence of invasive pneumococcal disease [4, 
5]. However, these vaccines have limitations and do not protect against all 
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pneumococcal serotypes. The inclusion of only a select number of CPS 
serotypes into vaccines has also had a profound effect on pneumococcal 
epidemiology. Whilst the incidence of invasive pneumococcal disease caused 
by vaccine serotypes has declined, the incidence of disease from non-vaccine 
serotypes is increasing [6, 10, 479]. This is likely to be a result of horizontal 
gene transfer which enables serotype shifts [6, 8]. There is also some evidence 
to suggest that the vaccines available do not confer good protection in 
individuals at the extremes of age (< 2 and > 60 years old), the 
immunocompromised or pregnant women [261, 480]. 
 
5.1.3 Objectives 
The aim of this chapter is to investigate whether AuNPs could serve as delivery 
system for a glycoconjugate vaccine against pneumococcus to improve 
protection over current alternatives. Current pneumococcal vaccines contain 
several CPS serotypes to protect against those most associated with causing 
disease however this study will focus on just one, serotype 3. CPS serotype 3 is 
one of the most commonly associated with disease and was subsequently 
chosen to be included in both PPV23 and Prevnar 13 vaccines. It is also the 
simplest CPS serotype of those currently identified from S. pneumoniae, 
consisting of a repeating tetrasaccharide. CPS serotype 3 repeating unit is 
present in several other S. pneumoniae CPS serotypes and is cross-reactive 
with serotype 8 which is also associated with causing disease [481-483]. If 
successful with conjugating CPS serotype 3 onto AuNPs then it may be 
possible to apply this method to coupling other CPS serotypes for a polyvalent 
vaccine. 
 Several methods will be employed to aid the coupling of CPS onto 
protein carrier loaded AuNPs and characterised to ensure antigenicity is 
retained. The CPS glycoconjugate will then be tested in a mouse model to 
determine its protective efficacy against a lethal challenge of S. pneumoniae as 
well as measuring immunoglobulin responses to identify the immune responses 
evoked. 
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5.2 Materials and Methods 
 
5.2.1 Coupling chemistry for CPS onto gold nanoparticles 
Thiol maleimide coupling was initially used to couple pneumococcal serotype 3 
capsular polysaccharide (CPS; ATCC®) onto protein conjugated AuNPs using a 
similar approach to one previously mentioned. However, despite varying 
reagent conditions and increasing concentrations of EDC/NHS and EMCH this 
method was unsuccessfully for coupling CPS. A second approach using a 
cyanogen bromide derivative, 1-cyano-4-dimethylaminopyridine 
tetrafluoroborate (CDAP), was also used in an attempt to couple CPS onto 
AuNP conjugated proteins [11, 259]. CPS was solubilised in PBS at 10 mg/mL 
before adding 2.3 M CDAP in 0.1 M acetonitrile. After 30 seconds, 0.2 M 
triethylamine followed by amine coupled AuNPs. The reaction was left to 
incubate overnight at 4 °C before adding ethanolamine to quench the reaction. 
Conjugation with CDAP was unfavourable to AuNPs, often resulting in AuNP 
aggregation shown by a colour change to the reaction mixture and a skewed 
plasmon spectrum. 
A reductive amination approach was also used to conjugate CPS onto 
AuNPs [254, 260, 261]. This was done by solubilising 1.6 mg CPS in 990 µL 
PBS and adding 10 µL 2 M NaBH4 (in 0.1 M sodium bicarbonate) for 1 hour at 
room temperature before dialysing in ultrapure water overnight at 4 °C and 
lyophilising. The lyophilised product was dissolved at 2 mg/mL in PBS 
containing 4 µM sodium meta-periodate in the dark at 23 °C for 90 minutes. 
Oxidation of the CPS was quenched by adding 100 µL ethylene glycol solution. 
The oxidised CPS was dialysed in ultrapure water overnight at 4 °C and 
lyophilised. Oxidised CPS was solubilised to 1 mg/mL in 0.5 M sodium 
cyanoborohydride (in 0.1 M sodium bicarbonate), pH 8.1. AuNPs coupled with 
either TetHc or an aminated MHDA linker, prepared as previously described, 
were centrifuged at 1366 x g for 10 minutes and resuspended into the CPS, 
cyanoborohyrdide solution. The mixture was allowed to incubate at room 
temperature for 7 days with gentle agitation. Progress of conjugation was 
monitored by removing aliquots at various times points and measuring the 
absorption spectra for a spectral shift in λmax. Once conjugation was complete, 
50 µL 2 M sodium borohydride (in 0.1 M sodium bicarbonate) was added for 1 
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hour at room temperature. The newly formed glycoconjugates were centrifuged 
and resuspended in PBS with 260 µL 13 mg/mL alhydrogel. 
As well as confirming conjugation using optical absorption, a western blot 
using a rabbit polyclonal antibody raised against TetHc and sera against CPS 
(Statens Serum Institut) was performed. Protein concentration was measured 
using a BCA assay whilst CPS concentration was content was measured by the 
previously described phenol-sulphuric acid assay, using the native CPS as a 
standard. 
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5.3 Results 
 
5.3.1 CPS conjugation 
Several methods were employed in an attempt to conjugate pneumococcal 
serotype 3 capsular polysaccharide (CPS) onto protein conjugated AuNPs. The 
first was using thiol maleimide coupling, as described in the previous chapter. 
However, despite varying reagent conditions and increasing concentrations of 
EDC/NHS and EMCH to generate a maleimide derivatised CPS, this method 
proved unsuccessful. Measurements of AuNP plasmon spectra after thiol 
maleimide coupling showed no change to the extinction and western blots were   
negative for CPS conjugation. A second method using a cyanogen bromide 
derivative, 1-cyano-4-dimethylaminopyridine tetrafluoroborate (CDAP), was also 
employed for conjugating CPS. Treatment of polysaccharides with CDAP 
results in random activation of hydroxyl groups to which a bifunctional linker can 
be attached [259]. The simplicity of this three-step reaction was appealing but is 
limited in its application for AuNP conjugation, resulting in aggregation of 
AuNPs as shown by a change in solution colour and the plasmon spectra, 
Figure 5.2. Reductive amination was another technique used, adapted from the 
methods of Laferrière et al. and Jennings [260, 261]. This involved generating 
ananomeric aldehyde at the reducing termini of CPS by reducing carboxyl 
groups to alditols prior to limited treatment with periodate, Figure 5.3. Using mild 
conditions, the degree of oxidation was limited to approximately 25% of 
carboxyl residues to avoid altering the conformation or antigenicity of the 
polysaccharide [12]. Protein coupled AuNPs were added to the newly formed 
aldehyde derivatives which underwent alkylimino-de-oxo-bisubstitution to form a 
reactive imminium cation. Sodium cyanoborohydride (NaBH3CN) was chosen to 
reduce the immine, which took approximately 7 days. Once conjugation was 
complete, sodium borohydride was added to reduce any remaining aldehyde 
groups and the conjugate purified using centrifugation and resuspended into 
PBS with 0.26% (w/v) alhydrogel. The mechanistic approach for reductive 
amination coupling is outlined in Figure 5.4. 
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Figure 5.2. UV-visible absorption spectra for glycoconjugates using CDAP 
coupling chemistry. Displayed are AuNPs (black), AuNPs functionalised with 
MHDA (red), AuNPs functionalised with MHDA coupled with TetHc (blue) and 
AuNPs coupled with TetHc and S. pneumoniae serotype 3 CPS (green). 
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Figure 5.3. Skeletal structure of S. pneumoniae serotype 3 CPS illustrating the 
repeating glucuronic acid and glucose tetrasaccharide [→4)-β-D-GlcUA-(1→3)-
β-D-Glc-(1→]. The anomeric aldehyde for reacting with amines is circled  
 
 
 
 
 
 
Chapter 5                       A Glycoconjugate Vaccine Against Pneumococcus 
132 
 
 
 
 
 
 
 
 
Figure 5.4. Reaction scheme of reductive amination between CPS and protein 
coupled AuNPs; (1) mild oxidation of carboxyl groups at the reducing end of 
CPS to aldehydes, (2) addition of AuNP-protein to form an imminium cation 
(secondary aldimine), (3) reduction of immine using cyanoborohydride to form a 
secondary amine. 
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5.3.2 Glycoconjugate characterisation 
The progression of CPS coupling onto AuNPs was monitored by removing 
aliquots and measuring the optical extinction of AuNPs for a shift in λmax. 
Measurements were taken every other day until there was a plateau of readings 
for λmax, Figure 5.5. A red-shift in λmax of 20 nm from 532 nm for AuNP-TetHc to 
552 nm indicates an overall increase in the mean diameter of AuNP conjugates 
as a result of CPS conjugation. This large shift in λmax is indicative of a large 
molecular weight molecule binding to the gold surface. The extinction peak is 
also much broader for AuNP-TetHc-CPS which suggests the size distribution of 
particles is much larger. This is likely to be due to variable lengths of the 
repeating tetrasaccharide unit on the particles, Figure 5.6. 
Following conjugation of the antigens, the samples were examined by 
western blotting, Figure 5.7. The glycoconjugate was released from AuNPs 
using 11-mercapto-1-undecanol before it was separated using SDS-PAGE and 
transferred onto a nitrocellulose membrane. The membrane was incubated with 
a rabbit pAb specific to TetHc and rabbit antisera raised against S. pneumoniae 
serotype 3 CPS (Statens Serum Institut). Secondary antibodies raised against 
rabbit with a horseradish peroxidise conjugate were then added before the blot 
was visualised. Western blotting confirmed that the structural 
integrity/antigenicity of the CPS moieties remained intact following chemical 
activation and linkage to the protein carrier based upon their reactivity with the 
pAb. The gel also indicates CPS coupling to the TetHc protein carrier from the 
extended banding region of the conjugated CPS relative to the unconjugated 
control. 
A phenol-sulphuric acid assay was used to determine the concentration 
of CPS present in glycoconjugates. Using concentrated sulphuric acid, CPS 
was hydrolysed and dehydrated into monomeric furfural molecules which then 
formed a chromagen upon addition of phenol [427]. This method allows for a 
reliable and sensitive determination of polysaccharides down to 1 nmol, with a 
linear relationship between absorbance and concentration up to 150 nmol [263]. 
Using this assay, the amount of CPS measured was determined to be 100 
µg/mL. 
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Figure 5.5. Progressive UV-visible absorption spectra for CPS coupling to 
AuNP-TetHc over 9 days; Plasmon spectra of aliquots undergoing reductive 
amination at days 1, 3, 5, 7 and 10 (A), maximum extinction (λmax) from spectra 
measured during the time course (B). 
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Figure 5.6. UV-visible absorption spectra for glycoconjugates using reductive 
amination coupling chemistry. Displayed are AuNPs (black), AuNPs 
functionalised with MHDA (red), AuNPs functionalised with MHDA coupled with 
TetHc (blue) and AuNPs coupled with TetHc and S. pneumoniae serotype 3 
CPS (green). 
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Figure 5.7. Western blot of AuNP-TetHc-CPS separated using a NuPAGE 4-
12% Bis-Tris gel; LiCor protein marker (a), AuNP-TetHc-CPS treated with 11-
mercapto-1-undecanol (b and c), 1 µg CPS (d and e). A rabbit pAb against Hc 
and rabbit antisera against CPS serotype 3 were used to bind TetHc and CPS, 
respectively. Goat anti-rabbit HRP conjugated secondary antibodies were used 
to detect primary antibody binding. 
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5.3.3 Immunoglobulin response 
An immunisation and protection study was designed alongside colleagues at 
Glasgow University to test the protection of nano-glycoconjugate vaccines 
against a S. pneumoniae inhalation challenge. Immunisations were carried out 
at Glasgow University in MF1 mice with a 100 µL priming dose followed by two 
booster immunisations at the same volume using Prevnar13, AuNP-TetHc, 
AuNP-CPS or AuNP-TetHc-CPS with an aluminium hydroxide adjuvant 
(alhydrogel). In a 100 µL dose, Prevnar 13 contains 0.44 µg of each CPS 
serotype (except serotype 6B which is 0.88 µg) [480]. Therefore a similar dose 
of 0.5 µg serotype 3 CPS was used for the nano-glycoconjugate immunised 
mice. Five weeks post immunisation 100 µL of blood was taken from the tail 
vein of each mouse and shipped to Exeter where antibody isotypes and IgG 
specific subclasses were measured using an ELISA. 
Total IgG concentrations showed that average IgG titres were higher in 
mice immunised with either AuNP-TetHc-CPS or Prevnar 13 and lowest for 
AuNP-CPS immunised mice. However, there was no statistically significant 
difference in IgG concentration between any of the immunised groups. An IgG 
concentration of approximately 200 µg/mL was measured from sera taken from 
each group, Figure 5.8. CPS-specific IgG concentrations were also measured 
and indicated that mice immunised with AuNP-TetHc-CPS exhibited 
significantly higher anti-CPS IgG titres than those immunised without a protein 
carrier (AuNP-CPS; p < 0.05). Moreover, despite the mice being immunised 
with the same concentration of CPS serotype 3 there was a significantly higher 
concentration of anti-CPS IgG from mice immunised with AuNP-TetHc-CPS 
rather than Prevnar 13 (p < 0.001). The amount of anti-CPS IgG generated from 
AuNP-CPS was also significantly higher than Prevnar 13 (p < 0.001), Figure 
5.8. 
Since CPS is a T-independent antigen, IgM responses were also 
measured. The highest IgM concentration generated was found in mice 
immunised with Prevnar 13, which was significantly higher than AuNP-TetHc-
CPS (p < 0.01). There was no other significant difference in IgM concentration 
between any of the other immunisation groups, Figure 5.10. 
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Figure 5.8. Total IgG concentration in sera collected from six mice, five weeks 
post immunisation with the antigen indicated and determined using quantitative 
ELISA. Error bars are calculated using the standard error of the mean. 
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Figure 5.9. CPS-specific IgG concentration in sera collected from six mice, five 
weeks post immunisation with the antigen indicated and determined using 
quantitative ELISA. Error bars are calculated using the standard error of the 
mean. * p < 0.05, *** p < 0.001 
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Figure 5.10. Total IgM concentration in sera collected from six mice, five weeks 
post immunisation with the antigen indicated and determined using quantitative 
ELISA. Error bars represent the standard error of the mean; asterisks indicate 
significant differences (p < 0.01) 
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IgG subclasses IgG1 and IgG2a were measured as an indicator of Th2 or Th1 
immune responses, respectively. This identified Prevnar 13 as inducing a 
predominant IgG1 response, relative to IgG2a, making up a large proportion of 
total IgG (p < 0.01). Mice immunised with AuNP-TetHc-CPS however generated 
a predominant IgG2a response, with a relatively low IgG1 concentration (p < 
0.01). The IgG2a concentration generated by AuNP-TetHc-CPS immunised 
mice was significantly higher than any other group (p < 0.01). Subclass 
switching from IgG1 to IgG2a was also evident in AuNP-CPS immunised mice 
(p < 0.05) whilst those receiving AuNP-TetHc had an equal concentration of 
IgG1 and IgG2a, Figure 5.11. Further clarification of IgG subclass switching is 
illustrated in Figure 5.12 which shows a ratio of IgG1 in relation to IgG2a. 
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Figure 5.11. Total IgG and IgG subclass concentration in sera collected from 
groups of six mice, five weeks post immunisation with the antigen indicated and 
determined using quantitative ELISA. Error bars are calculated using the 
standard error of the mean. * p < 0.05, ** p < 0.01 
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Figure 5.12. Relative concentrations of IgG1 and IgG2a in sera from MF1 mice 
after immunisation with the antigens indicated. Figure presented as a ratio of 
IgG2a:IgG1. Each point is the mean of values from five mice. Error bars are 
calculated using the standard error of the mean. 
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5.3.4 Protection study 
Four weeks after the final immunisation boost of nano-glycoconjugates, MF1 
mice were challenged IN with 2.5 x 105 CFU 50 µL-1 S. pneumoniae Xen10; a 
bioluminescent version of the parent strain A66.1 serotype 3. Using this strain 
enabled unaltered in vivo imaging of the disease as it progressed through the 
mice, Figure 5.10. Mice were imaged every 24hours and scored according to 
the degree of luminescence. Within 48 hours post infection (hpi) signs of the 
disease were evident in PBS mice, with the lungs being the area of greatest 
colonisation. As the time course continued to 72 hpi, the degree of infection 
relative to the bioluminescence in PBS mice is greater and the number of 
animals showing signs is higher. There is also a lung infection in one of the 
AuNP-TetHc immunised mice. Eight days post infection and colonisation of the 
nasopharynx is evident in one of the mice immunised with Prevnar 13. Infection 
was only ever apparent in either the lungs or nasopharynx of the mice. Any 
mouse which showed signs of colonisation eventually succumb to infection, 
appendix 3. 
The experiment was terminated after 10 days, and the survivability of 
each immunisation group recorded, Figure 5.11. The only group with 100% 
survival were those immunised with AuNP-TetHc-CPS. Both AuNP-CPS and 
Prevnar 13 immunised mice had 83% survival whilst the AuNP-TetHc had 67% 
survival. There was however no significant difference in mean survival between 
any of the test groups. A survival rate of 16% was afforded in PBS mice which 
was a statistically significant difference between these mice and the three test 
groups (p < 0.01). 
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Figure 5.13. In vivo imaging using FxPro imaging of MF1 mice challenged IN 
with 2.5 x 105 CFU 50 µL-1 S. pneumoniae Xen10 four weeks post SC 
immunisation; Luminescence scale in radiance (p/sec/cm2/sr) (a), PBS 
immunised mice 48 hpi (b), PBS immunised mice 72 hpi (c), AuNP-TetHc 
immunised mice 72 hpi (d), Prevnar 13 immunised mice 8 days pi (e). 
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Figure 5.14. Survival curve for MF1 mice challenged IN with 2.5 x 105 CFU 50 
µL-1 S. pneumoniae Xen10 four weeks post SC immunisation. 
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5.4 Discussion 
 
5.4.1 CPS conjugation 
Thiol maleimide, CDAP and reductive amination coupling chemistries were 
employed for conjugating pneumococcal CPS serotype 3 onto a TetHc protein 
carrier on AuNPs. Of these methods, reductive amination was the most 
successful and was chosen for further optimisation. Whilst the conditions 
required for reductive amination can create a harsh environment for the 
antigens concerned, steps were taken to avoid this wherever possible. Firstly, 
the formation of aldehyde groups at the reducing termini of CPS was facilitated 
by mild periodate oxidation rather than peroxide which can reduce the 
immunogenicity of antigens [484]. Sodium cyanoborohydride was chosen as the 
primary reducing agent since, unlike sodium borohydride, it reduces only Schiff 
bases without modifying other chemical groups in the sample [485]. Finally, the 
reaction was carried out in sodium bicarbonate rather than sodium hydroxide, 
which is a weaker nucleophile and results in a slower reaction time but is less 
likely to create any by-products by reacting with any residues which are 
sensitive to strong bases [486]. Moreover, reductive amination coupling has 
several advantages over other coupling techniques used such as the direct 
formation of neoglycoconjugates rather than using CDAP which creates cross-
linked network conjugates [487]. 
UV/Vis spectroscopy analyses indicated that CPS had covalently linked 
to TetHc. The extinction peak was also much broader for AuNP-TetHc-CPS 
suggesting the size distribution of particles is much broader, likely to be due to 
variable lengths of the repeating tetrasaccharide unit on the particles. SDS-
PAGE and western blotting confirmed that not only was the structural integrity of 
the antigens intact, based on their reactivity with specific antibodies, but also 
the conjugation of CPS which displayed a lower molecular weight banding 
pattern to the unconjugated control. This may be the result of selection from the 
coupling chemistry favouring shorter tetrasaccharide repeats or a result of the 
highly charged polysaccharide moving atypically through the gel after protein 
attachment. 
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5.4.2 Immunoglobulin response 
Polysaccharide antigens are weak immunogens unable to elicit T-independent 
immune response. However, conjugation to a protein carrier recruits Th cells 
which boost the antigen-specific immune response, stimulate isotype switching 
and evoke immunological memory [62, 488]. This was demonstrated by 
immunising MF1 mice with AuNP-TetHc-CPS, AuNP-CPS, AuNP-TetHc or 
Prevnar 13 and measuring the immunoglobulin responses. Analysis of the 
resulting serum samples indicated that mice immunised with the glycoconjugate 
generated a significantly higher concentration of anti-CPS IgG than those 
immunised with AuNP-CPS. Nano-glycoconjugate immunised mice also 
exhibited significantly higher IgG2a titres (2-fold) as a result of isotype 
switching. 
 The currently licensed glycoconjugate vaccine against pneumococcus, 
Prevnar 13, was used to evaluate the efficacy of coupling a glycoconjugate onto 
AuNPs. Despite mice being immunised with the same concentration of CPS 
serotype 3, mice immunised with AuNP coupled glycoconjugate induced a 
significantly higher concentration of anti-CPS IgG (p < 0.001). Stimulation of 
isotype switching was also more evident in AuNP-TetHc-CPS immunised mice 
which generated a lower IgM titre and a dominant IgG2a response. In mice, the 
production of the IgG2a antibody isotype is widely recognised as characteristic 
of a Th1 response, which is required for the generation of Tm [389]. Greater 
stimulation of a Th1 immune response could mean an improved immunological 
memory over Prevnar 13, resulting in fewer booster shots required for protective 
immunity, which currently stands at 4 [489]. These results show that the delivery 
of glycoconjugates by gold nanoparticles can significantly improve the T-
depending immune response generated by the vaccine, suggesting the 
potential for improved long-term immunity. 
 
5.4.3 Protection study 
The efficacy of nano-glycoconjugated vaccines against pneumococcus was 
tested by challenging mice with a bioluminescent variant of S. pneumoniae 
A66.1 serotype 3, named Xen10 [490]. Once the experiment had been 
terminated after 10 days, AuNP-TetHc-CPS immunised mice had the highest 
degree of survival at 100% which, despite being significantly different to AuNP-
TetHc immunised mice, showed no difference to any other immunised group. 
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Moreover, there was a high degree of protection afforded by the negative 
control, AuNP-TetHc immunised mice, which may be due to the triggering of an 
innate immune response. To overcome this, the time between final 
immunisation and challenge should be extended in future studies. In addition, 
future studies will need to evaluate the ability of gold nanoparticles to improve 
the protective ability of glycoconjugates based on additional CPS serotypes 
including but not limited to those covered by the Prevnar 13 vaccine currently 
on the market to determine if this technology can be more generally applied with 
similarly positive results. 
 
5.4.4 Conclusions 
 Covalent coupling of CPS onto AuNP conjugated proteins was 
successfully achieved using reductive amination chemistry and characterised 
using measuring plasmon shifts and western blotting.  
Coupling CPS onto a TetHc protein carrier resulted in a greater CPS-
specific IgG immune response and IgG2a titre. 
 Coupling a pneumococcal glycoconjugate vaccine onto AuNPs resulted 
in a dominant Th1 immune response characterised by an IgG2a dominant titre, 
suggesting an improved T-dependent immune response capable of long term 
protection. 
 These results suggest that the gold nanoparticle delivery technique can 
be applied to improve the glycoconjugate vaccine currently available to protect 
against S. pneumoniae infections.  
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Chapter 6: Discussion and Future Work 
 
 
6.1 Discussion 
The overall goal of this project was to identify a suitable NP composite for use 
as a vaccine delivery system and explore some of the chemistries available to 
conjugate antigens onto NPs. Once antigens were successfully coupled onto 
AuNPs the further aim was to test the efficacy of this newly designed antigen 
delivery system for use in glycoconjugate vaccines against a number of 
biologically important human pathogens including Y. pestis, B. mallei and S. 
pneumoniae. 
From the extensive choice of NP materials to choose from non-
degradable NPs were selected for surface presentation of antigens. Recent 
developments in inorganic chemistry have allowed the fabrication of well-
dispersed metal NPs of various compositions for exploiting as promising 
candidates in biomedical applications. Among them are AuNPs, which have 
been appraised for their excellent biocompatibility and low cytotoxicity [308]. 
AuNPs have been used in humans since the 1950’s, which suggests that future 
licensing of a NP vaccine might be easier if it were made from gold [491]. In this 
study, AuNPs were chosen because they can be synthesised to a variety of 
sizes and shapes which can be manipulated by varying the conditions used to 
reduce gold (III). Of the methods used to generate AuNPs, citrate reduction was 
determined to be the optimal method, generating spherical particles which were 
near monodisperse. The spherical shape afforded by this technique is has been 
demonstrated as an important feature for increased uptake into dendritic cells, a 
key component of the adaptive immune response [492, 493].  Moreover, 
clearance of nanospheres in rodents after immunisation is much greater than 
for nano-filaments (10-fold) which may be important in reduced toxicity [492]. 
The monodisperse population of particles generated is thought to be important 
for consistent antigen loading and epitope density on the NP surface. We 
believe this consistent antigen delivery will allow us to reproducibly produce 
homogenous vaccines suitable for reliably determining the protective ability of 
vaccine candidates. 
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Another advantage of using AuNPs is the unique optical properties 
offered by gold due to LSPR. This was manipulated to characterise the surface 
of AuNPs based on the localised plasmon penetration depth which is limited to 
90 nm and is therefore exclusive of the surrounding media [279]. These 
properties enabled the measurement of substances bound to the nanoparticle 
surface to characterise surface modifications in a label-free manner, something 
which is unrealistic for other NP composites. Moreover, the gold composition of 
NPs used in this study enables surface functionalisation with thiol containing 
compounds, which have a high affinity for gold (approximately 200 kJ mol-1) 
[494]. As such, the use of MHDA as a bi-functional linker for antigen coupling 
readily forms a self-assembled monolayer on the AuNP surface [495]. 
Having established that AuNPs were a suitable scaffold for vaccine 
design, we next sought to test the ability of these NPs to be conjugated with 
protein antigens. Proteins were selected based on their ability to induce a 
strong immune response (TetHc) or use as subunit vaccine candidates (F1, 
Hcp1 and FliC) in previous studies. All four proteins were successfully coupled 
to AuNPs. Of these, F1 coupled AuNPs were chosen for immunising BALB/c 
mice in preliminary experiments to test the effects of AuNPs on inducing an IgG 
response because F1 has previously been demonstrated to provide significant 
protection as a subunit vaccine against a lethal challenge of Y. pestis [340]. 
These immunisation experiments showed that AuNP coupled F1 induced an 
elevated and prolonged IgG response compared to the protein alone, 
suggesting that this delivery method has the potential to improve existing 
vaccine candidates. One explanation for this could be due to the size and shape 
of the nanoparticles being conducive to repetitive antigen presentation, which is 
known to lead to an efficient cross-linking of B cell receptors [496, 497]. In turn, 
B cell cross-linking gives rise to a more sustained production of antibodies; a 
phenomenon commonly associated with B cell recognition of viral proteins. 
Alternatively this elevated antibody production could be due to an increased 
uptake of F1 antigen into dendritic cells. 
Protein subunit vaccines have long been investigated for their protective 
ability, and our data suggests that conjugation to AuNPs could improve their 
effectiveness. However, these vaccines have had limited success in achieving 
full protection. In contrast, conjugating a protein antigen to polysaccharides has 
proved to be a much more successful strategy. For example, Hib, 
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meningococcal type C and S. pneumoniae vaccines. One of the reasons for 
their success is polysaccharides are known to be one of the most immunogenic 
bacterial antigens when delivered to mammalian cells but are generally not 
recognised by T cells and therefore induce a T-independent immune response. 
One of the biggest problems with glycoconjugate formation is the use of toxic 
reagents and inefficient yield of resulting glycoconjugates. Thus, the next step in 
this study was to test whether AuNPs could be used to deliver a glycoconjugate 
vaccine consisting of previously identified vaccine candidates. The first 
glycoconjugate designed in this study was against B. mallei using LPS coupled 
to protein antigens previously characterised as binding to AuNPs. One of the 
reasons for targeting this organism for vaccine development was based on 
other studies suggesting that a vaccine capable of inducing a T-dependent 
immune response is likely to be required for protection against glanders and 
melioidosis [498, 499]. Previously, this was achieved through co-immunising 
LPS with a covalently linked protein carrier [429, 439, 485]. In doing so, it is 
believed that the protein carrier elicits T cell help for B cells recognising the O-
antigen [500]. Whilst these studies have proven that immunoglobulin isotype 
switching does occur to a more favourable T-dependent response with 
glycoconjugate vaccines, there has not yet been any challenge studies to test 
the protective capabilities of these vaccines. However, Brett and Woods were 
able to show that immunising rabbits with LPS O-antigen conjugated to flagellin 
proteins elicited a high IgG titre which was capable of protecting diabetic rats 
from a B. pseudomallei challenge [429]. Glycoconjugation using B. 
thailandensis LPS onto protein carrier-AuNPs was performed using thiol-
maleimide coupling. One of the advantages of using this chemistry was the 
preservation of the O-antigen which remained unaltered by the coupling 
method. Moreover, the adjuvantal lipid A is also presented on the surface which 
is able to stimulate an innate immune response through its activation of TLR 2 
and TLR 4 [501]. Whilst the presence of lipid A might prove useful in these 
preliminary studies for increasing the immune response, further developments 
may require cleavage of the lipid A due to its endotoxicity [502]. The promising 
data gained from this study using B. thailandensis LPS glycoconjugate coupled 
to AuNPs is reflected by its approval to be tested in a macaque model of 
infection for further investigation. 
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Some of the most compelling data for NP use in vaccine delivery came 
from the glycoconjugate vaccine developed against S. pneumoniae in this 
study. Using the same coupling chemistry as the one used to synthesise 
Prevnar 13, we were able to show elevated antigen-specific IgG titres for CPS 
conjugated AuNPs in comparison to a currently available pneumococcal 
vaccine [503]. This was true not only of glycoconjugated CPS on AuNPs but 
also without a protein carrier to recruit T cell involvement. Glycoconjugated 
AuNPs were able to generate a significantly higher titre of IgG2a, and ratio to 
IgG1, compared with Prevnar 13. This suggests a role for AuNPs in inducing 
immunoglobulin subclass switching which is a key feature of glycoconjugate 
vaccines and is essential for generating higher avidity antibodies and 
immunological memory [504]. 
To determine how AuNPs were able to induce their adjuvantal effect, 
some preliminary studies were performed to look into the mechanisms which 
regulate their uptake into macrophage cells. Transmission electron microscopy 
(TEM) was used to identify whether AuNPs were taken up by phagocytic cells 
and if they could be imaged. After one hour incubation with AuNPs, J774A.1 
macrophages were fixed using 4% paraformaldheyde and 1% glutaraldheyde 
before setting in epon812 polymer resin. 70 nm sections were cut from the resin 
using a microtome and then imaged using TEM, Figure 6.1. Due to the high 
electron density of the particles, AuNPs can be clearly seen as distinct black 
dots. In a second image, Figure 6.2, the AuNP is at the cell’s periphery and 
appears to be surrounded by an invaginated membrane vesicle, suggesting 
phagocytosis. Due to the 70 nm cross section taken through the cell, we were 
able to conclude that these particles were inside macrophage cells. 
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Figure 6.1 A transmission electron micrograph of a 70 nm slice through a 
J774A.1 macrophage cell after 1 hour incubation with AuNPs (arrow). Bar is 10 
µm. 
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Figure 6.2 A transmission electron micrograph of a 70 nm slice through a 
J774A.1 macrophage cell after 1 hour incubation with AuNPs (arrow). Bar is 10 
µm. 
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Once confirmed as being taken up by murine macrophages, it was then 
the intention to establish some of the mechanisms by which nanoparticles are 
taken up by cells. This was to be determined by staining for the presence of 
endosomal compartments in macrophages after incubation with AuNPs. AuNPs 
were coupled with GFP using carbodiimide chemistry followed by incubation 
with J774A.1 macrophages for 1 hour. Confocal-laser scanning microscopy was 
used to image the co-localisation of GFP-fluorescent AuNPs with macrophage 
cells, Figure 6.3. The image shows a clear association between the cells and 
GFP conjugated AuNPs. AuNPs also appear to be located in the cytosolic area 
of macrophage cells with no GFP fluorescence detected in the nucleus of the 
cell; a result consistent with other studies [193]. The experiment was then 
repeated to determine whether phagocytic vesicles were formed to internalise 
AuNPs. A fluorescently tagged antibody against lysosomal-associated 
membrane protein 1 (LAMP1) was used which identifies markers present in late 
endosome formation, specifically the fusion event between a phagosome and a 
lysosomes to form a phagolysosome, Figure 6.5 [505]. A series of optical 
sections were stacked (Z-stacked) by moving the focal point through the depth 
of the cell to determine to position of fluorescent indicators within the cell, 
Figures 6.6 and 6.7. From these images the presence of a LAMP1 within the 
cell is clear however there is no co-localisation with GFP conjugated AuNPs. 
One explanation for this could be the Cy5 fluorescence quenching the GFP 
emission or proteolytic degradation of the amide conjugated GFP in the 
phagolysosome. Whilst there are several triggers identified for initiating 
phagocytic uptake by professional phagocytes, size dependency is one of the 
most important [203]. Phagocytosis is usually triggered in response to larger 
particles, typically 500 nm [198]. Since the NPs used in this study are only 15 
nm in diameter, the association of AuNP uptake and phagocytosis is unusual. 
Uptake into phagosomes could be due to an aggregation effect of the NPs on 
the surface of the macrophages. Once aggregation reaches a certain size (> 
500 nm) this could trigger a phagocytic response to engulf AuNPs. In addition, 
there are GFP conjugated AuNPs within the cytosol which are not associated 
with LAMP1. This could suggest the particles are able to enter macrophage 
cells through clathrin-independent pathways which typically avoid lysosomal 
fusion [506]. Alternatively there are some suggestions that NPs are able to 
enter cells by penetrating through the plasma membrane exclusive of any 
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macrophage uptake mechanisms [507]. However, the mechanisms involved in 
NP uptake into mammalian cells remains to be characterised better. 
 
 
 
 
 
 
 
Figure 6.3 A confocal microscopy image of J774A.1 macrophage cells, stained 
with DAPI (blue), after 2 hours incubation with GFP conjugated AuNPs (green). 
Bar is 20 µm. 
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Figure 6.4 A confocal microscopy image of J774 macrophage cells after 1 hour 
incubation with GFP conjugated AuNPs (green). Bar is 10 µm. 
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Figure 6.5 A confocal microscopy image of J774A.1 murine macrophage cells, 
stained with DAPI (blue), after 2 hours incubation with GFP conjugated AuNPs 
(green) and probed with LAMP1 endosomal marker (red; arrow). Bar is 10 µm. 
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Figure 6.6 A 4.54 µm z-cross section slice of J774 macrophage cells, stained 
with DAPI (blue), after 2 hours incubation with GFP conjugated AuNPs (green) 
and probed with a Cy5 conjugated anti-LAMP1 endosomal marker (red). Bar is 
10 µm. 
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Figure 6.7 A 9.08 µm z-cross section slice of J774 macrophage cells, stained 
with DAPI (blue), after 2 hours incubation with GFP conjugated AuNPs (green) 
and probed with a Cy5 conjugated anti-LAMP1 endosomal marker (red). Bar is 
10 µm. 
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Identifying the mechanisms involved in intracellular uptake of antigens is 
crucial in understanding how vaccine antigens are processed as part of the 
immune response they elicit. Endocytic uptake of molecules includes 
phagocytosis, macropinocytosis, clathrin- and caveolae-mediated endocytosis, 
which follow the principle components of the endocytic pathway. Once 
molecules are internalised by an invagination, or “ruffling” of the plasma 
membrane, the newly formed early endosome and matures into a late 
endosome [508]. Late endosomes fuses with lysosomes to form 
endolysosomes which express LAMP1 and degrade the endocytosed cargo 
[509]. Degraded peptides are then displayed on MHC II receptors for CD4+ T 
cell recognition [510]. However, if NPs are able to internalise within cells 
exclusive of endosomal pathways this could result in protein degradation by the 
proteosome and a subsequent display of peptides on CD8+ T cells. This could 
be particularly beneficially for vaccines against viruses or intracellular 
pathogens, such as the ones described in this study, since Tc cells play a key 
role in providing protection against intracellular infections. 
 
6.2 Future work 
Delivery of both protein and glycoconjugate vaccine candidates using AuNPs 
has been successfully demonstrated. One of the reasons it is believed that this 
delivery method is successful at increasing the immune response may be due 
to the highly repetitive antigen density on the surface of AuNPs. However, it 
may be possible to couple multiple antigens onto the NP surface for developing 
a polyvalent vaccine. Polyvalent vaccines are able to provide protection against 
several pathogens in a single, or fewer number of doses, making it a more 
favourable immunisation strategy than several doses of multiple vaccines. 
Polyvalent vaccines have also been shown to be economically favourable due 
to reduced storage and transport costs. 
Organisation of antigens in glycoconjugates on the AuNP surface could 
be rearranged so that a protein carrier is distal to the NP. This may lead to a 
faster immune response as protein epitopes are presented to the immune 
system so the rate at which peptides are processed by B cells and presented on 
MHC molecules for T cell recruitment is faster. Moreover, other polysaccharides 
could be tested using the NP delivery system described in this study, such as 
capsular polysaccharide from B. pseudomallei (and certain strains of B. 
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thailandensis) and the various other S. pneumoniae CPS serotypes. S. 
pneumoniae serotype 1 in particular would be an excellent candidate for AuNP 
conjugation, which has a repeating trisaccharide of sugars similar to type 3. The 
similarities between these two sugars means the chemistry may be adaptable 
for conjugation. S. pneumoniae CPS serotype 1 is also biologically relevant and 
is included in both PPV23 and Prevnar 13 vaccines; it has been identified as an 
emerging serotype associated with invasive pneumococcal disease in 
developing countries [511]. Moreover, S. pneumoniae CPS 1 is zwitterionic and 
is therefore recognisable to T cells without the need for a protein carrier [61]. As 
previously mentioned, future development of a glycoconjugate vaccine 
consisting of LPS for human use may require cleavage of the lipid A region due 
to its endotoxicity. Whilst the current method of lipid A cleavage consists of 
boiling LPS in a harsh acidic environment, it may be possible that more 
tolerable conditions could be used if LPS is conjugated onto AuNPs due to the 
semi-solid surface state afforded by NPs. Alternative methods might include the 
selective cleavage of ketosidic linkages in the LPS core region using ceric 
ammonium nitrate or enzymatic removal using keto-deoxyoctulosonate 
hydrolase A, found in the membranes of H. pylori and F. tularensis [360]. The 
current inclusion of lipid A in the B. thailandensis LPS used in this study is likely 
to adjuvant the immune response so its removal in future studies may require 
the addition of exogenous lipid A in the form of MPLA. 
The immunology data presented in this study provides an insight into the 
immune response elicited by the various vaccines devised. However, future 
studies may benefit from measuring T cell responses directly through T cell 
proliferation and T cell memory assays. Antibody affinity assays could also be 
carried out using an array reader to establish whether higher affinity antibodies 
are generated against antigens conjugated onto AuNPs. Protection assays 
should be run for longer to determine whether any long-term protection is 
afforded. 
Furthermore, a more detailed understanding of how NP vaccines are 
able to elicit an improved immune response requires a more detailed approach. 
One way in which this could be developed further is by analysis of MHC 
molecules on the surface of professional phagocytes. Using methods such as 
quantitative polymerase chain reaction (qPCR) one could measure the 
expression of MHC molecules on the surface of macrophages in response to 
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NP vaccines. A comparison of MHC expression on macrophages incubated with 
a NP conjugated antigen compared with an unconjugated antigen could identify 
whether NPs elicit MHC I presentation of antigens. 
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Appendix A. Virulence factors of B. pseudomallei and B. mallei and their 
relevance in an animal model. 
Virulence factor 
 
Description 
 
Relevance to animal 
models 
 
Secreted proteins of 
the Type II secretion 
system (T2SS) 
 
Includes protease, lipase 
and phospholipase C 
which are all secreted by 
B. pseudomallei T2SS 
[512]. B. mallei also 
exports these proteins but 
poorly, possibly due to 
mutations in two T2SS 
genes [343, 357] 
Exoproducts secreted by 
T2SS play a minor role in 
B. pseudomallei 
pathogenesis in a Syrian 
hamster model of infection 
[512] 
Type III secretion 
system (T3SS) 
 
Termed the Burkholderia 
secretion apparatus (Bsa), 
the T3SS of B. mallei and 
B. pseudomallei shares 
homology to the 
Salmonella inv/spa/prg and 
Shigella ipa/mxi/spa 
T3SS’s [186, 513, 514]. A 
needle-like injectisome is 
used to deliver secreted 
proteins, known as 
effectors, directly into the 
cytosol of host cells [448]. 
Effectors are then able to 
manipulate a variety of 
cellular functions such as 
host immune responses, 
intracellular trafficking or 
inducing apoptosis [446, 
447].Some secreted 
effectors have also been 
identified as enabling 
endocytic vacuole escape 
and intercellular spreading 
[345, 387, 513]. 
B. pseudomallei mutants 
lacking the Bsa T3SS 
cluster are unable to 
escape from endocytic 
vacuoles and have 
reduced replication in a 
murine macrophage cell 
line [513]. 
Type IV pili (TFP) 
 
Deletion of a putative pilus 
structural protein (pilA) 
results in reduced 
adherence to human 
epithelial cells [515]. 
Deletion of a putative pilus 
structural protein (pilA) 
from B. pseudomallei 
resulted in reduced 
virulence in BALB/c mice 
by the intranasal route 
[515]. TFP proteins were 
highly immunogenic in 
BALB/c mice but failed to 
protect against a lethal B. 
mallei aerosol challenge 
[516] 
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Secreted protein of the 
Type V secretion 
system (T5SS) 
 
Important for intracellular 
motility of B. mallei, B. 
pseudomallei and B. 
thailandensis. Designated 
the Burkholderia 
intracellular motility (BimA) 
protein, it is localised at the 
bacterial surface to bind 
actin and then promote 
polymerisation for actin-
based motility [500, 517-
519]. In B. mallei and B. 
pseudomallei this 
promotes cell fusion, 
leading to the formation of 
multinucleated giant cells 
[350]. 
The virulence of B. mallei 
bimA mutants was 
comparable to wild type 
strain in a Syrian hamster 
model of infection [384]. 
Recombinant BimA 
generated significant 
protection in BALB/c mice 
against lethal inhaled 
challenges of B. mallei and 
B. pseudomallei [251]. 
Secreted proteins of 
the Type VI secretion 
system (T6SS) 
 
Hcp and VgrG assemble 
into a cell-penetrating 
needle to deliver effector 
proteins into host cells 
[384, 389-391]. T6SS 
plays a role in 
multinucleated giant cell 
formation since these were 
absent when RAW264 
cells were infected with B. 
pseudomallei T6SS 
mutants [351] 
B. mallei and B. 
pseudomallei T6SS 
mutants are highly 
attenuated in hamsters 
and mice [384, 385]. 
Quorum sensing 
 
The B. mallei genome 
contains two luxI homologs 
which produce four 
quorum-sensing molecules 
that are recognised by four 
luxR homologs [520, 521]. 
B. pseudomallei encodes 
three luxI homologs, 
producing seven quorum-
sensing molecules [522-
524]. It has five luxR 
homologs to detect these 
signals. 
Mutations to luxI and luxR 
homologs in B. 
pseudomallei and B. mallei 
results in reduced 
virulence in hamster and 
mouse models of infection 
[521-523]. 
Flagellin 
 
Flagellin, encoded by fliC, 
is involved in B. 
pseudomallei motility [349, 
361]. The role of flagellum-
mediated motility in 
virulence has largely been 
attributed to its ability to 
enhance the invasion of 
host epithelial cells [359, 
377, 380, 381]. 
B. pseudomallei flagellin 
mutants are attenuated in 
mice when delivered 
intranasally [377, 380]. 
Antibodies raised against 
B. pseudomallei FliC 
provide passive protection 
against B. pseudomallei 
infection in a diabetic rat 
model [382]. 
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Lipopolysaccharide 
(LPS) 
 
Consisting of a conserved 
lipid A and core region for 
structure and anchoring 
into the outer membrane. 
The variable O-antigen 
region, comprising of a 
repeating D-glucose and L-
talose protects the 
bacterium against host 
defences, particularly 
serum killing [264, 357, 
403]. This has been 
demonstrated by 
constructing mutants of the 
gene cluster in B. 
pseudomallei required for 
O-antigen synthesis and 
showing they are more 
susceptible to macrophage 
killing by RAW 246.7 cells 
and serum killing by the 
complement system [403, 
408]. 
Passive protection studies 
of mAb’s raised against B. 
mallei or B. pseudomallei 
LPS O-antigen were 
protective against a lethal 
challenge of glanders or 
melioidosis in a mouse 
model of infection [409-
412]. LPS purified from B. 
pseudomallei or B. 
thailandensis is able to 
provide (short-term) 
significant protection 
against an inhalation 
challenge of B. 
pseudomallei [414]. 
Capsular 
polysaccharide 
 
A 200 kDa group 3 
capsular polysaccharide 
produced by both B. mallei 
and B. pseudomallei 
comprising of a 
homopolymer [392, 393]. 
The role of capsular 
polysaccharide in virulence 
is due to evasion of host 
defences, specifically the 
complement system, by 
reducing C3b-mediated 
opsonisation and 
phagocytosis [397]. 
Capsule is also believed to 
be required for survival 
and replication in 
macrophages by protecting 
the bacterium from 
reactive nitrogen and 
oxygen intermediates 
[398]. 
B. pseudomallei capsular 
mutants are highly 
attenuated in both mice 
and hamsters and B. 
mallei capsular mutants 
are avirulent [394-396]. 
Passive immunisation of 
mice using monoclonal 
antibodies raised against  
capsular polysaccharide 
provided significant 
protection against an 
intraperitoneal and 
intranasal challenge with 
B. pseudomallei [411, 
412]. 
Type III and type IV O-
PS 
 
Functions relating to 
polysaccharide 
biosynthesis and transport 
in B. pseudomallei [344, 
413]. Neither cluster is 
present in B. mallei [343]. 
Mutants lacking either type 
III or type IV O-PS show 
an increased time to death 
in a mouse model of B. 
pseudomallei compared 
with wild-type [413]. 
 
Appendices 
168 
 
Appendix B. In vivo imaging using FxPro imaging of MF1 mice challenged IN 
with 2.5 x 105 CFU 50 µL-1 S. pneumoniae Xen10 four weeks post SC 
immunisation; Luminescence scale in radiance (p/sec/cm2/sr) 
 
     
1A and B) PBS immunised 24 hpi 
 
    
     
2A and B) PBS immunised 48 hpi 
2C and D) Prevnar 13 immunised 48 hpi 
1A 1B 
2A 2B 
2C 2D 
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2E and F) AuNP-TetHc immunised 48 hpi 
2G and H) AuNP-TetHc-CPS immunised 48 hpi 
2I and J) AuNP-CPS immunised 48 hpi 
2E 2F 
2G 2H 
2I 2J 
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3A) PBS immunised 74 hpi 
3B) Prevnar 13 immunised 74 hpi 
3C) AuNP-TetHc immunised 74 hpi 
3D) AuNP-TetHc-CPS immunised 74 hpi 
3E) AuNP-CPS 74 hpi immunised 74 hpi 
3A 3B 
3C 3D 
3E 
Appendices 
171 
 
    
    
     
 
4A) PBS, B and C) Prevnar 13, D) AuNP-TetHc, E and F) AuNP-TetHc-CPS, G) 
AuNP-CPS immunised 8 days post infection.
4A 4B 
4C 4D 
4E 4F 
4G 
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